

GLUTATHIONE S-TRANSFERASES AND  
ARACHIDONIC ACID CASCADE: EFFECTS  
OF DIETARY VITAMIN E AND SELENIUM  
IN FEMALE ALBINO RATS

THESIS SUBMITTED FOR THE DEGREE OF  
*DOCTOR OF PHILOSOPHY*

BY  
*ANURADHA DESAI*



SCHOOL OF LIFE SCIENCES  
UNIVERSITY OF HYDERABAD  
HYDERABAD 500 046  
INDIA


1997


Enrolment No. PL 5989

***To my parents***

## STATEMENT


I hereby state that the work presented in this thesis entitled **"Glutathione S-transferases and arachidonic acid cascade: Effects of dietary vitamin E and Selenium in female albino rats"** has been carried out by me under the supervision of Dr. P. Reddanna and that this has not been submitted for any degree or diploma of any other University earlier.


  
(Dr. P. Reddanna)  
Research supervisor  
**Dr. P. Reddanna**  
READER  
School of Life Sciences  
Univ of Hyderabad  
HYDERABAD - 500 134


  
(D. Anuradha)  
Research student

## CERTIFICATE

This is to certify that Ms. **D. Anuradha**, has carried out the research embodied in the present thesis under my supervision and guidance for the full period prescribed under the Ph.D. ordinance of this University. I recommend her thesis entitled "**Glutathione S-transferases and arachidonic acid cascade: Effects of dietary vitamin E and Selenium in female albino rats**" for submission for the degree of Doctor of Philosophy of this University.

  
Dr. P.Reddanna  
Supervisor  
*Dr. P. Reddanna*  
READER  
School of Life Sciences  
Univ of Hyderabad  
HYDERABAD - 500 134.

  
Prof. P.R.K.Reddy  
Head,  
Deptt. of Animal Sciences  
H E A D  
DEPTT. OF ANIMAL SCIENCES  
SCHOOL OF LIFE SCIENCES  
UNIVERSITY OF HYDERABAD  
HYDERABAD - 500 046

  
Prof. A.R.Reddy  
DEAN,  
School of Life Sciences  
Dean, School of Life Sciences  
University of Hyderabad,  
Hyderabad-500 134. (India)

# CONTENTS

Contents		I
List of Figures		II-V
List of Tables		VI-VII
Abbreviations		VIII- IX
Acknowledgments		X-XI
Introduction	01	-23
Methodology		24-36
Chapter 1: Vitamin E, selenium, oxidative stress and antioxidant defenses		37-47
Chapter 2: Structural characterization of GSTs during oxidative stress induced by vitamin E and/ or Se deficiency		48-58
Chapter 3: Functional characterization of GSTs during oxidative stress induced by vitamin E and/ or Se deficiency		59-69
Summary and conclusions		70-72
References		73-86

## LIST OF FIGURES

- Fig. 1: Phase I and Phase II drug detoxification mechanisms.
- Fig. 2: The mercapturic acid pathway.
- Fig. 3: Current model for the interorgan cycle of mercapturic acid formation.
- Fig. 4: The catalytic and non-catalytic functions of GSTs.
- Fig. 5: Leukotriene biosynthesis
- Fig. 6: Prostaglandin biosynthesis.
- Fig. 7: The metabolism of glutathione.
- Fig. 8: Interorgan homeostasis of GSH.
- Fig. 9: The recycling of tocopherol, ascorbic acid, glutathione and NADPH.
- Fig. 10: The proposed role of vitamin E and selenium in the arachidonic acid cascade.
- Fig. 11: Separation of vitamin E on RP-HPLC.
- Fig. 12: RP-HPLC analysis of MDA.
- Fig. 13: Separation of GSH, GSSG and Paba Glu on HPLC.
- Fig. 14: Vitamin E levels in liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets for 13 weeks.
- Fig. 15: Selenium levels in liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets.
- Fig. 16: Growth curves of rats fed on vit.E and/or Se supplemented and deficient diets.
- Fig. 17: Tissue somatic indices of rats fed on vit.E and/or Se supplemented and deficient diets.

- Fig. **18**: Lipid **peroxidation** in liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. **19**: Activity levels of Se-GSH Px with **H<sub>2</sub>O<sub>2</sub>** in the cytosolic fractions of liver and lung tissues of rats fed on **vit.E and/or** Se supplemented and deficient diets.
- Fig. 20: Levels of GSH in liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. **21**: Levels of GSSG in liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig.22: Activity levels of **γ-glutamylcysteine** synthetase in the cytosolic fractions of liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. 23: Activity levels of glutathione reductase in the cytosolic fractions of liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig.24: Activity levels **of γ-glutamyl** transpeptidase in the cytosolic fractions of liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. 25: Activity levels of glutathione S-transferases in the cytosolic fractions of liver and lung tissues of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. 26: Affinity purification of rat liver **and/or** lung cytosolic GSTs.
- Fig. 27: **SDS-PAGE** of liver cytosolic proteins of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. 28: Immunoblots of liver cytosol and affinity purified GSTs of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. 29: SDS-PAGE of liver and lung affinity purified GSTs of rats fed on vh.E **and/or** Se supplemented and deficient diets.
- Fig. 30: Relative subunit concentration of liver affinity purified GSTs of rats fed

on vit.E **and/or** Se supplemented and deficient diets separated on SDS-PAGE.

Fig. 31: RP-HPLC analysis of affinity purified liver GSTs of (A) -E+Se (B)+E-Se (C)-E-Se (D)+E+Se rats.

Fig. 32: Relative subunit concentration of liver affinity purified GSTs of rats fed on vit.E **and/or** Se supplemented and deficient diets separated on RP-HPLC.

Fig. 33: **SDS-PAGE** of lung cytosolic proteins of rats fed on vit.E and /or Se supplemented and deficient diets.

Fig. 34: Immunoblots of lung cytosol and affinity purified GSTs of rats fed on vit.E **and/or** Se supplemented and deficient diets.

Fig. 35: Relative subunit concentration of lung affinity purified GSTs of rats fed on vit.E **and/or** Se supplemented and deficient diets separated on SDS-PAGE.

Fig. 36: RP-HPLC analysis of affinity purified lung GSTs of (A) -E+Se (B)+E-Se (C)-E-Se **(D) +E+Se rats**

Fig. 37: Relative subunit concentration of lung affinity purified GSTs of rats fed on vit.E **and/or** Se supplemented and deficient diets separated on RP-HPLC.

Fig. 38: Separation of affinity purified hepatic GST isozymes **of +E+Se** rats separated on **CM-cellulose** column **chromatography**.

Fig. 39: SDS-PAGE of liver GST isozymes **of +E+Se** rats on CM-cellulose column chromatography.

Fig. 40: **Anion** exchange chromatography **of +E+Se** rat liver CM-cellulose column flow through fraction on DE 52 cellulose column chromatography.

Fig. 41: Activity levels of non-Se-GSH Px with CHP in the cytosolic fractions of liver and lung tissues of rats fed on **vit.E and/or** Se supplemented and deficient diets.

Fig. 42: Activity levels of non-Se-GSH Px with CHP in the affinity purified GSTs



of liver and lung tissues of rats fed on vit.E **and/or** Se supplemented and deficient diets.

Fig. 43: Activity levels of GSTs with **13-HPODE** in the cytosolic fractions of liver and lung tissues of rats fed on vit.E **and/or** Se supplemented and deficient diets.

Fig. 44: Activity levels of GSH Px with **13-HPODE** in the **affinity** purified GSTs of liver and lung tissues of rats fed on vit.E **and/or** Se supplemented and deficient diets.

Fig. 45: Activity levels of GSTs with **15-HPETE** in the cytosolic fractions of liver and lung tissues of rats fed on vit.E **and/or** Se supplemented and deficient diets.

Fig. 46: Activity levels of GSH Px with **15-HPETE** in the affinity purified GSTs of liver and lung tissues of rats fed on vit.E **and/or** Se supplemented and deficient diets.

Fig. 47: Separation of prostaglandin standards on TLC.

Fig. 48: RP-HPLC analysis of GSTs catalyzed **LTC<sub>4</sub> formation**.

## LIST OF TABLES

- Table 1: Rat GST nomenclature based on subunits.
- Table 2: The 3 stages of **lipid** peroxidation
- Table 3: Composition of the vitamin E and Se deficient diets.
- Table 4: Summary of assay conditions for various classical GST substrates.
- Table 5: Purification profile of liver **GSTs of rats** fed on -E+Se diet.
- Table 6: Purification profile of liver **GSTs of rats** fed on +E-Se diet.
- Table 7: Purification profile of liver **GSTs of rats fed on -E-Se** diet.
- Table 8: Purification profile of liver **GSTs of rats fed on +E+Se** diet.
- Table 9: Purification profile of liver **GSTs of rats** fed on vit.E **and/or** Se supplemented and deficient diets.
- Table 10: Purification profile of lung GSTs of rats fed on -E+Se diet.
- Table 11: Purification profile of lung GSTs of rats fed on +E-Se diet.
- Table 12: Purification profile of lung GSTs of rats fed on -E-Se diet.
- Table 13: Purification profile of lung GSTs of rats fed on +E+Se diet.
- Table 14: Purification profile of lung GSTs of rats fed on **vit.E and/or** Se supplemented and deficient diets.
- Table 15: Substrate specificities of rat liver GST **isozymes** separated on CM-cellulose column **chromatography** to classical substrates.
- Table 16: Substrate specificities of rat liver GST isozymes separated on CM-cellulose column chromatography to conventional substrates.
- Table 17: Synthesis of prostaglandins catalyzed by liver affinity purified GSTs of vit.E **and/or** Se supplemented and deficient diets.

Table 18: Synthesis of prostaglandins catalyzed by **lung** affinity purified GSTs of vit.E **and/or** Se supplemented and deficient diets.

Table 19: **LTC<sub>4</sub>** synthase activity of affinity purified liver and lung GSTs **of** vit.E **and/or** Se supplemented and deficient diets.

## LIST OF ABBREVIATIONS

AA	<b>arachidonic</b> acid
Ab	antibody
ARE	<b>antioxidant</b> responsive element
<b>BCIP</b>	<b>5-bromo-4-chloro-3-indoyl</b> phosphate
BHT	butylated hydroxytoluene
CDNB	<b>1-Chloro-2,4-dinitrobenzene</b>
CHP	<b>cumene hydroperoxide</b>
<b>CM-cellulose</b>	carboxy methyl cellulose
COX	cyclooxygenase
DAN	diaminonaphthalene
DCNB	<b>1,2-dichloro-4-nitrobenzene</b>
DE 52	diethyl aminoethyl cellulose
FAHP	fatty acid hydroperoxide
GCS	<b>γ-glutamylcysteine</b> synthetase
GGT	<b>γ-glutamyl transpeptidase</b>
GSH	<b>glutathione</b> reduced
GSSG	glutathione oxidized
GST	glutathione S-transferase
HETE	hydroxyeicosatetraenoic acid
HODE	hydroxyoctadecadienoic acid
HPETE	hydroperoxyeicosatetraenoic acid
HPLC	high performance liquid <b>chromatography</b>
HPODE	hydroperoxyoctadecadienoic acid
LOX	lipoxygenase
LT	leukotriene
LX	lipoxin
MDA	malondialdehyde
NBT	<b>nitroblue</b> tetrazolium
Non-Se-GSH Px	<b>non-selenium-glutathione</b> peroxidase
PAH	poly aromatic hydrocarbon
PG	prostaglandin
<b>PGI</b>	prostacyclin
<b>PLA<sub>2</sub></b>	phospholipase <b>A<sub>2</sub></b>
PUFA	polyunsaturated fatty acid
ROS	reactive oxygen species
<b>SDS-PAGE</b>	sodium dodecyl sulphate <b>polyacrylamide</b> gel electrophoresis

Se	selenium
Se-GSH Px	<b>selenium-glutathione</b> peroxidase
SOD	superoxide <b>dismutase</b>
<b>TBA</b>	<b>thiobarbituric</b> acid
<b>TFA</b>	<b>trifluoroacetic</b> acid
TLC	thin layer <b>chromatography</b>
TX or Tx	thromboxane
vit.E	<b>vitamin</b> E
XRE	xenobiotic responsive element
g	gram
<b>hr</b>	hour
L	liter
u	micro
M	molar
<b>min</b>	minute
<b>nm</b>	nanometer
s	second

## A CKNO WLEDGEMENTS

*I would like to place on record my deep sense of gratitude to Dr. P. Reddanna, for his inspiring and expert guidance in carrying out this study. I feel privileged for having stimulating discussion with him and for his critical suggestions. I am very much indebted to him for the constant encouragement and affection shown during the years of my association with him.*

*I would like to thank Prof. A. R. Reddy, Dean, School of Life Sciences and Prof. P.R.K. Reddy, Head, Department of Animal Sciences for providing the necessary facilities for this study.*

*I wish to thank Prof. Ch. R. K. Murthy, Dr. Mohan C. Vemuri and Dr. Aparna Dutta Gupta for extending their lab facilities.*

*I would like to thank Dr. Srinivas Reddy, Mr. Muralidhar Reddy, Mr. Ramakrishna, Dr. Narasa Reddy, Dr. Kiranmai, Mrs. Usha, Mrs. Uma, Mr. Madhava Reddy, Ms. Neeraja, Mr. Bhagavan, Mr. Raheem and former colleagues for the good times we spent together in the lab.*

*I am very thankful to Dr. Hildenbrandt of Penn State University for critically reading the manuscript.*

*I thank Mr. Murali, Dr. Rama Devi, Mr. Kantha Rao, Mr. Thaha, Dr. Prabhavathi, Dr. Rukmini Devi, Dr. Prasuna and Ms. Vasanthi for their lively company during my stay in the campus.*

*I thank Mr. Nagesh, Mr. Sivaram and Mr. Sudhakar for their assistance in the lab.*

*/ wish to express my profound gratitude to my grand mother, mother-in-law, parents, Prasad mamayya, sisters, brother, brothers-in-law, Vijayakka, Lalitha, Jayaram anna, Ramana, **and Dasarath** but for whose patience, moral support, understanding and encouragement, this could not have been successfully completed*

*I wish to thank my husband Veeru for his friendship, balance sense of humor and lively company which made my stay in this lab a memorable one. His continuous help and co-operation together with his patient endurance has been instrumental in many ways.*

*Financial assistance from Indian Council of Medical Research is gratefully acknowledged.*

*Desai*

# ***INTRODUCTION***




## GENERAL INTRODUCTION

### 1.1.0.0. Glutathione S-transferases


Drug **detoxification** mechanism is an inherent system of living organisms. Xenobiotics are detoxified and eliminated from the body by either phase I or phase II drug detoxification systems (Fig. 1). Phase I metabolism involves an initial oxidation of the xenobiotics by cytochrome P450 (CYP) monooxygenases. This step is followed by phase II **metabolism**, which frequently involves conjugation reactions catalyzed by glutathione S-transferases (GSTs), **UDP-glucuronosyl transferases**, and sulfotransferases. Some of the xenobiotics like diphenols and thiocarbamates directly activate GSTs of phase II **detoxification** system. The glutathione (GSH) conjugates thus formed are transported out of cells for further metabolism by  $\gamma$ -**glutamyl** transpeptidase and **dipeptidases**, that catalyze the sequential removal of the **glutamyl** and glycyl moieties, respectively. The resulting cysteine **S-conjugates** can be acetylated by intracellular **N-acetyl-transferase** to form the corresponding **mercapturic acids** (**N-acetyl-cysteine S-conjugates**) which are then released into the circulation and delivered to the kidney for excretion in urine, or they may undergo further metabolism (Fig. 2). **Mercapturic acid** biosynthesis is generally considered to be an interorgan **process**, with the liver serving as the major **site** of glutathione conjugation and kidney being the primary site for conversion of glutathione conjugates to cysteine conjugates (Fig. 3). Thus GSTs comprise a family of phase II drug detoxification enzymes catalyzing the conjugation of GSH with the **electrophilic** compounds produced from biotransformation of exogenous xenobiotics and also from endogenous substances (Mannervik and **Danielson**, 1988; Coles and **Ketterer**, 1990; Tsuchida and Sato, 1992).

### 1.1.2.0. Classification of GSTs

In mammals cytosolic GSTs are encoded by at least 4 **multigene** families which include  $\alpha$  (a), **mu** ( $\mu$ ),  $\pi$  ( $\pi$ ), and  $\theta$  ( $\theta$ ) class GSTs (Mannervik



**Fig. I: PHASE I AND PHASE II DRUG DETOXIFICATION MECHANISMS**




**Fig. 2: THE MERCAPTURIC ACID PATHWAY**

*et al.*, 1985; Ketterer and Christodoulides, 1994). The cytosolic GSTs from the rat, mouse and man share common structural and catalytic properties. Isozymes from these species were grouped with respect to **N-terminal** amino acid sequence, substrate **specificities**, sensitivities to inhibitors and **immunological** cross reactivity. An additional classification of GST nomenclature is by their subunit resolution on **SDS-PAGE** (Bass *et al.*, 1977). In this study, both systems of nomenclature will be followed (summarized in Table 1). The genetic relationship among subunits is believed to be as follows: a family- **Ya<sub>1</sub>, Ya<sub>2</sub>, Yc, Yk** and Yfetus; **μ** family- **Yb<sub>1</sub>, Yb<sub>2</sub>, Yn<sub>1</sub>, Yn<sub>2</sub>** and Yo; **π** family- Yp; and **θ** family- subunit 5 and subunit 12. Evolutionarily, cytosolic GSTs were derived from common origin as illustrated by their considerable homology of > 70% according to amino acid sequencing within gene families and 20-30 % homogeneity between gene families. The GST **isozymes** have generally been found to occur as homodimers and **heterodimers** of subunits ranging in size from 17 to 28 kDa (Mannervik and **Dannielson**, 1988). Rat liver contains at least **18** dimers made up of 13 different subunits (**Tsuchida** and Sato, 1990).

### 1.1.3.0. Mechanistic aspects of GSTs

The active site of GST is composed of two domains, smaller one for binding of glutathione (**G-site**) and the larger hydro phobic domain for electrophilic substrate (**H-site**). All GSH binding sites have a high specificity towards GSH, except for theta class GSTs (Meyer, 1993). Similarly, the affinity of the electrophilic domain is also high for many electrophiles especially **1-chloro-2,4-dinitrobenzene (CDNB)**, a classical substrate used for most studies involving GSTs.

The exact mechanism of GST-catalyzed reaction is still a subject of debate. The most likely mechanism involves the lowering of pKa of GSH from pH 9.0 to about 6.5 at the active site to form a potent nucleophilic species, the thiokte anion GSH<sup>-</sup>. It was hypothesized that a tyrosine residue found at the N- terminus of most cytosolic GSTs is responsible for ionizing GSH (Ji *et al.*, 1992b). Once the **GS** is



(Courtesy of Hinchman and Ballatori, 1994)

Fig 3 : Current model for the interorgan cycle of mercapturic acid formation; (1) GSH conjugation reactions occur predominantly in the liver, catalyzed by glutathione **S-transferases** (GST), (2) glutathione conjugates (GS-E) are released from liver into bile or the circulation, (3) renal  **$\gamma$ -glutamyltransferase** (gGT) and dipeptidase (DP) activities catabolize circulating glutathione conjugates to the corresponding cysteine conjugates (**Cys-E**), (4) glutathione conjugates released into bile are degraded by gGT activity in the biliary tree and small intestine, (5) cysteine conjugates formed in kidney or gut are released into the circulation and transported back to the liver for acetylation by **N-acetyltransferases** (NAT), (6) mercapturates (N-Ac-Cys-E) are released from liver and transported to the kidney, and (7) mercapturates cleared by the kidney or those formed by renal **N-Acetyltransferase** activity are excreted into urine.

**Table 1: Rat GST nomenclature based on subunit**  
**Gene family**

<b>a</b>		<i><b>n</b></i>	<b>G</b>
1-1 (Y <sub>a</sub> )	3-3 (Y <sub>b</sub> ,)	7-7 (Y <sub>p</sub> )	5-5
2-2 ( <b>Y<sub>c</sub></b> )	<b>4-4 (Y<sub>b2</sub>)</b>		12-12 (Y <sub>rs</sub> )
8-8 (Y <sub>k</sub> )	6-6 (Y <sub>n</sub> ,)		
10-10 ( <b>Y<sub>c2</sub></b> )	9-9 ( <b>Y<sub>n2</sub></b> )		
	<b>11-11 (Y<sub>o</sub>)</b>		

From Ketterer and Christodoulides, 1994.

formed in the active site of GST, it becomes capable of reacting spontaneously by nucleophilic attack with electrophilic xenobiotics that are situated in close proximity. Thus, catalysis by GST occurs through the combined ability of the enzyme to promote the formation of GS<sup>-</sup> and to bind hydrophobic electrophilic compounds at a closely adjacent site. Several lines of evidence suggest that binding of GSH is accompanied by a conformational change of the protein (Mannervik and Dannielson, 1988). The role of glutathione has been dissected into two components *i.e.*, making the enzyme **catalytically** competent by inducing a conformational change as well as providing the functional thiol group for the reaction to be catalyzed. **Enzymatically**, the GSTs function by a sequential mechanism requiring both substrates to be bound before any product is released (Jakobson *et al.*, 1979). Mechanisms concerning the glutathione peroxidase (GSH Px) activity of these enzymes has been hypothesized in a two- step reaction. First, GSH reacts with the peroxide yielding the corresponding alcohol and the sulfenic acid of GSH (GSOH) (Eq. 1).




In the second step (Eq. 2), the sulfenic acid reacts with another GSH molecule producing oxidized glutathione (GSSG) and **H<sub>2</sub>O**, which is non-**enzymatic**. Jakoby and Habig (1980) suggested a simple "proximity effect" in which the GSTs bind GSH and an electrophile and that the **electrophilicity** of the second substrate then determines the reaction rate.


#### 1.1.4.0. Reactions catalyzed by GSTs

GSTs catalyze 3 major reactions viz. **conjugation**, oxidation-reduction and isomerization (Fig. 4). GSTs also catalyze the addition **reactions** towards epoxides including leukotriene **A<sub>4</sub>** (**LTA<sub>4</sub>**) and arene epoxides (**Chasseaud**, 1979; **Samuelsson**, 1983; Chang *et al.*, 1987b). In each reaction GSH functions as the nucleophilic reactant towards an electrophilic substrate. The most sensitive and


### 1. Conjugation Reactions



### 2. Reduction Reactions



### 3. Isomerization Reactions



### 4. Binding

In addition to its catalytic activities, GSTs can also non-enzymatically bind numerous compounds such as bilirubin, heme and thyroid hormones.

**Fig. 4: The Catalytic and Non-catalytic Functions of GSTs**



widely used substrate to study GST is CDNB, a reaction easily analyzed **spectrophotometrically**. The newly discovered theta class GST, Yrs-Yrs do not react with CDNB but efficiently conjugates reactive **sulfate** esters formed from carcinogens (Hiratsuka *et al.*, 1990). Majority of substrates for GSTs are xenobiotics and include many known carcinogens in addition to a number of therapeutic compounds.

A second class of reactions catalyzed by GSTs are oxidation-reduction reactions, where GSTs exhibit peroxidase activity, commonly denoted as **non-selenium-glutathione** peroxidase (non-Se-GSH Px) activity. The substrates that GST reduce include fatty **acid**, **phospholipid** and DNA hydroperoxides. As these compounds are generated by **lipid** peroxidation and oxidative damage to **DNA**, it has been proposed that GST as well as other **GSH-dependent** enzymes help combat oxidative stress (**Mannervik**, 1986). Both a- and  $\theta$ - class GSTs are particularly high in this GSH Px activity. Detoxification of lipid hydroperoxides by microsomal GSTs can occur *in situ*, whereas detoxification of lipid hydroperoxides by cytosolic GSTs require prior release of fatty acid hydroperoxides by phospholipase **A<sub>2</sub>** (PLA<sub>2</sub>) (Tan *et al.*, 1984). A second peroxidation reaction catalyzed by GSTs includes the reduction of the endoperoxide **prostaglandin H<sub>2</sub>** (**PGH<sub>2</sub>**) to **PGF<sub>2 $\alpha$</sub>**  (Burgess *et al.*, 1987; Hong *et al.*, 1989; Chang *et al.*, 1990).

GSTs also catalyze reactions of positional isomerization. An example of a GST-mediated reaction is the isomerization of **PGH<sub>2</sub>** to the biologically active PGE<sub>2</sub> and PGD<sub>2</sub>, the major steps in eicosanoid biosynthesis (Christ-Hazelhof *et al.*, 1976; Burgess *et al.*, 1987), GSTs also catalyze the conversion of A<sup>5</sup>-ketosteroids to  **$\Delta^4$ -ketosteroids** (Benson *et al.*, 1977).

In addition to their catalytic role, GSTs are known to bind to a number of hydrophobic compounds including heme, **bilirubin**, and steroids (Vander Jagt *et al.*, 1985). As a result of this binding **function**, the most abundant GST isozyme from rat liver was originally termed as **ligandin**, which was later identified as an a-class GST (Habig *et al.*, 1974). The abundance of GST in both rat and human liver

suggests that the binding function may be of even greater **significance** than its catalytic role (Tipping and Ketterer, **1981**).

#### 1.1.5.0. **Cytosolic** GSTs

In **1961**, Booth and co-workers undertook a systematic evaluation of the nature of **GSH-conjugation** reactions from rat liver. They demonstrated that 82% of the GST activity towards **1,2-dichloro-4-nitrobenzene** (DCNB) was found in the soluble fraction, and only 4% located in the microsomes (Booth *et al.*, **1961**). Not surprisingly, these results led to widespread examination of those GSTs located in cytosolic fractions.

Glutathione-agarose and **S-hexylglutathione-agarose** have been extensively used to purify cytosolic GSTs (**alpha**, **mu**, **pi** and **sigma** classes). Class **mu**, **pi** and **sigma** GSTs are adsorbed efficiently by both glutathione-agarose and S-hexylglutathione-agarose, whereas the **alpha** class do not display strong affinity for S-hexylglutathione-agarose but most **isozymes** of this class are efficiently adsorbed by glutathione-agarose (Hayes, **1986**).

The cytosolic GSTs in all vertebrate species exist either as homodimers or heterodimers. The multiple cytosolic GSTs have been identified by analytical methods such as **SDS-PAGE**, isoelectric focussing, western blotting. In recent times, HPLC has been increasingly employed to identify GST subunits (Johnson *et al.*, **1992**). Tissue specific expression is one of the characteristic feature of GSTs and the degree of heterogeneity of GSTs and their **isozyme** profiles vary from tissue to tissue within species (Awasthi and Singh, **1985**; Hayes, **1988**; Tsuchida and Sato, **1990**; Johnson *et al.*, **1992**). In **addition**, sex related differences in the levels of GST activity and subunit composition also has been suggested in mammalian tissues (Hatayama *et al.*, **1986**; Carrillo *et al.*, **1991**). Male rats had higher concentrations of **u** class subunits and lower **a** class subunits compared to female rats (Carrillo *et al.*, **1991**). Rat liver shows **Ya**, **Yb** and **Yc** subunits whereas **Ya** subunit is lacking in **brain**, heart and **lung** (Thyagaraju *et al.*,

1986b; Johnson *et al*, 1992). Both 'a' and 'u' class GSTs are found in low concentrations while 'π' class is the predominant **isozyme** in **lung** (Carmichael *et al*, 1988; Cossar *et al*, 1990).

#### 1.1.6.0. Glutathione S-transferases in eicosanoid metabolism

Arachidonic acid (AA) is the most abundant **polyenoic fatty** acid found in the phospholipids of mammalian tissues. It is a biosynthetic precursor of several classes of biologically active eicosanoids. Once arachidonic acid is released from membrane phospholipids, it is metabolized by one of the two pathways-lipoxygenase (LOX) and cyclooxygenase (COX) and produce a spectrum of biologically active compounds termed as eicosanoids (Fig. 5&6). The COX produces prostaglandins (PGs), thromboxanes (TXs), and prostacyclin (**PGI**), whereas the LOX pathway leads to the formation of leukotrienes (LTs) and lipoxins(LXs). These eicosanoids are extremely potent biologically active compounds with bewildering variety of actions.

The **first** report implicating GSTs in the metabolism of eicosanoids appeared in 1975 when Cagen and co-workers reported that GSTs mediated conjugation of GSH to **PGA<sub>2</sub>** (Cagen *et al*, 1975). A year later, the group led by **Christ-Hazelhof** using purified GSTs from sheep lung and liver showed that these enzymes were efficient in catalyzing the reduction and **isomerization** of the endoperoxide **PGH<sub>2</sub>** to all known PGs (**Christ-Hazelhof et al**, 1976). When AA becomes available in response to a specific stimulation in a PG metabolizing **cell**, the first step in PG formation is the PGH synthase catalyzed incorporation of two molecules of oxygen to form PGH<sub>2</sub>, via the intermediate PGG<sub>2</sub> (Hamberg *et al*, 1974). **PGH<sub>2</sub>** is a common precursor for the synthesis of **PGIs** and TXs as well as classical PGs- **PGD<sub>2</sub>**, **PGE<sub>2</sub>** and **PGF<sub>2α</sub>**.

The action of isomerase on the endoperoxide moiety of **PGH<sub>2</sub>** lead to **PGE<sub>2</sub>** and PGD<sub>2</sub> formation whereas reductases act on **PGH<sub>2</sub>/PGE<sub>2</sub>/ PGD<sub>2</sub>** to yield **PGF<sub>2α</sub>**. Previously GSTs have been implicated in the biosynthesis of PGs from




Fig. 5: Leukotriene Biosynthesis




Fig. 6: Prostaglandin Biosynthesis

**PGH<sub>2</sub>** (Burgess *et al.*, 1987; Chang *et al.*, 1987a). **PGD<sub>2</sub>** is formed by the **isomerization** of the **9,11-endoperoxide** to 9-hydroxy and **11-keto** groups. This catalytic activity has been demonstrated in cytosol of certain rat tissues-lung, **stomach, brain**, and skin (Yamamoto, 1982). The formation of **PGE<sub>2</sub>** is also isomerization reaction converting the endoperoxide to a ketone at C-9 and an alcohol at **C-11**. The formation of **PGE<sub>2</sub>** by GST was established in human brains by Ogarachi *et al.* (1987) and in rat brain by Thyagaraju *et al.* (1986a).

Tissue specific enzymes that result in the formation of products characteristic of a given tissue determine the metabolic fate of **PGH<sub>2</sub>**. **PGH<sub>2</sub>** is exclusively converted to thromboxane **A<sub>2</sub>** in platelets catalyzed by thromboxane A synthase, whereas, in vascular **epithelium**, it is transformed mostly into **PGI<sub>2</sub>** by **PGI** synthase. Such classical PGs such as **PGF<sub>2α</sub>**, **PGE<sub>2</sub>** and **PGD<sub>2</sub>** are formed in most tissues but to differing degrees. Thus tissue specificity appears to be an important factor in the regulation of physiological functions. **PGF<sub>2α</sub>** is widely distributed in various organs of mammals and shows a variety of biological activities including uterine smooth muscle contractions and **luteolysis**. GSTs have been implicated in the prostaglandin biosynthesis by virtue of its endoperoxidase activity (Chang *et al.*, 1987a).

In addition to their role in PG biosynthesis, GSTs also have been implicated in LT biosynthesis. The LTs are very reactive compounds involved in **hypersensitivity** and inflammatory disease processes such as asthma and allergic reactions. Controlling the production of these bioactive lipids is the continuing focus of pharmaceutical **research**. The major LTs are **LTA<sub>4</sub>**, **LTB<sub>4</sub>**, **LTC<sub>4</sub>**, **LTD<sub>4</sub>** and **LTE<sub>4</sub>**. The latter three compounds are collectively referred to as "Slow reacting substances **of anaphylaxis**" (SRS-A). They are potent bronchoconstrictors in several species including humans, with specific effects on the peripheral airways (Dahlen *et al.*, 1980; Smedgard *et al.*, 1982). The first step in the formation of LTs is the oxidation of unesterified arachidonic acid by **5-lipoxygenase**. The product of this **reaction**, 5-hydroperoxyeicosatetraenoic acid (5-HPETE) may be reduced by various peroxidases producing 5-hydroxyeicosatetraenoic acid

(5-HETE) or alternatively undergo enzymatic/nonenzymatic conversion to the unstable allelic epoxide LTA<sub>4</sub>. LTA<sub>4</sub> serves as a precursor for the biosynthesis of LTB<sub>4</sub> as well as cysteine containing LTs. The conversion of LTA<sub>4</sub> to LTC<sub>4</sub> by GSH conjugation has been proposed. It is well established that endogenous compounds as well as xenobiotics may form epoxides and that GSH conjugation is a significant route in their biotransformation (Reddy *et al.*, 1982). Thus LTA<sub>4</sub> can act as a substrate for GSTs. In several cell lines, the LTA<sub>4</sub> to LTC<sub>4</sub> reaction has been shown to be catalyzed by GSTs (Hammarstrom and Samuelsson, 1980). LTC<sub>4</sub> is enzymatically transformed into a more potent biological mediator, LTD<sub>4</sub> and LTE<sub>4</sub> by sequential action of  $\gamma$ -glutamyl transpeptidase (Tate *et al.*, 1976) and a dipeptidase (Lee *et al.*, 1983). Formation of LTF<sub>4</sub> from LTC<sub>4</sub> by the removal of glycine catalyzed by carboxy peptidase A was also demonstrated (Reddanna *et al.*, 1988). Although the exact role of cytosolic GSTs in LTC<sub>4</sub> biosynthesis is unclear, there is evidence for a unique LTC<sub>4</sub> synthase that is distinct from any previously isolated GST (Soderstrom *et al.*, 1988; Penrose *et al.*, 1992).

#### 1.1.7.0. Induction of GSTs as part of adaptive response to oxidant stress

It is apparent that the species, strain, age, sex and organ influence the responsiveness of rodent GST to inducing agents (Hayes and Pulford, 1995). Tissues expressing high activities of GSTs are protected from cytotoxic damage elicited by electrophiles for which the conjugation to GSH is readily catalyzed. Not all GST subunits are induced to the same extent by drugs. Meyer *et al* (1993) examined GST subunit induction by 1,2-dithiole-3-thione in intestine, kidney, liver, lung and stomach and showed that the pattern of induction varies significantly in different organs. GSTs are over-expressed in certain tumor types and measurement of GSTs in serum of pathological specimens can be used to follow the course of the disease and the success of intervention (Primiano and Novak, 1992). The earlier stages of hepatocarcinogenesis are characterized by dramatic increase in the expression of the rat GSTP1 gene. Though this class of GST is ubiquitously distributed, but is found only in relatively small amounts in normal rat liver (Sato, 1989). Measurement of plasma hGSTP1-1 levels has shown that this

protein is dramatically increased in lung cancer (Beckett and Hayes, 1993). Epidemiological studies suggest that individuals who are homozygous null at the GSTM1 locus may have an increased risk of developing various types of neoplastic diseases, including cancer of lung, bladder, colon and stomach (Seidegard and Pero, 1985). **hGSTM1a-1a** and **hGST M1b-1b** are active towards certain epoxides of poly aromatic hydrocarbons (PAH) found in cigarette smoke and other combustion products which makes efforts focused on the area of lung cancer. **hGST M1-1** deficiency also contributes to individual susceptibility to **asbestos**-induced pulmonary disease (Smith *et al.*, 1994). Both phenobarbital and **1,2-dithiole-3-thione** are potent GST inducers in male than in female sprague dawley rats (Meyer *et al.*, 1993), whereas **3-methylcholanthrene** is a slightly better inducer of hepatic GST in female than male rats (Igarashi *et al.*, 1987). GSTs also participate in the development of drug resistance in patients undergoing chemotherapy (Hayes and **Pulford**, 1995).

GST induction as a part of an adaptive response mechanism to xenobiotic stress is widely distributed in nature (Vos and Van **Bladderden**, 1990). It in turn involves the induction of many drug- metabolizing enzymes (Talalay and Spencers, 1990). Collectively, these detoxification enzymes provide protection against a diverse spectrum of harmful compounds. Besides providing protection against chemicals of foreign **origin**, GSTs are involved in protection against oxidative stress. Hence an attempt is made to study the antioxidant defense mechanism of GSTs in liver and lung tissues of rats subjected to oxidative stress. Oxidative stress can be **defined** as the inability of an organism to protect tissues from free radicals generated by exogenous and endogenous toxic substances. Oxidative stress can be induced by either hyperoxic conditions, **H<sub>2</sub>O<sub>2</sub>**, exercise, chemical inducers or vitamin E (**vit.E**) and selenium (Se) deficiency. GSTs of **μ** family are known to be induced by the endogenous toxicants of oxidative stress such as free radicals generated by xanthine-xanthine oxidase reaction (Murata *et al.*, 1990). Rushmore *et al* (1991) showed the induction of GST Ya **mRNA** by hydrogen peroxide. Oxidant stress, in the form of swimming exercise induced **Y<sub>a2</sub>** subunit in




the hepatic tissue of female rats (Veera Reddy *et al.*, 1995). Selenium deficient rats are generally exposed to increased intracellular levels of  $\text{H}_2\text{O}_2$  because of lack of Se-GSH Px. This resulted in **over-expression** of hepatic GST isozymes (Arthur *et al.*, 1987) as a compensatory **mechanism**. The a family of GST-Ya, with highest peroxidase activity (Tu and Reddy, 1985), is known to be induced during Se deficiency (Chang *et al.*, 1990).

#### 1.2.0.0. Oxygen toxicity

Oxygen ( $\text{O}_2$ ) is indispensable to **life**, except for certain anaerobic microorganisms. The principal function of  $\text{O}_2$  in biological system is to serve as the terminal oxidant in cellular **respiration**, thus providing energy for the **organism**. However,  $\text{O}_2$  as a double edged **sword**, induces toxic effects above atmospheric conditions (21%). Exposure of adult humans to pure  $\text{O}_2$  for as little as 6 hours can cause chest soreness, cough and sore throats in few people (Halliwell, 1994) and further exposure leads to irreparable damage of the lung **alveoli**. The lung tissue is one of the organs exposed to the highest tissue  $\text{pO}_2$  under normal conditions and is also the first target of oxygen toxicity *in vivo* at normobaric oxygen partial pressure (Johnson *et al.*, 1981; Jamieson *et al.*, 1986). Severe morphological and functional alterations in the lung are caused by inhaling elevated concentration of oxygen often resulting in death (Crapo *et al.*, 1980a). The damaging effects of oxygen on aerobic organisms vary considerably with the type of organism **used**, its physiological state, diet and age. Oxygen toxicity is also influenced by the presence in the diet of varying amounts of vitamins, heavy metals, antioxidants and polyunsaturated fatty acids (PUFAs). The earliest explanation for the toxicity of  $\text{O}_2$  was related to its effects on key enzymes associated with energy **metabolism**. Although  $\text{O}_2$  inhibits certain enzymatic activities, this proved insufficient to explain the mechanism of  $\text{O}_2$  toxicity. Gerschman and co-workers (1954) and Harman (1956) hypothesized that the possible cause of  $\text{O}_2$ 's dark side may not be  $\text{O}_2$  itself, but rather due to the reactive products produced during partial reduction of  $\text{O}_2$ . It has long been known that metabolism of  $\text{O}_2$  to water occurs by sequential addition

of four electrons (Eq. 3). However, in the event of incomplete tetravalent **reduction**,  $O_2$  is converted to superoxide anion radical ( $O_2^-$ ), hydrogen peroxide ( $H_2O_2$ ), and/or the highly reactive hydroxyl radical ( $\cdot OH$ ), all of which are known as reactive oxygen species (ROS) (Scandalios, 1993).



In addition to being ROS, both  $O_2^-$  and  $\cdot OH$  are also free radicals. Free radicals are species capable of independent existence and contain one or more unpaired electrons. It is the presence of these unpaired electrons that confer the high reactivity often associated with free radicals. ROS not only includes oxygen radicals but also contain non-radicals such as  $H_2O_2$ , singlet oxygen and hypochlorous acid (**HOCl**).


### 1.2.1.0. Sources of Free radicals

Exposure of tissue to free radicals leads to tissue damage with **lipids**, proteins, and DNA as the targets for free radical injury. Although the ROS have been involved in various tissue pathologies, they are an integral part of normal aerobic **metabolism**. Phagocytic cells produce ROS through the NADPH-Oxidase system to destroy invading microorganisms (**Forman** and Thomas, 1986). The damage produced by superoxide radicals liberated from phagocytic cells can spill beyond the integrated target and produce injury to surrounding tissues. Peripheral cells such as fibroblasts and lymphocytes use  $O_2^-$  as a growth regulator (**Burdon**, 1992). Numerous catalytic cytosolic enzymes also contribute to generation of  $O_2^-$  and  $\cdot OH$  and partially to  $H_2O_2$ . Xanthine oxidases are well-known sources of  $O_2^-$  generation as indicated by *its* ability to reduce cytochrome C (McCord and **Fridovich**, 1968). For example cytochrome **P-450** and cyclooxygenase all generate **ROS** through their normal catalytic cycles. Recently, yet another free **radical**, nitric acid (NO), has been implicated as a regulator of physiological processes (Moncada *et al.*, 1991). ROS are formed **endogenously** and **exogenously** (Halliwell and Gutteridge, 1989). Autooxidation reactions also

generate  $\text{O}_2^\cdot$ . Organic compounds such as ascorbate, flavins and tetrahydrofolate, which readily undergo one electron oxidation produce  $\text{O}_2^\cdot$  (Fridovich 1989 and references therein). Endogenous sources of  $\text{H}_2\text{O}_2$  include reactions involving various oxidases such as xanthine and amino acid oxidases as well as dismutation of  $\text{O}_2^\cdot$ . Regardless of the precise role free radicals or ROS play in tissue damage, most studies suggest that biological macromolecules are the primary targets for their action. Phospholipids, the major constituents of biological membranes are highly susceptible to oxidative attack (Halliwell and Chirico, 1993).

### 1.2.3.0. Lipid Peroxidation

Lipid peroxidation is a chain-reactive process with three distinct stages. These stages are **initiation**, propagation and termination (Table 2). It is initiated by abstraction of a **H** atom by those species with sufficient oxidation potential towards divinyl methane groups of PUFAs. These oxidizing species include such free radicals as **OH**, **ROO** $\cdot$ , **RO** and **NO** or ROS such as singlet oxygen ( $^1\text{O}_2$ ) and **O<sub>3</sub>**. Neither **O<sub>2</sub>**, **O<sub>2</sub> $\cdot$**  nor **H<sub>2</sub>O<sub>2</sub>** are themselves sufficiently reactive to abstract **H** atoms from PUFAs, and therefore cannot initiate lipid peroxidation (Halliwell and Gutteridge, 1989). These ROS **can**, however, initiate **lipid** peroxidation, in the presence of redox-active transition metals. For example, **H<sub>2</sub>O<sub>2</sub>** undergoes **homolytic** cleavage in the presence of transition metals producing perhaps the most reactive oxidizing free **radical**, **OH** (Eq. 4). This reaction is often referred to as the Fenton **reaction**. The **OH** is also formed by the transition metal assisted Haber-Weiss reaction (Eq. 5) ( KoppenoL 1990).



Transition metals in particular iron and copper, stimulate membrane oxidative damage at the initiation and/or propagation steps. Another initiator of lipid peroxidation is  $^1\text{O}_2$ , which causes damage to both plant and animal tissue (Cadenas, 1984).

**Table 2: The 3 stages of lipid peroxidation**

$RH \rightarrow R^{\bullet}$	Initiation	(Eq. 6)
$R^{\bullet} + O_2 \rightarrow ROO^{\bullet}$	Propagation	(Eq. 7)
$ROO^{\bullet} + R'H \rightarrow ROOH + R^{\bullet}$		(Eq. 8)
$ROO^{\bullet} + ROO^{\bullet} \rightarrow ROOR + O_2$	Termination	(Eq. 9)
$ROO^{\bullet} + \text{vitamin E} \rightarrow ROOH + \text{vitamin E}^{\bullet}$		(Eq. 10)

The free radical attack on the membrane PUFA leads to the abstraction of a hydrogen atom resulting in a **carbon-centered** lipid radical (Eq. 6). In the aerobic environment of the membrane bilayer, the lipid radical reacts with the molecular oxygen at a diffusion controlled rate ( $10^9 \text{ M}^{-1} \text{ s}^{-1}$ ), yielding a lipid peroxyl radical with rearrangement of double bonds to yield a conjugated diene (Eq. 7). Peroxyl radicals are, in **turn**, capable of abstracting a second hydrogen atom from an adjacent **PUFA**, thereby leading to propagation of the chain reaction (Eq. 8). Alternatively, a chain breaking antioxidant such as vit.E scavenges the peroxyl radical and prevents further membrane oxidative damage (Eq. 10). Regardless of the target molecule, the reaction with the lipid peroxyl radical usually results in a formation of a lipid hydroperoxide. With the propagative nature of lipid **peroxidation**, a simple initiation event produces many lipid hydroperoxides. The membrane PUFA content and as well as  $O_2$  availability both control the extent of propagation

In the presence of transition metals, lipid hydroperoxides undergo decomposition and produce more reactive alkoxyl or peroxyl radicals. A second fate of alkoxyl and peroxyl radicals is the cleavage of **carbon-carbon** bonds, resulting in the formation of secondary decomposition products including alkenals, **hydroxyalkenals**, and alkanes (Esterbauer *et al.*, 1990). Termination of lipid

peroxidation can occur by coupling of peroxy radicals producing non-radical products and  $O_2$  (Eq. 9) or free radical scavenging by antioxidants (Eq. 10).

Secondary by-products of **lipid** peroxidation may be responsible for much of the free radical-mediated damage occurring during oxidative stress. ROS are involved in the mediation of a variety of pathophysiological conditions. Biological systems, however, are equipped with well developed antioxidant defense mechanisms to either regulate the production of ROS or to convert the highly reactive oxygen species into less reactive. Lipid peroxidation may also be responsible for liver necrosis in rats, white muscle disease in sheep and **encephalomalacia** in chicks. These abnormalities occur as a result of a dietary deficiency of two important antioxidants, vit.E and Se. Lipid peroxidation occurs in tissues of rats fed on vit.E deficient diet and is increased by concomitant Se deficiency (Tiidus *et al*, 1993; Awad *et al*, 1994).

### 1.3.0.0. Antioxidant Defense Systems


Under conditions of normal metabolic conditions, tissues have adequate defense mechanisms to minimize damage caused by oxidative stress. Antioxidants, can be defined as "compounds that protect biological systems against the potentially harmful **effects** of processes or reactions that can cause excessive oxidations" (Krinsky, 1992). Mammalian cells are usually equipped with both enzymatic and non-enzymatic antioxidants. The enzymatic antioxidant defenses include superoxide dismutase (SOD), catalase, Se-GSH **Px**, GSTs and glutathione reductase. The **non-enzymatic** biological antioxidants are vit.E, ascorbic **acid**, carotenoids, GSH, cysteine and uric acid. Various antioxidants being both lipid and water soluble, are found in all parts of cells and tissues, although each specific antioxidant often shows a characteristic distribution **pattern**. Deficiency of nutritionally derived antioxidants such as vitamin C and E and excess production of ROS favours oxidative stress. The characterization of biological antioxidant defense constitutes one of the most active fields of free radical research today (Halliwell, 1990).

### 1.3.1.0. Non-enzymatic defense systems

#### 1.3.1.1. Glutathione

The  $\gamma$ -glutamyl cycle serves a diverse series of critical cellular defensive functions including free radical scavenging, detoxification of electrophiles and the maintenance of **thiol-disulfide** status (Fig. 7). GSH is the key compound of the  $\gamma$ -glutamyl cycle (Sen *et al.*, 1992). It is the most abundant nonprotein **thiol** in eukaryotic cells with several important biological functions. GSH has been known as a substrate for GSTs and GSH **Px**, enzymes involved in the detoxification of xenobiotic compounds and reduction of hydroperoxides (Meister, 1991; Hwang *et al.*, 1992). GSH also acts as an efficient scavenger of superoxide radical (**O<sub>2</sub><sup>-</sup>**), hydroxyl radicals (OH) and singlet oxygen (Halliwell and Gutteridge, 1989). It is actively involved in the recycling of  **$\alpha$ -tocopheryl** and semihydroascorbate radicals (Halliwell and Gutteridge, 1989), protein **conformation**, cytoskeletal organization (Larsson *et al.*, 1983), modulation of enzyme activity (Gilbert, 1984) and acts as a reservoir for cysteine (Tateishi *et al.*, 1977). Reduced GSH is present at a relatively high concentrations in the body, ranging from ~ 1 **mM** in skeletal muscle to 10 **mM** in eye lens. The intracellular ratio of GSH to GSSG (**GSH/GSSG**) is usually maintained at a relatively high level (> 10) by a glutathione reductase catalyzed recycle pathway. Liver plays a central role in the synthesis as well as complex inter-organ homeostasis of GSH (Beatty and **Reed**, 1980; Deneke and Fanburg, 1989). In the cell GSH is synthesized by two **cytoplasmic** enzymes namely  **$\gamma$ -glutamylcysteine** synthetase (GCS) and GSH synthetase. **GCS** is the rate limiting enzyme in  $\gamma$ -glutamyl cycle (Richman and Meister, 1975).

The interorgan homeostasis of GSH is summarized in figure 8. In addition to export of hepatic GSH into the plasma and uptake by **extrahepatic** tissues, hepatic GSH is also released into the bile (Lauterburg *et al.*, 1984). GSH is exported from tissues such as lung and liver in its oxidized **form**, glutathione disulfide (GSSG), and as glutathione conjugates (GSX). GSSG is produced when peroxides are detoxified by GSH **Px** (Fig. 7, step 9) and is recycled back to the reduced form by glutathione reductase (Fig. 7, step 12) at the expense of NADPH.




**Fig. 7: The Metabolism of Glutathione**

(Courtesy of Meister and Anderson, 1983)

However, in the absence of adequate reducing equivalents, cellular **thiol** balance is preserved by export of GSSG and uptake by the kidney (**McIntyre** and Curthoys, 1980). GSX is formed when reactive metabolites conjugate with GSH spontaneously or enzymatically by the GSTs (Fig. 7, step 7). Subsequent removal of the  **$\gamma$ -glutamyl** moiety by  $\gamma$ -glutamyl transpeptidase (GGT) (Fig. 7, step 3) and cleavage of glycine by a dipeptidase yields a cysteinyl conjugate (Fig. 7, step 4). In the kidney, the cysteinyl conjugate is **N-acetylated** and excreted as mercapturic acid (Fig. 7, step 8) (DeLeve and **Kaplowitz**, 1990).  **$\gamma$ -Glutamyl amino** acids formed in this way are converted to **5-oxoproline** and the corresponding free amino acids by  $\gamma$ -glutamyl cyclotransferase (Fig. 7, step 5). **5-Oxoproline** is converted to glutamate in the **ATP-dependent** reaction catalyzed by **5-oxoprolinase** (Fig. 7, step 6).

GSH serves as an antioxidant by reacting directly with free radicals (Fig. 7, step **11**) and by providing substrates for GSH Pxs (Fig. 7, step 9) and GSH transhydrogenases (Fig. 7, step 10). The enzymes of the GSH cycle and their **locational** specificity provide the framework for **intracellular** maintenance of tissue GSH concentrations and interorgan transport of GSH. Toxic oxygen intermediates arising from both normal cellular metabolism and exogenous oxidants are removed by GSH Pxs and other **GSH-related** detoxification mechanisms (Coles and Ketterer, 1990; Jain *et al.*, 1992). GSH thus plays a primary role in protection of tissues against **oxidative** injury (Deneke and Fanburg, 1989). A number of **experimental** observations show an association between decreased cellular GSH and increased **susceptibility** of lung cells to damage by oxidants (Deneke and Fanburg, 1989; Martensson *et al.*, 1989). In contrast, conditions that enhance cellular GSH supply are associated with resistance to oxidant damage (Brown *et al.*, 1992). GSH status can be affected by oxidative stress by the metabolism which include exposure of the cell to high concentrations of hydroperoxides or electrophilic compounds or by inhibition of the enzymes of GSH biosynthesis (Reed, 1990). Any one of these scenarios can result in the depletion of intracellular GSH concentrations.





(adapted from Deneke and Fanburg, 1989)

### 1.3.1.2. Vitamin E

The primary lipophilic antioxidant located in membranes and lipoproteins is vit.E (Taylor *et al.*, 1976). A major biological function of  **$\alpha$ -tocopherol** is to act as a lipid antioxidant and free radical scavenger that is capable of terminating chain reactions among **PUFA** molecules. The free radical scavenger action of  **$\alpha$ -tocopherol** depends on the ability of donation of the phenolic hydrogen atom to a fatty **acyl free radical**, which resolves the unpaired electron of the radical so that free radical attack on further molecules of unsaturated fatty acid is prevented. The primary oxidative product of vit.E in this reaction is tocopheroxyl radical and eventually to a-tocopherol quinone (McCay and King, 1980; Diplock 1985). The quinone can be reduced back to alcohol either by ascorbic acid (Niki *et al.*, 1982) or possibly **enzymatically** using the reducing equivalents from GSH and NADPH (**Tappel, 1962**) (Fig. 9). The efficiency of vit.E in protecting against lipid peroxide damage is remarkable considering its concentration in cell membranes. Besides its role in nonenzymatic lipid **peroxidation**, vit.E was shown to be a potent inhibitor of lipoxygenase (Reddanna *et al.*, 1985; 1989) and aids in the reduction of hydroperoxides (Cucurou *et al.*, 1991). Lung eicosanoid synthesis was shown to be affected by vit.E (**Meydani et al.**, 1992). Vitamin E inhibits some of the reactions leading to the formation of lipoxygenase and cyclooxygenase products (**Panganamala and Cornwell**, 1980) and also inhibits platelet aggregation *in vitro* and *in vivo* (Stuart, 1982). Vitamin E deficiency, on the other hand depressed synthesis of PGF in testis (Carpenter, 1981) and muscle (Chan *et al.*, 1980). Vitamin E is known to significantly protect lung tissue from damages after **NO<sub>2</sub>** or **O<sub>3</sub>** exposures (Elasayed *et al.*, 1988) and tobacco smoke (Arriess *et al.*, 1988). Alterations of vit.E status has been associated with the development of cardiovascular disease (Gey *et al.*, 1987) and impaired immune response (Panush and Delafuente 1985). Animal research has demonstrated that a high PUFA intake increases the vit.E requirement (Horwitt, 1986).





Fig. 9. The recycling of tocopherol, ascorbic acid, glutathione and NADPH

A wide variety of pathological alterations occur in animals and humans with Se and vit.E deficiency. Necrosis of smooth muscle of gizzard and intestine may be a prominent lesion in turkey, ducklings and quail (Van **Vleet** 1982). Ultrastructural study of the early alterations in rat liver in response to **Se-vit.E** deficiency showed disruption of hepatocyte plasma membranes at the sinusoidal border (Svoboda and **Higginson**, 1963). Other Se-vh.E deficiency lesions include gastric **ulceration**, exudative diathesis, **encephalomalacia**, pancreatic damage and testicular necrosis. The biochemical pathogenesis of Se-vh.E deficiency diseases has become clearer with the understanding of cellular antioxidant defense systems (Freeman and Crapo, **1982**; Hammond and Hess, 1985).

### 1.3.2.0. Enzymatic antioxidant defense systems



#### 1.3.2.1. Superoxide **dismutase** (SOD)

SOD occurs in different forms, depending on the cellular fraction (**Fridovich**, 1989). The cytosolic enzyme is a Cu-Zn requiring enzyme, whereas **mitochondrial** form requires Mn for activity. The SODs may play a role against  $O_2^-$  generating systems such as **xanthine/xanthine** oxidase. The  $H_2O_2$  produced via SOD (Eq. 11) is readily reduced to water by catalase or more importantly by various GSH Pxs present in the cell



#### 1.3.2.2. Catalase

Catalase is a **heme-containing** protein found predominantly in **the peroxisomes** (Halliwell and Gutteridge 1989). *In vitro*, catalase has been demonstrated to inhibit  $Fe^{+2}/H_2O_2$ -induced **lipid** peroxidation (Bucher *et al.*, 1983). Catalase and Se-GSH Px reduce  $H_2O_2$  to water (Eq. **12&13**), whereas SOD converts  $O_2^-$  to  $H_2O_2$  (Eq. 11).



### 1.3.2.3. Glutathione peroxidase

Selenium as an essential component of GSH **Px**, plays a critical role in protecting aerobic organisms from oxygen radical-initiated cell injury. The nutritional essentiality of selenium was first recognized in 1957 by Schwartz and **Foltz**. In 1973 **Rotruck et al** and **Flohe et al** discovered that Se is an essential structural component of GSH Px. Subsequently, it was demonstrated that Se, in the form of selenocysteine ([Se]cys) residue, is part of the catalytic **site** of GSH Px (Landstein *et al.*, **1981**). This lead to a broader conception of GSH Px as an integral part of the cellular **antioxidant** system which protects the cell from oxidative damage (Tappel, 1980). GSH Px is located in the cytosol and mitochondria] matrix of many cells. It is a **tetramer** of identical subunits, molecular weight ranges from **19** to 23 kDa with each monomer containing a gram atom of Se in the form of ([Se]cys) (Landstein *et al.*, 1979).

Se-GSH Px catalyzes the two electron reduction of **H<sub>2</sub>O<sub>2</sub>** as well as several organic hydroperoxides as shown in equations 13 & 14 respectively. Thus, this enzyme differs from a group of Se-independent GSH Pxs (**non-Se-GSH Px**), the GSTs, that can use the latter only (organic hydroperoxides) as peroxide substrates.



Although this enzyme exhibits a broad specificity towards the peroxide substrate, it is very specific for GSH as a hydrogen donor. **Approximately** 36% of the total Se is associated with the Se-GSH Px in rat liver ( Tappel *et al.*, 1984). The enzyme activity is significantly decreased in the absence of dietary Se, and the specific activity of **Se-GSH Px** varies as a logarithmic function of Se in the diet (Chow and **Tappel**, 1974). Se-GSH Px is also involved in the reduction of fatty acid hydroperoxides and cyclic endoperoxides generated during the production of

prostaglandins, **leukotrienes** and related compounds via COX and LOX pathways (Maddipati and Marnett, 1987; Brucchausen *et al*, 1988). As a result of its action on the reduction of hydroperoxides, it is known to be involved in the inhibition of COX and LOX enzymes (Reddanna *et al*, 1989). Therefore, the modulation of Se-GSH Px activity by dietary Se is of great interest because it plays an important role both in the cell defense against oxidative damage and in the regulation of PG and LT biosynthesis (Hong *et al*, 1989; Reddanna *et al*, 1989). Since Se levels are highly correlated with the Se-GSH Px activity, this enzyme is often used as a biochemical marker of Se status in animals. Non-Se-GSH Px activity associated with the GSTs significantly induced during Se deficiency (Lawrence *et al*, 1978; Chang *et al*, 1990), which catalyzes the reduction of organic hydroperoxides only. Selenium deficiency results in loss of GSH Px activity (Hill *et al*, 1987; Ji *et al*, 1988), increased plasma GSH concentration (Hill *et al*, 1987), and increased GSTs in liver (Hill *et al*, 1987; Chang *et al*, 1990), skeletal muscle (Ji *et al*, 1988) and myocardium (Charles Kumar *et al*, 1992; Ji *et al*, 1992a).

Todate, four **Se-GSH Pxs** have been characterized 1. classical GSH Px I (**Flohe *et al***, 1973; Rotruck *et al*, 1973); 2. phospholipid hydroperoxide GSH **Px**, (PHGSH Px) (Ursini *et al*, 1982); 3. plasma GSH **Px**, (GSH Px-P) (Maddipati and Marnett, 1987) and 4. gastrointestinal GSH **Px**, (GSH **Px-GI**) (Chu *et al*, 1993). Similar substrate **specificities** are found for the peroxidases - GSH Px I, GSH Px-P, and GSH Px-GI. All catalyze the reduction of **H<sub>2</sub>O<sub>2</sub>**, **ter-butyl** hydroperoxide, **cumene** hydroperoxide (CHP) and linoleic acid hydroperoxide (Esworthy *et al*, 1991). Low levels of Se are regularly and significantly correlated with the severity of hepatic lesions observed in liver disease and alcoholism (Korpela *et al*, 1985). Also an absolute or relative deficit of Se has been implicated in the development of cancers (Ostero and Prellwitz 1990). The anticarcinogenic action of Se in animal models is well established (**Ip** and Hayes, 1989; **Ip** and Ganther, 1990; Lei *et al*, 1990). The most important human deficiency disease responsible to Se is Keshan's disease, which shows cardiomyopathy (Whanger, 1989). Se toxicity is well

characterized in animals and humans by neurological, hoof and hair alterations (Crinton and O'connor 1978).

#### 1.3.2.4. Glutathione reductase

The catalytic activity of glutathione reductase has a central role in the biochemistry of GSH. It serves to maintain GSH essentially completely in its reduced form (Meister and Anderson, 1983).



The intracellular ratio of GSH, usually maintained by GSH recycle pathway protects the erythrocytes from **H<sub>2</sub>O<sub>2</sub>-induced** oxidative stress in new born babies (Clashen *et al.*, 1992). Exhaustive exercise is also known to increase glutathione reductase in rat skeletal muscles (Ji and Fu, 1992).

#### 1.4.0.0. Vitamin E, selenium and arachidonic acid cascade

Vitamin E and Se-GSH Px could play the more specific role of modulating the enzymic oxidation of AA as shown in the figure 10. The immediate oxygenation products of the enzymatic and nonenzymatic oxidation of AA include the formation of HPETE and cyclic endoperoxides. These products both serve as precursor for the biosynthesis of PG and LT, and have significant influence on the enzymes associated with the AA cascade. Se-GSH Px reduces the reactive fatty acid hydroperoxide (FAHP) and thus influences both the enzyme activities and product profiles.

The free radicals are an integral part of both the COX catalyzed reaction and **LTA<sub>4</sub>** biosynthesis. Vitamin E interferes with the essential radicals involved with the catalytic cycles of LOX **reaction**, thus influencing product **formation**. In addition, **vit.E** can protect the LOX from its self catalyzed inactivation by the free radicals generated during this reaction (Lands *et al.*, 1984). Similarly, vit.E could also modulate the COX catalyzed reaction in which the essential role of free radicals has been established. The COX is a heme requiring enzyme having both




Fig 10 : The proposed role of vitamin E and selenium in the arachidonic acid **cascade**  
 E , vitamin E, Se, selenium; Se-GSH-Px, **selenium-dependent** glutathione peroxidase;  $\ominus$ , inhibition;  $\oplus$ , **activation**; 0 ?, controversial reports,  $\oplus$  , activates at low concentration and inhibits at high **concentration**



oxygenase and peroxidase activities. The peroxidase reaction of COX generates free radicals which can **co-oxidize** a host of xenobiotics, including precarcinogens. **Selenium**, as an integral part of Se-GSH Px is known to involve in this reaction by reducing the endoperoxide to less reactive alcohols (Whelan *et al.*, 1986). Vitamin E as a chain breaking antioxidant has a role in regulating the enzymatic production of these endoperoxides. Thus by removing FAHP activators and essential radicals, Se-GSH Px and vit.E could play a major role in regulating the biosynthesis of PG and LT (Fig. 10) (Panganamala and **Cornwell**, 1980; Reddy *et al.*, 1988; Reddanna *et al.*, 1989). Vitamin E is a potent inhibitor of LOX (Reddanna *et al.*, 1985; 1989) and the mechanism appears to be not based on its antioxidant but by its peroxidase activity (Cucurou *et al.*, 1991). Non-Se-GSH Px associated with GSTs also reduces FAHPs but ~ 50 times less efficient than Se-GSH Px (Hong *et al.*, 1989). Thus, LT biosynthesis by way of **5-LOX** pathway may be partly controlled by cellular FAHP **levels**, which is in turn under the **influence** of Se-GSH Px and **non-Se-GSH Px**.

#### 1.5.0.0. Present scope of the work

Oxygen free radicals generated during normal cellular metabolism are detoxified effectively by efficient antioxidant defense system of the ceD (Freeman and Crapo, 1982). However these defense mechanisms are far from perfect, especially under nutritional deficiency **and/or oxidative** stress, where the rate of oxygen radical generation may exceed the ability of the system to detoxify free radicals, resulting in tissue damage. Although liver is equipped with abundant antioxidant enzymes and other scavenging systems, the high metabolic rate and central role in detoxification make **it** one of the targets for free radical damage in the body, **moreso** under impaired antioxidant defenses. Lung is one of the organ exposed to the highest tissue **pO<sub>2</sub>** under normal conditions and it is possible that oxygen radicals are of special importance during oxidative stress in the lung tissue. In **general**, the cellular free radical defense systems play an important role in preventing a radical-mediated tissue damage. Vitamin E as a scavenger of free radicals and potent inhibitor of lipoxygenases and Se as an integral part of

Se-GSH **Px**, have the potential to protect the tissue from the oxidative stress. GSTs, represent one of the most important detoxifying systems in the liver and **lung** for numerous endogenous as well as exogenous toxicants. The role of GSTs in the detoxification of a number of xenobiotics has been extensively studied. However there is not much emphasis on the involvement of GSTs in the detoxification of endogenous toxicants especially on those formed during oxidative stress. Hence in the present study an attempt is made to study the antioxidant defense mechanisms in the lung and hepatic tissues of rats subjected to oxidative stress by feeding on diets deficient in **vit E** and Se. Among the antioxidant defenses particular attention is laid on glutathione **metabolism**, and glutathione S-transferases. In order to understand the physiological role of GSTs expressed during oxidative stress, the substrate specificities of individual **isozymes** with special reference to the reduction of organic peroxides and biosynthesis of eicosanoids was **undertaken**.

Wistar strain female albino rats at weanling stage were fed with vit.E and Se deficient (-E+Se, +E-Se and -E-Se) and supplemented (+E+Se) diets for a period of 13 weeks to impair and enhance antioxidant defenses respectively in the animals. The vit.E **and/or** Se deficient diets were chosen as they were known to induce oxidative stress in the animals. The first chapter, therefore, includes experiments designed to test the effectiveness of dietary treatment in inducing nutritional deficiency as well as oxidative stress in the rats. This chapter also includes the data on **γ-glutamyl** cycle enzymes to assess the compensatory defense mechanisms in the glutathione metabolism developed in liver and lung tissues in response to induced oxidative stress. In view of the induction of GSTs observed in vit.E **and/or** Se deficient animals, studies on purification and characterization of GSTs expressed in liver and lung tissues were undertaken in the second chapter. In the third chapter, studies on the physiological role of GSTs with special reference to their role in oxidative stress and arachidonic acid metabolism were **undertaken**.

# ***METHODOLOGY***

### 2.1.0.0. Materials

Arachidonic acid, **PGD<sub>2</sub>**, **PGE<sub>2</sub>**, **PGF<sub>2α</sub>**, **GSH**, **GSSG**, vitamin E (d-**α-tocopherol**), **NADPH**, **TBA** (thiobarbituric acid), **Alkaline phosphatase**, **Freund's** complete and incomplete adjuvants, **NBT** (nitroblue tetrazolium), **BCIP** (**5-bromo-4-chloro-3-indoyl** phosphate), **BHT** (**butylated hydroxytoluene**) and **DAN** (**2,3-diaminonaphthalene**) were purchased from Sigma Chemicals Company, St. Louis, **USA**. **<sup>3</sup>H** arachidonic acid was prepared on request by BARC, Bombay, **India**. TLC plates were purchased from Merck, Germany. Ion exchangers (**CM-cellulose**, DE 52 cellulose) were obtained from Whatman England Inc. HPLC grade **acetonitrile**, methanol, acetic **acid**, **trifluoroacetic acid**, triethylamine were purchased from SD fine Chemicals India Ltd., and **Spectrochem**, India Ltd. All other chemicals which have not been mentioned were procured from local chemical companies and were of high quality grade.

### 2.2.0.0. Animals and Dietary treatment

Wistar strain female albino rats at weanling stage weighing approximately 40 g were divided into 4 groups of twelve **each**. The basic diet (without vitamin E and selenium) (Table 3) was supplemented with 0.5 **mg** Se/Kg diet, as sodium **selenite**, and/or with 100 IU vitamin **E/Kg** diet, as d **α-tocopheryl** acetate to create the following dietary groups: -E+Se, +E-Se, **-E-Se** and +E+Se. The rats were housed in individual cages, given distilled water *ad libitum* and maintained on the diet for 13 weeks. Weight gained by the animals was monitored weekly.

After 13 weeks on the experimental diets, animals were anaesthetized with ether and subjected to a whole body perfusion with a chilled 0.85% NaCl solution to remove the circulating blood from the tissues. Lung and liver tissues were excised and rinsed with ice-cold deionized water to remove any residual blood and stored at -80° C until used. Only female rats were employed in the present studies to avoid the sex differences if any in the parameters studied.

**Table 3: Composition of the vitamin E and Se deficient diet**

<b>COMPONENT</b>	<b>AMOUNT %</b>
Vitamin free casein	20
Cellulose	5
Sucrose	63.7
Mineral mixture*	4
Vitamin mixture**	1
Choline chloride	1
DL-Methionine	0.3
Vitamin free corn oil	5

\* Selenium added as sodium selenite (0.5 **mg/Kg** diet) for the supplemented diets.

•• Vitamin E added as tocopheryl acetate (**100 IU/Kg** diet) for the supplemented diets.

### 2.3.0.0. Estimation of vitamin E

Vitamin E levels in liver and lung tissues were analyzed by HPLC as per the method described by Arun Sharma and Ajay Kumar, 1990 using D  $\alpha$ -tocopheryl acetate as an internal standard.

#### 2.3.1.0. Sample preparation


200 mg tissue was taken and homogenized in 1 mL of ethanol. To this homogenate 10 mg of internal standard was added. The sample was vortexed for about 1 min and 1 mL of n-Hexane was added and the mixture was again vortexed for 1 min. The sample was centrifuged for 5 min at 3000 rpm and the hexane layer was separated. This process of extraction was repeated again and the hexane pool was evaporated to dryness under a stream of nitrogen and the residue was dissolved in 100  $\mu$ L of methanol:diethyl ether (75:25 v/v).

#### 2.3.2.0. HPLC separation of vitamin E

50  $\mu$ L of tissue vitamin extract was injected onto the Shimpak CLC-ODS (0.45 X 25 cm) column and separated on Shimadzu LC 6AD HPLC system with methanol as the solvent at 1 mL/min flow rate. The eluant was monitored either on UV/VIS detector (297 nm) or fluorescence detector (Ex 295 nm, Em 340 nm). d- $\alpha$ -tocopheryl acetate was used as the internal standard. Tissue vit.E levels were calculated based on HPLC integration data of the sample and standard. A typical chromatogram of vitamin E separation on HPLC was presented in Fig. 11.

### 2.4.0.0. Estimation of selenium

Selenium was estimated according to the method of Alfthan (1984). Lung/liver tissue sample (100 mg), standards and blanks were taken into separate test tubes. The test tubes were covered with aluminium foils and few antibumping granules were added. To these tubes 0.4 mL of 1:20 sulfuric:perchloric acid (v/v) was added as digestion mixture, which results in complete recovery of resistant



**Fig. 11: Separation of vitamin E on RP-HPLC**

Column.	ODS, $\mu$ Bondapak (Waters)
Solvents:	Methanol
Flow rate:	1 mL/min
Detection:	296 nm


selenium species present in biological samples. The tubes were transferred to a heating block at ambient temperature in a fume hood and then the temperature of the block was raised to 120°C, slowly over a period of 40 **min** and the block was maintained at the same temperature for 20 **min**. Nitric acid (0.5 **mL**) was added to prevent charring of the sample. The block temperature was next set to 150° C for 1 hr followed by 180° C for 1.5 hr. The cessation of boiling and the evolution of perchloric acid fumes were taken as signs of complete digestion, which occurred between 60 to 90 **min**. At the end of heating period the digest was colorless.

The test tubes were cooled and a few drops of 30% hydrogen peroxide were added to each tube and heated for 10 min at 150° C. This step was repeated because **fumes** of nitrogen dioxide were observed. To each cooled tube 1 mL of 6 N HCl was added and the tubes heated at 110° C for 10 **min**. The tubes were removed from the heating **block**, 1 mL of 6 M formic acid and 1.5 mL of EDTA reagent were added to each tube and the contents were mixed **well**. The pH was adjusted to 1.5-2.0 with 4 M **ammonia**. Hereafter the tubes were protected from direct light by wrapping them with aluminium foil. To these tubes a 1 mL of 0.1% DAN reagent was **added**, mixed well and were placed in a water bath at 50° C for 30 **min**. The tubes were cooled briefly in cold water to facilitate better separation of phases, and then 2.5 mL cyclohexane was added. The tubes were stoppered and extracted vigorously, by shaking for 30 sec. The cyclohexane layer was transferred to 1-cm cuvette with a pasteur pipette and the fluorescence was measured at excitation and absorption wavelengths of 369 and 518 nm respectively using cyclohexane as blank in a fluorescence **spectrophotometer**.

#### 2.5.0.0. Estimation of malondialdehyde (MDA)

Lipid peroxidation was **measured**, as MDA levels, via TBA reaction using HPLC (Bird *et al*,1983). 350 **mg** of tissue was homogenized in 0.5 **mL** of 1.15% KCl and 0.5 **mM** BHA (in methanol) was added. To the sample 3 mL of 0.44 **mol** of  $\text{H}_3\text{PO}_4/\text{L}$  was added. After 10 min 0.042 mM TBA was added. The contents





**Fig. 12: RP-HPLC analysis of MDA**

Column: ODS,  $\mu$  Bondapak (Waters)  
Solvents: **Methanol: Water:** Acetic acid  
(65:35:0.1) pH 5.7  
Flow rate: 1 mL/min  
Detection: 280 nm

were heated for 30 **min** at 90° C and after cooling 10 **uL** of the sample was loaded onto **RP-HPLC**.

The sample was loaded onto **C<sub>18</sub>**u Bondapak (3.9 X 300 mm) column and eluted with 50 **mM KH<sub>2</sub>PO<sub>4</sub>**, pH 7.0:methanol (65:35) at 1 **mL/min** flow rate. The eluant was monitored at 532 **nm** (Fig. 12). The **trimethoxy** pentane was used as external standard. Basing on HPLC integration data and on comparison with the standard value, the concentration of MDA was calculated and expressed as **nmol** of MDA/g wet tissue.

## 2.6.0.0. Antioxidant defense systems

### 2.6.1.0. Assay of glutathione peroxidases

Perfused tissues were homogenized (20% w/v) in 25 **mM Tris-HCl**; pH 7.4, containing 1 **mM** EDTA, 2 **mM** GSH and 250 **mM** sucrose. The homogenate was centrifuged at 10,000 X g for 30 **min**. The activity was measured by monitoring the oxidation of NADPH at 340 **nm** in a reaction mixture containing 250 **mM** phosphate buffer; pH 7.0, 2.5 **mM** EDTA, 2.5 **mM** sodium azide, 1 **mM** **GSH**, 0.2 **mM** NADPH and enzyme, incubated for 5 **min** at room temperature. Total GSH Px activity was assayed by using 1.5 **mM** **cumene** hydroperoxide to initiate the **reaction**. The Se-GSH Px activity was assayed by using 0.25 **mM** hydrogen peroxide to initiate the **reaction**. Non-Se-GSH Px activity was calculated by subtracting Se-GSH Px activity from the total peroxidase activity (Reddy *et al.*, 1981). One unit of activity was defined as one **nmole** of NADPH oxidized per **min**.

### 2.6.2.0. Estimation of GSH/GSSG

**GSH/GSSG** in **tissue** samples was measured by a slightly modified HPLC method (Jayatilleke and Shaw, 1993). All animals were anesthetized with anesthetic ether prior to operation for tissue **perfusion**. Following **anesthesia**, the


whole tissue was perfused *in situ* via the portal vein with iced KCl to remove blood.

The perfused tissue (~ 1 g) was homogenized at 0° C for 30 s in 4 vol of iced 1.15% KCL. The homogenate was then immediately diluted 1:1 with 4% sulfo salicylic acid. Just prior to deproteinization, p-aminobenzoyl glutamate (Paba Glu) was added as an internal standard. The acidified samples were spun at 20,000 X g for 10 min and passed through a Sep-Pak Cartridge (waters) previously conditioned with 2 volumes of elution buffer. The filtrate was then analyzed for GSH/GSSG.

Samples were usually diluted in elution buffer 1:10 prior to loading into HPLC. Dilutions of 1:5 were used to measure GSSG in samples. After injecting, the compounds were eluted isocratically at 1 mL/min using 2.5 mM sodium phosphate buffer, pH 3.5; containing 0.005 M PIC-A (tetrabutylammonium phosphate) and 10% methanol and analyzed on 30 cm X 3.9 mm C<sub>18</sub>  $\mu$  Bondapak column. Peaks were detected by UV absorbance using a Shimadzu SPD-6AV UV-VIS detector at a wavelength of 190 nm. As shown in Fig. 13, areas were corrected for recoveries to the Paba Glu added as an internal standard. The column was regenerated by washing for 15 min with 50% methanol followed by 30 min of equilibration with elution buffer.

#### 2.6.3.0. Assay of $\gamma$ -glutamylcysteine synthetase

$\gamma$ -Glutamylcysteine synthetase activity was determined by the procedure described by Igarashi *et al* (1982). The standard assay reaction mixture (1.0 mL) contained 100 mM Tris-HCl; pH 8.2, 10 mM sodium L-glutamate, 10 mM L- $\alpha$ -aminobutyrate, 20 mM MgCl<sub>2</sub>, 5 mM disodium ATP, 2 mM EDTA, 10 mM sodium L-glutamate, 10 mM L-a-aminobutyrate, 20 mM MgCl<sub>2</sub>, 5 mM discidium ATP, 2 mM EDTA, 0.02 mg BSA and enzyme. The reaction was initiated by the addition of ATP. After incubation at 37° C for 30 min, the reaction was terminated by adding 1 mL of 10% TCA and centrifuged. The inorganic



**Fig. 13: Separation of GSH, GSSG and Paba Glu on HPLC**

Column: ODS,  $\mu$ i Bondapak (Waters)  
 Solvents: 13% Methanol in 25 mM  $\text{NaH}_2\text{PO}_4$ , pH 3.4 containing PIC-A  
 Flow rate: 1 mL/min  
 Detection: 190 nm  
 Sample: 250 ng each

phosphate released was determined by the method of Fiske and Subbarow (1925). One unit of enzyme activity was defined as the amount that catalyzes the release of 1 **nmole** of phosphate per **min**.

#### 2.6.4.0. Assay of glutathione reductase

Glutathione reductase was estimated according to the method of **Carlberg** and Mannervik (1985). The tissues were homogenized (20% w/v) in 10 **mM** phosphate buffer, pH 7.0 containing 1 **mM** EDTA and centrifuged at 10,000 X g for 30 min followed by 105,000 X g for 1 **hr**. The supernatant was used for enzyme assay. The reaction mixture in a volume of 1 mL contained 100 **mM** sodium phosphate; pH 7.6, 1 **mM** GSSG, 0.5 **mM** EDTA, 0.1 **mM** NADPH and enzyme source. The NADPH oxidation was recorded at 340 **nm** on UV/VIS spectrophotometer and the values expressed in **units/mg** protein. One unit of activity was defined as one nmole of NADPH oxidized per mm.

#### 2.6.5.0. Assay of $\gamma$ -glutamyl transpeptidase

$\gamma$ -Glutamyl transpeptidase activity was assayed with **L- $\gamma$ -glutamyl-p-nitroanilide** as substrate (Sato *et al.*, 1980). The tissues were **perfused** and homogenized (20% w/v) by adding **ice-chilled 1.15% KCl**. The standard assay mixture contained 50 **mM** Tris-HCl, 20 **mM** glycylglycine, 10 **mM** MgCl<sub>2</sub>, 4.4 **mM** **L- $\gamma$ -glutamyl-p-nitroanilide**, pH 8.0; in a final volume of 1 mL. The reaction was initiated by the addition of protein sample and incubated at 37° C for 30 min. One unit was defined as the formation of one **pmole** of **p-nitroanilide** formed/min.

#### 2.6.6.0. Assay of glutathione S-transferases

GST activity with CDNB was determined **spectrophotometrically** as **described** by Reddy *et al* (1983). Activities with other classical substrates were assayed as described by Habig and Jakoby (1981) (Table 4). All enzyme assays were carried out **spectrophotometrically** at 25° C. Blank activities were measured

**Table 4: Summary of assay conditions for various GST substrates**

Substrate	Buffer pH	[Substrate] mM	[GSH] mM	Absorbance nm	$\Delta\epsilon$
1,2-Dichloro-4-nitrobenzene	7.5	1.0	5.0	345	8.5
1-Chloro-2,4-dinitrobenzene	6.5	1.0	1.0	340	9.6
$\Delta^5$ -Androstene-3,17-dione	8.5	0.068	0.1	248	16.3
1,2-Epoxy-3-(p-nitrophenoxy)-propane	6.5	0.5	5.0	360	0.5
4-Nitropyridine-N-oxide	7.0	0.2	5.0	295	7.0
p-Nitrobenzyl chloride	6.5	1.0	5.0	310	1.9
Ethacrynic acid	6.5	0.2	0.25	270	5.0
p-Nitrophenyl acetate	7.0	0.2	0.5	400	8.79
Bromosulfophthalein	7.5	0.03	5.0	330	4.5
Cumene hydroperoxide	7.0	0.03	1.0	340	6.2
Hydrogen peroxide	7.0	0.25	1.0	340	6.2
t-Butyl hydroperoxide	7.0	1.5	1.0	340	6.2
13-HODE	7.0	0.03	1.0	340	6.2
15-HPETE	7.0	0.03	1.0	340	6.2

in the absence of enzyme and subtracted from experimental values to correct for possible **non-enzymatic** reactions. One unit of enzyme activity was defined as one **nmole** of product formed or one **nmole** of substrate consumed per **min**. Specific activities were given in **units/mg** protein.

### 2.7.0.0. Purification of GSTs

All purification steps were carried at **0-4°C**. After each dialysis step all the samples were centrifuged at 10,000 X g for 30 min in a Kubota centrifuge to remove denatured **protein**. The protein **concentration**, GST activity and **non-Se-GSH Px** activity were determined at each step of purification. The following buffers were used during purification of GSTs from tissues. Buffer A: 22 **mM** potassium phosphate, pH 7.0; Buffer B: 10 **mM** sodium phosphate, pH 6.0; Buffer C: 10 **mM** **Tris-HCl**, pH 8.0. A typical rat tissue purification of GSTs preparation was performed as follows:

#### 2.7.1.0. Preparation of crude extract

Female wistar strain albino rats of vit.E **and/or** Se supplemented and deficient dietary groups were **anesthetized**, liver and **lung** tissues were perfused and tissues were excised. The tissues were minced and homogenized in a **waring** blender to 20% (w/v) with buffer A containing 250 mM sucrose for 5 min and then in a porter elvehjem homogenizer with a teflon pestle. The homogenate was centrifuged at 10,000 X g for 30 min a Kubota centrifuge. The supernatant was filtered through glass wool to remove the floating **lipid** material and the filtrate **centrifuged** at 105,000 X g in a **Beckman** centrifuge using Ti 70 rotor. The final supernatant was passed through the glass **wool/cheese cloth**. The filtrate thus obtained was taken as cytosol of the tissue and referred to as the crude extract. The crude extract was **dialyzed** for 24 hr against 10 volumes of buffer A to remove the endogenous GSH which interferes with the binding of GSTs to the affinity **column**. The **dialyzed** tissue cytosol was applied onto GSH affinity **column**.

### 2.7.2.0. Glutathione linked **epoxy** activated **sepharose-6B** column

One **gm** of GSH was coupled to ten **gm** of epoxy activated sepharose-6B by the procedure of Simons and Vander Jagt (1977). The column was equilibrated with buffer A and the flow rate was adjusted to about 60 **mL/hr**. The dialyzed cytosol sample was applied onto the column and washed with the same buffer until no protein was recorded in the effluent. At that stage, the column was developed with 0.05M **Tris-HCl**, pH 9.6 containing 5 **mM** GSH. Activity appears as a single sharp peak of activity. The active fractions were concentrated and dialyzed as in the previous step.

### 2.7.3.0. Cation exchange **chromatography** on **CM-cellulose** column

The concentrated liver affinity purified GSTs of +E+Se animals was applied to a **CM-cellulose** column (2.5 X 15 cm), previously equilibrated with buffer B. The column was washed with the same buffer until the absorbance of the effluent at 280 **nm** was zero. The elution buffer was then changed to two linear gradients used in **succession**, 0-75 **mM** KCl and 75-200 **mM** KCl in buffer B. The first gradient was prepared from 500 **mL** of buffer B and the same amount of buffer B containing 75 **mM** KCl. The second one was prepared from 100 **mL** of buffer B containing 75 **mM** KCl and 100 **mL** of buffer B containing 200 **mM** KCl.

The active GST flow through fractions were referred to as the anionic peak. The sum of transferase activity in all fractions was calculated to estimate the total GST activity in each peak. The **cationic** peaks were pooled individually and concentrated by Centricon microconcentrator (**Amicon** Co, Danvers, MA) to determine the **subunit** composition with SDS gel electrophoresis. The anionic fractions were pooled and dialyzed against 100 volumes of buffer C for 24 hr (with 2 changes).



#### 2.7.4.0. Anion exchange chromatography on DE 52 cellulose Column

The dialyzed anionic sample from the previous step was loaded onto a DE 52 cellulose column (2.5 X 15) previously equilibrated with buffer C. The column was washed with the same buffer until the absorbance of the effluent at 280 nm was zero. The elution buffer was then changed to a linear gradient of 0-100 mM KCl prepared from 100 mL of buffer C and the same amount of buffer C containing 100 mM KCl.

#### 2.7.5.0. High performance liquid chromatography

Affinity purified GSTs of liver and lung tissues from vit.E and/or Se supplemented and deficient animals were further analyzed by reverse-phase HPLC (RP-HPLC) (Ostlund *et al.*, 1987) using a Bondapak C<sub>18</sub> (3.9 X 300 mm) column with minor modifications (Veera Reddy *et al.*, 1995). The column was eluted with a gradient elution using 0.1% (v/v) trifluoroacetic acid in 35% acetonitrile (solvent A) and 0.1% (v/v) trifluoroacetic acid in 85% acetonitrile (solvent B) solvent systems. The sample was injected in 100% solvent A and eluted with a linear gradient of 0-40% solvent B over a period of 45 min (Veera Reddy *et al.*, 1995). The eluted polypeptides were monitored at 214 nm and their relative abundance was determined from integrated peak areas. The relative subunit concentration was represented in arbitrary units. The induction of every subunit was calculated from RP-HPLC data and the total protein recovered at the final step of affinity purification protocol (Derbel *et al.*, 1993; Veera Reddy *et al.*, 1995).

#### 2.8.0.0. GST catalyzed Prostaglandin biosynthesis

##### 2.8.1.0. Extraction of PGs

The coupled assay system (standard incubation mixture) in a total volume of 1 mL contained 150 mM Tris-HCl, pH 8.0; 2 mM EDTA; 5 mM tryptophan, 1 mM GSH, 100 µg GSTs, 5 units of PGH synthase and 100 µM arachidonic acid containing 0.1 µCi <sup>14</sup>C arachidonic acid. The reaction mixture was incubated at

30°C for 1 **min** prior to the addition of 1 **mM hematin** to initiate the **reaction**. After incubation for 1 **min**, the reaction was quenched with 6 N HCl and reaction products were extracted twice with 3 volumes of **chloroform**. Organic phases were pooled and evaporated under **N<sub>2</sub>** and the residue was dissolved in a small volume of solvent system for TLC analysis.

#### 2.8.1.1. TLC analysis of PGs

The samples were spotted on TLC plates and the solvent system used for TLC was of ethyl acetate: **trimethyl** pentane: acetic acid: water (110:50:20:100) by the method of Chang *et al* (1987a). For **quantification**, the TLC plates were sprayed with 50% sulfuric acid and then heated at 120°C for 10 **min**. Different compounds were identified by their R<sub>f</sub> values with reference to the respective standards. The spots corresponding to respective prostaglandin standards on TLC plates were scraped **off** individually and the radioactivity was **quantitated** on liquid scintillation counter (**Beckman model-1800**). Activity levels were expressed in terms of % ratios of total PGs formed after deducting **non-enzymatically** formed PGs.

#### 2.9.0.0. GST catalyzed LTC<sub>4</sub> Synthesis

##### 2.9.1.0. Incubation and Extraction

The reaction mixture in a final volume of 1 **mL** contained 75 mM **Tris-HCl** (pH 8.0), 5 **mM** freshly prepared GSH and 100 **µg** of affinity purified GSTs or 25 **µg** of individual isozymes separated on **CM-cellulose** and DE 52 column **chromatography**. The reaction was initiated by transferring reaction mixture into **LTA<sub>4</sub> Me** (final concentration 30 **µM**) test tube, which was **previously** evaporated to dryness under **N<sub>2</sub>** gas. After 10 min of incubation the reaction was terminated by adding 200 **uL** of 6 N HCL. The blanks without GSTs were processed separately. The reaction mixture was then passed through a **C<sub>18</sub> Sep-Pak** cartridge (millipore) which was previously equilibrated with methanol and water. After

passing the sample through the cartridge, it was washed with 10 mL of double distilled water and air-dried. The adsorbed sample was then eluted with 2 mL of **methanol** each time and evaporated to dryness under nitrogen and redissolved in HPLC solvent.

#### 2.9.2.0. HPLC analysis

GST catalyzed **LTA<sub>4</sub>** Me products were separated on HPLC (Shimadzu LC 6AD) by the method of Chang *et al* (1987b) using **C<sub>18</sub>** column (3.9 X 300 mm) with the solvent system of methanol:water:acetic acid (65:35:0.1) (pH adjusted to 5.7 with TEM) at a flow rate of 1 mL/min. The eluant was monitored at 280 nm (SPD-6AV UV-VIS spectrophotometric detector) and identified based on the UV-VIS spectra and chromatography with standards. The **LTC<sub>4</sub>** Me formed was quantified basing on HPLC integration data and molar extinction coefficient of **LTC<sub>4</sub>** (40,000 cm<sup>-1</sup> mM<sup>-1</sup>).

#### 2.10.0.0. SDS Poly acrylamide gel electrophoresis (SDS-PAGE)

Poh/acrylamide gel electrophoresis was conducted according to the method of Laemmli (1971) in a 0.1% SDS on a vertical slab system. The gels contained 12% acrylamide with a 29:1 ratio of **acrylamide** to **N,N,N',N'-methylene-bis-acrylamide**.

Samples were boiled at 100<sup>o</sup> C for 5 min in the presence of loading dye containing SDS (0.1%), **2-mercaptoethanol** (5% v/v), **bromophenol blue** (0.001% w/v) and **glycerol** (10% v/v) in 63 mM **Tris-HCl**, pH 6.8. The protein mixtures were then subjected to electrophoresis on 3% (w/v) **polyacrylamide** stacking gel to dissociate proteins into their individual **polypeptide** chains in 125 mM **Tris-HCl**, pH 6. The electrode buffer contained 25 mM Tris base, 192 mM **glycine** and 0.1% SDS.

After the completion of the electrophoresis the gel was fixed in 7.5% acetic acid and 50% methanol and later developed with silver nitrate (Oakley *et al.*,

1980). Standard molecular weight markers of Pharmacia were simultaneously run and the molecular weight of the interested peptide was calculated using UVP-2000 gel documentation software **program**.

### **2.11.0.0. Immunological Studies**

#### **2.11.1.0. Raising of antisera against purified proteins**

Antibodies (Abs) were raised against affinity purified rat liver GSTs and their corresponding subunits; Ya (pooled **Ya<sub>1</sub>** and **Ya<sub>2</sub>**), Yb (pooled **Yb<sub>1</sub>** and **Yb<sub>2</sub>**) and **Yc** recovered from **RP-HPLC**. Similarly for **lung** tissue also antibodies were raised against lung affinity purified GSTs and Yc, Yb (pooled **Yb<sub>1</sub>** and **Yb<sub>2</sub>**), Yk and Yp subunits which were recovered from **RP-HPLC**. An antigen preparation at a final protein concentration of 0.4 to 1.0 **mg/mL** was mixed with an equal volume of Freund's complete adjuvant. The suspension was emulsified thoroughly before injecting subcutaneously at 6-8 sites on the dorsal part of New Zealand white male rabbits of 3 months old. Further immunization was carried out on days 7, 14 and 21. Some of the rabbits received one more injection on day 28 in order to elicit a stronger response. One week after the completion of the immunization series, rabbits which were found to contain useful titers of antibodies against the injected **protein**, as determined by double diffusion tests, were bled and the sera were collected and stored at -20°C.

#### **2.11.2.0. Western blot analysis (Immunoblotting)**

Western blot analysis of rat liver and lung tissue GSTs were conducted according to the published procedure of Towbin *et al* (1979). Equal amounts of cytosolic proteins from the tissue samples were separated by SDS-PAGE and **electroblotted** onto nitrocellulose sheets by semi dry blotting protocol of LKB. The gels were initially soaked in buffer A consisting of 20 **mM Tris-HCl** and 192 **mM** glycine in 20% **methanolic** water. The separated **peptides/proteins** were transferred with a current of 0.8 **mA/cm<sup>2</sup>** for 4h. The nylon membrane was then

blocked in solution B consisting of 20 **mM Tris-HCl**, pH 7.5; 500 **mM NaCl** and 2% Tween-20 for 3 **min**. Then nylon membrane was washed with buffer C consisting of 20 **mM Tris-HCl**, pH 7.5; 500 mM NaCl and 0.05% Tween-20 for 10 min followed by buffer D consisting of 20 mM **Tris-HCl**, pH 7.5; 150 mM NaCl and 0.05% Tween-20 for 10 min X 3 times each. The nylon membrane was then treated with buffer D containing 1% non fat dried milk and the primary antibody for **1hr**. The membrane was then washed thoroughly for 30 min with buffer C to remove non-specific binding of the antibody with the membrane. The membrane was then treated with buffer D containing secondary Ab (alkaline phosphatase) and allowed to bind to primary Ab for 1 hr. The nylon membrane was then washed with buffer C for 10 m X 3 times each and finally developed with buffer E consisting of 100 mM Tris-HCl; pH 9.5, 100 mM **NaCl**, 5 mM **MgCl<sub>2</sub>**, 4 mM NBT, 4.5 **mM BCEP** till the blue color appears on the membrane. The reaction was stopped by changing the membrane from buffer E to distilled water and later dried for photography.

#### **2.12.0.0. Protein Estimation**

Protein concentrations were estimated by the method of Lowry *et al* (1951) and also by the method of Warburg and Christian (1941). Blanks were subtracted where appropriate to correct for absorbance due to the interference of the buffers in the assay.

#### **2.13.0.0. Statistical analysis**

The data was analyzed with one-way analysis of variance followed by Student Newman Kucl's test. The significance was set at **P<0.05**.

# ***CHAPTER I***

### 3.1.0.0. INTRODUCTION

Molecular oxygen is an essential nutrient for higher forms of life. In addition to its normal physiological reactions, oxygen and **its** partially reduced forms, ROS oxidize a variety of macromolecular and simpler compounds in cells and fluids of the body. When ROS production is excessive, such as during prolonged aerobic exercise, or when antioxidant defense is severely hampered by nutritional deficiencies, or pharmacological intervention, an inadequate defense may be overwhelmed by the ROS, leading to extensive cell and tissue damage (Esterbauer *et al*, 1991).

When PUFAs on the biomembranes are attacked by free radicals in the presence of molecular **oxygen**, a chain of peroxidative reactions occur, eventually leading to the formation of hydrocarbon gases and aldehydes (eg; malondialdehyde). Byproducts of lipid peroxidation are the most frequently studied markers of oxidative tissue damage. As a protection against excessive oxidation, nature has developed a complex set of interactive antioxidant systems. Biological antioxidants include SOD, catalase,  **$\gamma$ -glutamyl** cycle enzymes like Se-GSH Px and glutathione reductase. Nonenzymatic biological antioxidants include tocopherols, ascorbic acid and glutathione. Nutritional deficiency provides an excellent model to study the dynamic balance between oxidative challenge and antioxidant defense in the biological **system**. Among the nutritional deficiencies, vit.E and Se form the most important dietary factors contributing **to** tissue antioxidant defenses.

Vitamin E functions as an important cellular antioxidant in the hydrophobic compartments, protecting PUFAs from lipid peroxidation (Burton and **Ingold**, 1989; Kagan *et al*, 1989). Consequently dietary vit.E deprivation and/or exercise may result in increased lipid peroxidation products such as MDA and possible disruption of membrane function (Sjodin *et al*, 1990; Tiidus *et al.*, 1993). Selenium has been recognized as an essential trace element in animal nutrition playing a protective role against peroxidative damage in the animal cells, mainly in

the form of GSH Px (Sunde and **Hoekstra**, 1980). Se deficiency is known to result in the loss of GSH Px activity, the enzymes involved in the reduction of hydroperoxides (Hill *et al.*, 1987; Ji *et al.*, 1988). The role of vit.E and Se in the prevention of coronary heart disease (**Van-Poppel** *et al.*, 1994; **Luoma** *et al.*, 1995), muscle damage and soreness (Kanter, 1994), cystic fibrosis (Kauf *et al.*, 1995) and cancer (Schwartz *et al.*, 1994) has been extensively studied. Although liver is equipped with abundant antioxidant enzymes and other scavenging systems, the high metabolic rate and central role in detoxification make it one of the main targets for free radical damage in the body, **moreso** under impaired antioxidant defenses. Animals fed on diet deficient in **vit.E and/or Se** nutrients develop a number of pathological conditions (Scott, 1978). In addition to respiratory **function**, the lung offers a first line of defense against environmental toxicants, pollutants and oxidants. **Lung** is the principal target organ for oxygen poisoning in mammals. Severe morphological and **functional** alterations in the **lung** are caused by hyperoxic conditions, often resulting in death (Crapo *et al.*, 1980b). Selenium deficiency has been shown to augment the pulmonary toxic effects of oxygen exposure in the rat (Hawker *et al.*, 1993).

A stable **intracellular** redox state is of vital importance to organisms (Krentzchmar and Klinger, 1990). Many enzymes require the essential **thiols** to be kept in reduced state. As the most important non-protein **thiol** source, GSH concentration in the cell is remarkably **high**. Liver is the major organ for *de novo* GSH synthesis and supplies 90% of the circulating GSH (Potter and **Tran**, 1993). From the studies in mice and rats, liver has been recognized as the central organ of the interorgan homeostasis of GSH, serving as the principal source of GSH for plasma (Lauterburg *et al.*, 1984). Lung, like liver and kidney shows a high rate of GSH turnover (Martensson *et al.*, 1989). Studies in isolated **perfused** rat **lung** indicate use of plasma GSH by the lung. **Thus** GSH and associated enzyme systems play an important role in mediating cellular antioxidant defenses. Liver and lung are the main tissues vulnerable to oxidative damage in animals subjected to oxidative stress. Hence in the present study the rate of **lipid** peroxidation and



the metabolism of glutathione in liver and lung tissues were analyzed in animals fed on vit.E and Se deficient diets in order to assess the oxidative stress induced in relation to the animals fed on vit.E and Se supplemented diets.

### **3.2.0.0. RESULTS**

Wistar strain female albino rats at weanling stage were divided into four groups of **12** animals each and they were fed on -E+Se, +E-Se, -E-Se and +E+Se diets for a period of 13 weeks. After the dietary treatment period, animals were killed by cervical dislocation. Liver and lung tissues were excised after perfusion with physiological saline and kept in **-80°C** until used for biochemical analysis.

#### **3.2.1.0. Vitamin E**

Feeding vit.E deficient (-E+Se, -E-Se) diet for a period of 13 weeks to wistar strain female albino rats, starting from the weanling stage, resulted in a significant decrease in vit.E levels both in liver and lung tissues when compared to supplemented animals (+E-Se and +E+Se) (Fig. **14A&B**). Vitamin E levels in these tissues fell to approximately 10% of levels of **+E+Se** animals.


#### **3.2.1.2. Selenium**

Similarly feeding animals with Se deficient diets (+E-Se and -E-Se) resulted in significant depletion of Se both in lung and liver tissues (Fig. **15A&B**). Selenium levels in the tissues of Se deficient animals fell to 5% of levels in Se supplemented animals.

#### **3.2.1.3. Growth and tissue somatic indices**


The dietary treatment given for a period of 13 weeks starting from weanling stage resulted in significant changes in the growth pattern (Fig. **16**) and tissue somatic indices (Fig. **17A&B**). Animals fed on vit.E and Se supplemented diets (+E+Se) maintained the highest growth pattern compared to all other groups,

**Fig. 14: Vitamin E levels in liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets for 13 weeks**




Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test.  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 15: Selenium levels in liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**




Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test.  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 16: Growth curves of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of 12 individual observations.

**Fig. 17: Tissue somatic indices of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean  $\pm$  SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

throughout the period of dietary treatment. Animals fed on -E-Se diets, on the other hand, showed the reduced growth rate compared to all the other groups studied. The other two groups (+E-Se and -E+Se) showed intermediate growth rate between +E+Se and -E-Se groups. Tissue somatic indices (TSI) of both liver and lung tissues were significantly lower in the +E+Se group of rats compared to all other groups (Fig. 17A&B).

#### 3.2.1.4. Lipid Peroxidation

RP-HPLC analysis was used to separate lipid peroxides in the form of MDA adduct from other chromogens absorbing at 532 nm. Use of HPLC eliminates artifacts due to the reaction of TBA with other body-fluid constituents to give different chromogens. As shown in Fig. 18A, significantly higher concentrations of MDA were observed in liver tissue of -E+Se (32%), +E-Se (106%) and -E-Se (136%) group of animals when compared to supplemented (+E+Se) animals. Similarly in lung tissue also higher levels of MDA were observed in -E+Se (35%), +E-Se (161%) and -E-Se (200%) animals when compared to supplemented animals (Fig. 18B).


#### 3.2.2.0. Antioxidant defense systems

The levels of cytosolic antioxidant enzymes like **Se-glutathione** peroxidase,  **$\gamma$ -glutamylcysteine** synthetase, glutathione reductase,  **$\gamma$ -glutamyl** transpeptidase and glutathione S-transferases were measured in liver and lung tissues of rats fed on the different diets. The levels of GSH and GSSG were determined in perfused tissues immediately after isolation.

##### 3.2.2.1. Se-glutathione peroxidase


Se-GSH **Px**, the enzyme involved in the reduction of inorganic and organic hydroperoxides, activity levels reached to insignificant levels in liver and lung tissues of Se deficient animals (+E-Se and -E-Se) compared to the Se supplemented ones (-E+Se and +E+Se) (Fig. 19A&B). This observation suggests

**Fig. 18: Lipid Peroxidation in liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test.  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 19: Activity levels of Se-GSH Px with  $H_2O_2$  in the cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).



the efficiency of dietary treatment in depleting tissue Se levels and thereby decreasing the activity levels of **Se-dependent** enzymes.

### 3.2.2.2. Reduced glutathione

The levels of both GSH and GSSG were determined simultaneously on RP-HPLC. In liver tissue GSH levels were significantly higher in +E-Se (66 %) and -E-Se (83.4%) animals when compared to +E+Se animals. In contrast, GSH levels in lung tissue were significantly lower in -E+Se (-24%), +E-Se (**-41.8%**) and -E-Se (-55.22%) animals when compared to +E+Se animals (Fig. **20A&B**).

### 3.2.2.3. Oxidized glutathione

In liver and lung tissues the levels of GSH were 5 fold higher than GSSG levels. GSSG levels in liver of Se deficient animals were significantly lower (-45% in +E-Se and **-45.7%** in -E-Se) when compared to Se supplemented (-E+Se and +E+Se) animals (Fig. **21 A**). However in lung tissue GSSG levels were significantly higher in -E+Se (70%), +E-Se (**181%**) and -E-Se (**216%**) animals when compared to that of +E+Se animals (Fig. **21B**).


### 3.2.2.4. $\gamma$ -Glutamylcysteine synthetase

Glutamylcysteine synthetase activity levels in both liver and lung tissues of -E+Se, +E-Se, and -E-Se animals were significantly higher compared to +E+Se groups (Fig. **22A&B**). In liver tissue GCS levels were significantly higher in -E+Se (70%), +E-Se (109%) and -E-Se (153%) group of animals. Similarly, in lung tissue higher levels of GCS were observed in -E+Se (40%), +E-Se (197%) and -E-Se (**210%**) groups when compared to +E+Se animals.

### 3.2.2.5. Glutathione reductase


Glutathione reductase activities in the present study were increased in the liver and lung of all deficient rats when compared to supplemented animals. The

**Fig. 20: Levels of GSH in liver and lung tissues of rats fed on vit.F. and/or Se supplemented and deficient diets**




Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 21: Levels of GSSG in liver and lung tissues of rats fed on vit E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test.  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 22: Activity levels of  $\gamma$ -glutamylcysteine synthetase in the cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test  
 Bars labelled with same letter are not significantly different from  
 one another ( $p < 0.05$ ).

hepatic glutathione reductase activities were significantly higher in -E+Se (46%), +E-Se (61%) and -E-Se (81%) animals when compared to that of +E+Se animals (Fig. 23A). Similarly in **lung** tissue, all deficient groups showed significantly higher levels (40% in -E+Se, 63% in +E-Se and 81% in -E-Se) compared to +E+Se animals (Fig. 23B).

### 3.2.2.6. $\gamma$ -Glutamyl transpeptidase

Liver, in spite of the highest concentration of GSH showed lesser GGT activity compared to lung tissue. GGT activity levels were significantly reduced in liver tissue of **vit.E and/or** Se deficient animals when compared to +E+Se animals (Fig. 24A). In contrast, GGT activity levels in the **lung** tissue of vit.E **and/or** Se deficient animals were significantly higher compared to that of +E+Se animals (Fig. 24B).


### 3.2.2.7. Glutathione S-transferases

The hepatic GST activities were significantly higher in +E-Se (48.5%) and -E-Se (77%) animals when compared to that of +E+Se animals (Fig. 25A). However in lung tissue all deficient groups showed significantly higher levels (48% in -E+Se, 40% in +E-Se and 80% in -E-Se) compared to +E+Se animals (Fig. 25B).

### 3.3.0.0. Discussion


**Vit.E**, as a chain breaking free radical scavenger, protects the tissue from **non-enzymatic** lipid **peroxidation**. Vit.E has been shown to be involved in the inhibition of LOX (Reddanna *et al.*, 1989, Lomnitski *et al.*, 1991) and in the reduction of hydroperoxides catalyzed by LOX (Cucurou *et al.*, 1991). Thus vit.E plays an important antioxidant role both against enzymatic and **non-enzymatic** lipid **peroxidations**. **Selenium**, as an integral component of Se-GSH Px, plays an important role in the reduction of organic and inorganic hydroperoxides.

**Fig. 23: Activity levels of glutathione reductase in the cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**




Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test.  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 24 : Activity levels of  $\gamma$ -glutamyl transpeptidase in the cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 25: Activity levels of GSTs with CDNB in the cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean  $\pm$  SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).



In view of their key role in tissue antioxidant defenses, vit.E **and/or** Se deficiency markedly reduced the growth rate of female albino rats (Fig. 16). As a result of this liver and lung tissue somatic indices also got affected (Fig. 17). The increase in the **TSI** of liver and lung tissues in vit.E **and/or** Se deficient animals in comparison to the supplemented group, is more due to the decrease in the body weights rather than increase in tissue weights.

The impaired antioxidant defenses as a result of induced vit.E and Se deficiency could be responsible for the observed increase in lipid peroxides in animals deficient in Se **and/or** vit.E (Fig. 18A). *In vivo*, **MDA** is formed almost exclusively from peroxidation of **PUFAs**, hence its presence is thought to be a prime indicator of the occurrence of tissue lipid peroxidation (Gutteridge and Halliwell, 1990). Similar increase in lipid peroxides was reported in liver, lung and cardiac muscles of animals fed on vit.E **and/or** Se deficient diets (Hafeman and Hoekstra, 1977; Tiidus *et al.*, 1993; Awad *et al.*, 1994; Rokizki *et al.*, 1994). The present study also has clearly demonstrated that liver and lung tissues of **vit.E and/or** Se deficient animals are vulnerable to impaired antioxidant defenses. Se-GSH Px and other Seleno peroxidases play a prominent role in the reduction of both inorganic and organic hydroperoxides in different compartments of cells. Selenium deficiency in the present study has resulted in significant depletion of Se-GSH Px activity levels (Fig. 19A). Similarly other Seleno peroxidases such as plasma GSH Px and phospholipid hydroperoxidase might have been reduced in Se deficient animals. In addition deficiency of vit.E also might be responsible for the observed increase in the levels of lipid peroxides in both liver and lung tissues of vit.E **and/or** Se deficient animals (Fig. 18A&B).

In the present study Se deficiency resulted in increased liver GSH levels (Fig. 20A). No significant differences, however, were observed in liver tissue of vit.E deficient animals (Fig. 20A). Hill and Burk (1982) have studied GSH metabolism in isolated rat hepatocytes and demonstrated that GSH synthesis and turnover are accelerated significantly by Se deficiency and not significantly by **vit.E**

deficiency. This implies that Se deficiency but not of vit.E accelerates **GSH** synthesis in rat liver. These changes were associated with increased activities of rate-limiting enzymes in the GSH turnover such as GCS in vit.E **and/or** Se deficient animals (Fig. 22A). Also glutathione reductase, another enzyme involved in GSH turnover, was also at higher levels in liver of vit.E and Se deficient animals (Fig. 23A). This increased glutathione reductase activity might be a mechanism for increasing GSH status to protect liver from the prevailing oxidant stress in nutrient deficient animals. The increased levels of GSH in Se deficient animals could be due to increased demand for GSH caused by increased tissue **lipid** peroxides.

GGT is an important component of the  $\gamma$ -glutamyl cycle in cells (Meister and **Anderson, 1983**). The  $\gamma$ -glutamyl bond can be cleaved by GGT, an enzyme located on the external surface of cell membranes of various tissues. Liver is known to have negligible GGT activity (Bray and Taylor, 1993). In the present study also GGT activity in liver was much lower compared to lung tissue (Fig. 24A). GGT activity levels in liver were further decreased in vit.E and Se deficient livers when compared to that **of +E+Se** animals. Hepatic uptake of plasma GSH is very low as a result of the relatively low levels of GGT activity in the liver (Lauterburg *et al.*, 1984). GSH as well as other  **$\gamma$ -glutamyl-containing** compounds, including GSSG and  $\gamma$ -glutamyl glutathione, react with GGT at the outer cell surface. The  $\gamma$ -glutamyl moiety is transferred to a suitable amino acid acceptor, and both the  $\gamma$ -glutamyl **amino** acid and cysteinylglycine are transported into the cell and reused for GCS and glutathione reductase reactions to enhance cellular GSH levels. Although the first step in GSH degradation is catalyzed by GGT, it seems unlikely that hepatic GGT is involved in the reaction in the liver, because of its low level and its further decrease by vit.E and Se depletions. Therefore, GSH release from liver is of primary importance in the GSH turnover. Perhaps, GSH **and/or** GSSG released into the blood are cleaved and reabsorbed in kidney and the lung tissues, containing very high activity levels of GGT and other related enzymes. In relation to this point, Hill and Burk (**1982**) observed that Se deficiency raised plasma GSH **plus** GSSG level but not cysteine levels in rats.

In addition to increased GSH levels, vit.E **and/or** Se deficiency has resulted in significantly higher activity levels of GST in liver tissue (Fig.25A). This observation is consistent with the results of Chang *et al.*, (1990) and Christensen *et al.*, (1994) where elevated GSTs were reported in response to Se deficiency. GSTs, are **multifunctional** proteins known mainly for detoxification of xenobiotics. The induction of GSTs in response to vit.E and Se deficiency indicates their possible role in antioxidant defenses also. GSTs of a family are known for their role in the reduction of organic peroxides (Chang *et al.*, 1990). It will be interesting to probe further on the specific isozymes of GSTs induced in response to nutritional deficiency and their involvement in antioxidant defenses.

Antioxidants and glutathione related enzymes play a significant role in the defense responses of the lung tissue to oxidant stress (Panus *et al.*, 1988). Se-GSH Px activities were decreased in Se deficient tissues (Fig. **19B**) which was also evidenced by studies of **Forman** *et al* (1983) and Jenkinson *et al* (1989). Se deficient lung has reduced activity of Se-GSH Px **and**, hence, limited capacity to metabolize  $H_2O_2$  and other peroxides. GSH exported **from** liver to the blood plasma is utilized by the lung, which like liver and kidney exhibits a high overall rate of GSH turnover. In the present study, Se and vit.E deficiency increased GGT activity of lung tissue (Fig. 24B). Activated GGT of **lung** tissue facilitates the import of substrates required for GSH synthesis. Exercise training is known to increase GGT activities of lung and muscles in rat, but decrease in liver (Sen *et al.*, 1992). During deficiency when hepatic efflux of GSH is **accelerated**, the lung tissue enjoys a greater ability to enrich its GSH-dependent antioxidant and detoxicant status.

Se **and/or** vit.E deficiency in the present study enhanced GCS activity of lung tissue (Fig. 22B). This effect was more pronounced in -E-Se animal tissues, which should result in higher GSH levels. On the contrary, GSH levels decreased in **lung** tissues of -E-Se animals (Fig. 20B). Lungs from Se deficient rats were shown to release glutathione in response to oxidative stress (Jenkinson *et al.*,

1987). Mice treated with buthionine **sulfoxamine** (BSO) reduce total lung GSH levels and thereby increasing the susceptibility to oxygen-induced lung damage (Smith and **Anderson**, 1992). Several lung disorders are believed to be characterized by an increase in alveolar oxidant **burden**, potentially depleting GSH levels in lung tissue (Martensson *et al.*, 1989). Low GSH has been linked to abnormalities in the lung surfactant system and the interaction between GSH and antiproteases in the epithelial lining fluid of patients. In new born rats and in adult mice GSH deficiency results in extensive damage to lung type 2 cells with decreased number of lamellar bodies and decreased amounts of **intraalveolar tubular myelin** (Martensson *et al.*, 1989, 1991). Thus when there is a marked decrease in cellular **GSH**, the normal physiological formation of reactive oxygen species is unopposed, and this leads to severe cellular damage.

The decreased GSH during vit.E **and/or** Se deficiency might be due to increased GSH utilization by enzymes such as GSTs, which are induced (Fig. 25B). The rate of depletion by these electrophilic agents is related to the level of GST activity in the cell. Thus GSSG levels were increased which is an indication of oxidative stress. The relatively high concentrations of GSSG may be due to concomitant increase in pulmonary GSTs and increased levels of peroxides in deficient tissues (Fig.22B). Jackson and Veal (1990) and Reuter and Klinger (1992) found a marked increase in GSSG levels of lung tissue after hypoxia and reoxygenation. Thus if the rate of GSH consumption exceeds that of import, a tissue may show a net deficit of GSH. The glutathione reductase activities were higher in the lung tissue of **vit.E and/or** Se deficient animals compared to that of supplemented animals, more pronounced in -E-Se lung tissue to recycle GSH (Fig.23B). Glutathione reductase levels, however, were lower in animals supplied with vit.E and Se compared to deficient animals, indicating the secondary role played by thiols in antioxidant defense mechanisms of lung tissue in the presence of **vit.E** and Se. Thus it is clear that vit.E and Se deficiency results in inducing oxidant stress in the **lung** tissue, which is being tackled mainly by cellular thiols. In the present study the observed increase in the levels of GST activities in nutrient

deficient animals suggests a compensatory role for glutathione in protecting hepatic and pulmonary tissues from the oxidative damage induced by vit.E and/or Se deficiency (Fig. 25B).

The present study therefore, reveals that lung tissue is relatively more susceptible to oxidative damage induced by vit.E **and/or** Se deficiency. As a result of induced oxidative stress, liver and **lung** tissues of vit.E **and/or** Se deficient animals showed induction of GSTs. Further studies, however, are required to identify the specific isozyme(s) of GST involved in antioxidant defenses.

## ***CHAPTER II***

#### 4.1.0.0. INTRODUCTION

In the first chapter it is demonstrated that either vit.E **and/or** Se deficiency induces oxidative stress in female albino rats. Vitamin E **and/or** Se deficiency also induced GSTs in lung and liver tissues significantly. In order to identify the isozymes of GSTs **induced**, GSTs were purified by affinity chromatography and further separated on SDS-PAGE. The **subunit** composition of GSTs, however, was analyzed on **RP-HPLC**.

Earlier differences in tissue **distribution** and expression of GST isozymes have been documented mainly by comparison of SDS-PAGE and immunoblotting (Tu *et al.*, 1983; Hayes and Mantle, 1986). However, there were and still are problems with cross-reactivity of GST antibodies and quantification by immunoblotting. Development of an HPLC technique by Ostlund *et al* (1987) significantly improved the ability to identify and quantify GST proteins, and has been used extensively (Ketterer *et al.*, 1988, Hayes *et al.*, 1990). In the present study the HPLC technique is modified so that all known subunits can be separated with essentially baseline **resolution**.

#### 4.2.0.0. RESULTS


Female wistar strain albino rats at weanling stage were fed with -E+Se, +E-Se, -E-Se and +E+Se diets for a period of 13 weeks. After the dietary **regimen**, animals were killed and liver and lung tissues excised after **perfusion**. Cytosolic GSTs from tissues were purified by GSH linked agarose column chromatography. Fig. 26 represents the typical chromatogram of affinity purification of rat liver and/or lung cytosolic GSTs.

##### 4.2.1.0. Hepatic GSTs

##### 4.2.1.1. Affinity chromatography

Purification of GSTs by **GSH-affinity** chromatography was carried out five

**Fig. 26: Affinity purification of rat liver and/or lung cytosolic GSTs**





times separately for each group using pooled liver tissue (12 g) from respective groups. Table 5 to 8 shows the typical purification profiles of GSTs from liver tissues of -E+Se, +E-Se, -E-Se and +E+Se animals. As shown in the profiles, increase in specific activity was observed in liver crude extracts (10,000 X g) of +E-Se (49%) and -E-Se (77%) animals when compared to that of +E+Se animals. Similarly the specific activity levels in the cytosolic fractions (105,000 X g supernatant) of +E-Se and -E-Se animals also were much higher compared to +E+Se animals. As a result, the overall purification fold of +E-Se (33%) and -E-Se (43%) animals decreased when compared to -E+Se and +E+Se animals. This observed increase in the specific activity levels in the crude extracts as well as cytosolic fractions and decrease in the final fold purification are indicative of induction of GSTs in the liver tissue of +E-Se and -E-Se animals. Also the total affinity purified GST protein levels were much higher in +E-Se (50%) and -E-Se (77%) animals than the levels found in +E+Se animals. No appreciable differences in specific activity (37 U/mg protein) and % yield (~70%) were observed in the affinity purified liver GSTs of animals fed on **vit.E and/or** Se supplemented and deficient diets. The comparison of total activity, total protein and yield at the final step of liver GST purification for all the dietary groups is represented in table 9.

#### 4.2.1.2. SDS-PAGE and western blot analysis of GSTs from cytosolic extracts

The affinity **purified** liver GSTs were resolved into 3 subunits on SDS-PAGE (Fig. 27, lane 1&6) with molecular weights of 25.6, 27 & 28 kDa, which were designated as **Ya**, Yb and **Yc** respectively, as per the nomenclature of Mannervik *et al* (1985). In order to determine whether increased GST activity in +E-Se and -E-Se was due to an increased amount of GST protein, equal amounts of liver cytosol protein (20 **µg**) was loaded and separated on SDS-PAGE (Fig. 27). Western blotting analysis was performed after electrophoresis using polyclonal antibodies raised against affinity purified liver GSTs (Fig. 28A), rat liver Yc (Fig. 28B), rat liver Yb (Fig. **28C**) and rat liver Ya subunits (Fig. 28D).

**TABLE 5: PURIFICATION PROFILE OF LIVER GSTs OF  
RATS FED ON -E+Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %	Purification fold
10,000 X g	837.5	2417	0.346	100	<b>1</b>
105,000 Xg	743.0	1279	0.581	<b>88.73</b>	1.68
Affinity pooled	563.6	<b>15.4</b>	36.6	67.3	105.8

Each value is the mean of five individual observations.  
One unit is defined as one **umole of thioether formed/min.**

**TABLE 6: PURIFICATION PROFILE OF LIVER GSTs OF  
RATS FED ON +E-Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %	Purification fold
10,000 X g	1152	2458	0.469	100	1
105,000 X g	1035	1281	0.808	<b>89.8</b>	1.72
Affinity pooled	765.4	20.8	36.8	<b>66.4</b>	78.46

Each value is the mean of five individual observations.  
One unit is defined as one umole of thioether fonnred/min.

**TABLE 7: PURIFICATION PROFILE OF LIVER GSTs OF RATS FED ON -E-Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %.	Purification fold
10,000 Xg	1344.5	2409	0.558	100	1
105,000 X g	1222.3	1268	0.964	91	1.728
Affinity pooled	919.7	24.79	37.1	66.31	66.48

Each value is the mean of five individual observations.

One unit is defined as one **umole** of thioether **formed/min**.

**TABLE 8: PURIFICATION PROFILE OF LIVER GSTs OF RATS FED ON +E+Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %.	Purification fold
10,000 Xg	762.9	2422	0.315	100	1
105,000 Xg	693.6	1275	0.544	90.9	1.729
Affinity pooled	511.0	14	36.5	67.0	115.9

Each value is the mean of five individual observations.


One unit is defined as one **umole** of thioether **formed/min**.

**TABLE 9: PURIFICATION PROFILE OF LIVER GSTs OF RATS FED ON vit.E AND/OR Se SUPPLEMENTED AND DEFICIENT DIETS**

<b>Step</b>	<b>Total activity units (U)</b>	<b>Total protein (mg)</b>	<b>Yield</b>
-E+Se	<b>564 ± 89*</b>	<b>15.4 ± 2.0*</b>	36.6 ± 2.1 *
+E-Se	<b>765 ± 110<sup>b</sup></b>	<b>20.8 ± 3.2<sup>b</sup></b>	36.8 ± 2.3 <sup>a</sup>
-E-Se	920 ± 173 <sup>b</sup>	<b>24.8 ± 3.6<sup>b</sup></b>	37.0 ± 2.9*
+E+Se	<b>511 ± 93*</b>	<b>14.0 ± 2.3*</b>	36.5 ± 2.8*

Each value is the mean ± SD of five individual observations. One unit is defined as one **umole** of thioether formed/min. The same alphabet denotes no significant difference between the two groups in each column. Significance was set at  $p < 0.05$ .

**Fig. 27: SDS-PAGE of liver cytosolic proteins of rats fed on vit.E **and/or** Se supplemented and deficient diets**



- Lane: 1. 1  $\mu$ g liver affinity purified GSTs  
 2. 20  $\mu$ g -E+Se liver cytosolic proteins  
 3. 20  $\mu$ g +E-Se liver **cytosolic** proteins  
 4. 20  $\mu$ g -E-Se liver cytosolic proteins  
 5. 20  $\mu$ g +E+Se liver cytosolic proteins  
 6. 2  $\mu$ g liver affinity purified GSTs

**Fig. 28: Immunoblots of liver cytosol and affinity purified GSTs of rats fed on vit.E **and/or** Se supplemented and deficient diets separated on SDS-PAGE and probed with antibodies raised against**

**A. Rat liver affinity purified GSTs B. Rat liver GST Yc subunit  
C. Rat liver GST Yb subunit D. Rat liver GST Ya subunit**

**Blot A to D**

Lane 1. 1  $\mu\text{g}$  rat liver affinity purified GSTs

Lane 2. 20  $\mu\text{g}$  -E+Se rat liver cytosolic proteins

Lane 3. 20  $\mu\text{g}$  +E-Se rat liver cytosolic proteins

Lane 4. 20 ng -E-Se rat liver cytosolic proteins

Lane 5. 20  $\mu\text{g}$  +E+Se rat liver cytosolic proteins

Lane 6. 2  $\mu\text{g}$  rat liver affinity purified GSTs




Figure 28A shows a clear induction of **Yc** and Ya subunits in -E+Se, +E-Se and -E-Se animals when cytosolic proteins separated on **SDS-PAGE** were probed with anti-affinity purified GST antibodies (compare lane 2,3,4 to lane 5). Similar results were observed when the proteins were probed with GST Yc antibody (Fig. 28B). Western blot analysis with GST Ya antibodies further showed the induction of Ya subunit in -E+Se, +E-Se and -E-Se animals, more so in -E-Se animals when compared to that of +E+Se animals (Fig. 28D). No significant changes were observed in Yb subunit (Fig. **28A&C**).

#### 4.2.1.3. SDS-PAGE analysis of affinity purified GSTs


In order to further characterize the GSTs, equal amounts (3  $\mu$ g each) of affinity purified GSTs from vit.E **and/or** Se supplemented and deficient animals were separated on SDS-PAGE (Fig. 29). The relative concentration of subunits were analyzed by measuring subunit concentration on **UVP-gel** documentation system and also from the total protein recovered at the final step of purification (Fig. 30). The relative concentration of Ya subunit was significantly higher in liver tissues of **-E+Se** (34%), **+E-Se** (61%) and **-E-Se** (164%) animals compared to that of **+E+Se** animals. Further Yc subunit was also induced in -E+Se (24%), +E-Se (57%) and -E-Se (62%) animals when compared to that of +E+Se animals (compare lanes 2,3&4 with 1 in Fig. 30).

#### 4.2.1.4. Reverse-phase HPLC analysis of affinity purified GSTs

In order to further **quantitate** the specific induction of GST subunits during vit.E **and/or** Se deficiency, equal amounts of affinity purified GSTs were separated on reverse-phase HPLC (Fig. **31A,B,C&D**). Individual peaks obtained were identified based on their order of elution as per the profile given by Johnson *et al* (1992) and were confirmed by comparison of HPLC profiles of individual isozymes and SDS-PAGE analysis. When relative subunit concentrations were **compared**, **Ya<sub>2</sub>** was the major Ya-sized subunit in the rat liver, which was significantly higher in -E+Se (1.43 fold), +E-Se (2.42 fold) and -E-Se (3 fold)



**Fig. 29: SDS-PAGE of liver and lung affinity purified GSTs of rats fed on vitE and/or Se supplemented and deficient diets**




Lane 1 to 4 corresponds to liver GST proteins (3 ug each) purified **from**

1. +E+Se 2. -E-Se 3. +E-Se 4. -E+Se animals

Lane 5 to 8 corresponds to lung GST proteins (3  $\mu$ g each) purified **from**

5. +E+Se 6. -E-Se 7. +E-Se 8. -E+Se animals

**Fig. 30: Relative subunit concentration of liver affinity purified GSTs of rats fed on vit.E and/or Se supplemented and deficient diets separated on SDS-PAGE**



Values represent mean + SD of five individual experiments. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 31: RP-HPLC analysis of affinity purified liver GSTs of  
(A)-E+Se (B)+E-Se (C)-E-Se (D) +E+Se rats**

Equal protein (100  $\mu$ g) was loaded to RP-HPLC


Column: ODS (Waters)

Solvent: A. 35% **Acetonitrile** + 0.1% TFA


B. 85% **Acetonitrile** + 0.1% TFA

Flow rate: 1 mL/min

Detection: 214 nm



**Fig. 32: Relative subunit concentration of liver affinity purified GSTs of rats fed on vit.E and/or Se supplemented and deficient diets separated on RP-HPLC**



Bars represent mean  $\pm$  SD of five individual experiments. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p \leq 0.05$ ).

animals (Fig. 32). Similarly **Yc** was also induced in all deficient animals by 1.2 fold in -E+Se, 1.63 fold in +E-Se, and 1.82 fold in -E-Se animals compared to that of +E+Se animals. **Ya<sub>1</sub>** subunit was induced only in -E-Se (1.78 fold) animals (Fig. 32C).

#### **4.2.2.0. Lung GSTs**

##### **4.2.2.1. Affinity chromatography**

Like liver GSTs, lung GSTs were also purified from equal quantities (16 g) of pooled tissue from **vit.E and/or** Se deficient and supplemented animals by affinity chromatography for 3 times. The data was presented in tables 10, 11, 12 & 13. Comparison of specific activities during the first step of purification (crude extract of 10,000 X g supernatant) indicated increase in the specific activities in -E+Se (33%), +E-Se (64%) and -E-Se (76%) animals compared to the level observed in +E+Se animals. The purification fold was decreased by 16% in -E+Se, 40.12% in +E-Se and 39.13% in -E-Se animals. Further total GST protein obtained after affinity purification in lung tissues of -E+Se (48.5%), +E-Se (93%), and -E-Se (98%) animals were significantly higher when compared to the protein levels obtained for +E+Se animals. All these observations demonstrate the induction of lung GSTs in **vit.E and/or** Se deficient animal\*; No significant differences were observed in specific activity (17 U/mg protein) and % yield (~90%) of affinity purified lung GSTs of **vit.E and/or** Se supplemented and deficient diets. Comparison of total activity, total protein and yield of affinity purified lung GSTs for the **vit.E and/or** Se supplemented and deficient diets was presented in table 14.

##### **4.2.2.2. Western blot analysis of cytosolic extracts**

The affinity purified GSTs were resolved into 4 **subunits** on SDS-PAGE with molecular weights of 24, 25, 27 and 28 **kDa**, which were designated as **Yp**, **Yk**, **Yb** and **Yc** respectively, based on their molecular weights (Fig. 33). The subunit induction was analyzed by separating equal amounts (40 **µg** each) of

**TABLE 10: PURIFICATION PROFILE OF LUNG GSTs  
OF RATS FED ON -E+Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %	Purification fold
10,000 X g	15.56	1765	0.008	100	1
105,000 Xg	15.10	1019	0.015	97.02	1.805
Affinity pooled	14.30	0.815	17.61	92.24	2147

Each value is the mean of three individual observations.  
One unit is defined as one  $\mu\text{mole}$  of thioether **formed/min.**

**TABLE 11: PURIFICATION PROFILE OF LUNG GSTs  
OF RATS FED ON +E-Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %	Purification fold
10,000 X g	19.9	1803	0.011	100	1
105,000 X g	18.45	2025	0.014	92.68	1.27
Affinity Pooled	17.92	1.062	16.80	90.0	1527

Each value is the mean of three individual observations.  
One unit is defined as one  $\mu\text{mole}$  of thioether **formed/min.**

**TABLE 12: PURIFICATION PROFILE OF LUNG GSTs  
OF RATS FED ON -E-Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %.	Purification fold
10,000 X g	21.75	1834	0.012	100	1
105,000 Xg	20.43	1121	0.018	93.92	1.54
Affinity pooled	18.36	1.07	17.1	90.67	1554

Each value is the mean of three individual observations.  
One unit is defined as one umole of thioether formed/min.

**TABLE 13: PURIFICATION PROFILE OF LUNG GSTs  
OF RATS FED ON +E+Se DIET**

Step	Total activity units (U)	Total protein (mg)	Specific activity (U/mg)	Yield %.	Purification fold
10,000 X g	11.25	1677	0.007	100	1
105,000 Xg	10.35	1030	0.01	92.03	1.49
Affinity pooled	9.39	0.549	17.11	88.45	2553

Each value is the mean of three individual observations.  
One unit is defined as one umole of thioether formed/min.

**TABLE 14: PURIFICATION PROFILE OF LUNG GSTs OF RATS FED ON vit.E AND/OR Se SUPPLEMENTED AND DEFICIENT DIETS**

Step	Total activity units (U)	Total protein (mg)	Yield
-E+Se	14.3± 1.6 <sup>a</sup>	0.82 ± 0.08 <sup>a</sup>	17.6 ± 1.6 <sup>a</sup>
+E-Se	17.92± 2.0 <sup>a</sup>	1.06± 0.12 <sup>a</sup>	16.8 ±1.9*
-E-Se	18.36± 2.9 <sup>a</sup>	1.07 ± 0.11 <sup>a</sup>	17.1 ± 2.0 <sup>a</sup>
+E+Se	9.39 ± 1.3 <sup>b</sup>	0.55 ± 0.07 <sup>b</sup>	17.1 ± 1.8 <sup>a</sup>

Each value is the mean + SD of three individual observations. One unit is defined as one **umole** of thioether **formed/min**. The same alphabet denotes no significant difference between the two groups in each column. Significance was set at  $p < 0.05$ .



cytosolic proteins from -E+Se, +E-Se and -E-Se and +E+Se animals on SDS-PAGE (Fig. 33) and probing them with **polyclonal** antibodies raised against affinity purified lung GSTs (Fig. 34A), lung **Yc** (Fig. 34B), lung Yb (Fig. 34C), lung **Yk** (Fig. 34D) and lung Yp subunits (Fig. 34E). Comparison of lanes 2,3&4 with that in lane 5 of Fig. **34A&B** clearly showed an induction of Yc subunit in vit.E **and/or** Se deficient animals. No significant changes, however, were observed in Yb, Yk and Yp subunits in **vit.E and/or** Se deficient animal tissues compared to that of supplemented animals (Fig. **34A,C,D&E**).

#### **4.2.2.3. SDS-PAGE and RP-HPLC analysis of affinity purified GSTs**

Equal amounts (3 **µg**) of affinity purified lung GSTs from vit.E **and/or** Se deficient and supplemented animals were separated on SDS-PAGE (Fig. 29) and relative subunit concentrations were analyzed based on **UVP-gel** documentation data and from the total protein recovered at the final step of affinity purification (Fig. 35). A significant induction of Yc subunit was observed in -E+Se (2.84 fold), +E-Se (4.82 fold) and -E-Se (7.48 fold) animals in comparison with +E+Se animals (compare lanes 6,7&8 with 5 in Fig. 35). No significant changes, however, were observed in Yb, Yk and Yp subunits.

In order to verify the specific induction of subunits in **vit.E and/or** Se deficient tissues, equal amounts (100 **µg**) of affinity purified GSTs were separated on RP-HPLC using Waters **C<sub>18</sub>** analytical column (Fig. 36 **A,B,C&D**). When relative subunit concentrations were analyzed, a significant induction of Yc subunit was observed in -E+Se (2.9 fold), +E-Se (4.86 fold) and -E-Se (7.76 fold) animals when compared to that **of +E+Se** animals (Fig. 37).

Thus SDS-PAGE, immunoblots and RP-HPLC analysis of affinity purified GSTs have clearly demonstrated the induction of **Ya<sub>2</sub>** and Yc subunits in liver and Yc only in lung tissue of vit.E **and/or** Se deficient animals when compared to those in +E+Se animals.

**Fig. 33: SDS-PAGE of lung cytosolic proteins of rats fed on vit.E and/or Se supplemented and deficient diets**



Lane: 1. 1  $\mu$ g lung affinity purified GSTs  
 2. 40  $\mu$ g -E+Se lung cytosolic proteins  
 3. 40  $\mu$ g +E-Se lung cytosolic proteins  
 4. 40  $\mu$ g -E-Se lung cytosolic proteins  
 5. 40  $\mu$ g +E+Se lung cytosolic proteins  
 6. 3  $\mu$ g liver affinity purified GSTs

**Fig. 34: Immunoblots of lung cytosol and affinity purified GSTs of rats fed on vit.E and/or Se supplemented and deficient diets separated on SDS-PAGE and probed with antibodies raised against**


- A. Rat lung affinity purified GSTs    B. Rat lung GST Yc subunit**  
**C. Rat lung GST Yb subunit        D. Rat lung GST Yk subunit**  
**E. Rat lung GST Yp subunit**

**Blot A**


- Lane 1. 2 ug rat lung affinity purified GSTs  
 Lane 2. 40 ug -E+Se rat lung cytosolic proteins  
 Lane 3. 40  $\mu$ g +E-Se rat lung cytosolic proteins  
 Lane 4. 40  $\mu$ g -E-Se rat lung cytosolic proteins  
 Lane 5. 40 ug +E+Se rat lung cytosolic proteins  
 Lane 6. 1 ug rat liver affinity purified GSTs

**Blot B to D**

- Lane 1. 2  $\mu$ g rat lung affinity purified GSTs  
 Lane 2. 40 ug -E+Se rat lung cytosolic proteins  
 Lane 3. 40  $\mu$ g +E-Se rat lung cytosolic proteins  
 Lane 4. 40 ug -E-Se rat lung cytosolic proteins  
 Lane 5. 40  $\mu$ g +E+Se rat lung cytosolic proteins  
 Lane 6. 2 ug rat lung affinity purified GSTs



**Fig. 35: Relative subunit concentration of lung affinity purified GSTs of rats fed on vit.E and/or Se supplemented and deficient diets separated on SDS-PAGE**



Bars represent mean  $\pm$  SD of three individual experiments. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p \leq 0.05$ ).

**Fig. 36: RP-HPLC analysis of affinity purified lung GSTs of (A)-E+Se (B)+E-Se (C)-E-Se (D)+E+Se rats**

Equal protein (**100  $\mu$ g**) was loaded to RP-HPLC


Column: ODS (Waters)

Solvent: A. 35% Acetonitrile + **0.1% TFA**


B. 85% Acetonitrile + 0.1% TFA

Flow rate: **1 mL/min**

Detection: **214 nm**



**Fig. 37: Relative subunit concentration of lung affinity purified GSTs of rats fed on vit.E and/or Se supplemented and deficient diets separated on RP-HPLC**



Bars represent mean  $\pm$  SD of five individual experiments. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p \leq 0.05$ ).

#### 4.3.0.0. DISCUSSION

Vitamin E and Se deficiency is known to induce oxidative stress and simultaneously induce alternative antioxidant defenses, specifically glutathione-dependent defenses including GSTs (Mehlert and Diplock, 1985; Kim and Comb, 1993). In the present study also, induction of GSTs was observed in response to **vit.E and/or** Se deficiency (Chapter II, Fig. 25). However, it is not clear whether the increase in GST activity is due to an increased amount of GST protein or the activation of the enzyme systems. To unravel this, GSTs were purified by affinity chromatography and individual subunits were separated on **SDS-PAGE** and **RP-HPLC**.

GST activity is increased in many organisms following exposure to foreign compounds. From studies of rodents, the adaptive response to chemical stress is clearly pleiotropic in character and involves the induction of many drug-metabolizing enzymes (Spencer *et al.*, 1991; Hayes *et al.*, 1993; Borroz *et al.*, 1994). Collectively, these detoxification enzymes provide protection against a diverse spectrum of harmful compounds. Evidences suggest that, besides providing protection against chemicals of foreign **origin**, GSTs are involved in the protection against oxidative stress. It has been reported that in Selenium- and Copper deficient rats, which are chronically exposed to increased intracellular levels of hydrogen peroxide due to lack of Se-GSH **Px**, marked **over-expression** of hepatic GST isozymes is observed (Arthur *et al.*, 1987).

Rat GST subunits are preferentially induced by various drugs, including carcinogens like 3'-methylaminobenzene, **2-acetylaminofluorene** (Kitahara *et al.*, 1984) and **trans-stilbene** oxide (Tahir *et al.*, 1989) and anticarcinogenic agents such as BHA (Kitahara *et al.*, **1984**) and ethoxyquin (Kensler *et al.*, **1986**).

#### 4.3.1.0. Structural characterization of liver GSTs

In the present study oxidative stress induced by **vit.E** and Se deficiency resulted in the induction of hepatic GSTs, particularly Ya and **Yc** subunits



containing GSTs (Fig. 28). Therefore, increased GST protein appears to be responsible for the total elevation in GST activity with the classical substrate, CDNB. Similar induction of hepatic GSTs in Se deficiency was reported by Chang *et al* (1990) and Christensen *et al* (1994). The transcriptional activation of the GST genes may account for this increase in GST **subunit** levels. Chang *et al* (1990) proposed that an accumulation of peroxides during Se-deficiency might possibly bind to the corresponding receptor and the receptor-ligand complex would presumably interact with **chromatin** to activate the corresponding genes.

The liver Ya **subunit** was resolved into 2 different peaks, **Ya<sub>1</sub>** and **Ya<sub>2</sub>** on reverse-phase HPLC. In the present study **Ya<sub>2</sub>** is the major form of GSTs observed in the hepatic tissue of **+E+Se animals** (Fig. 31D). This observation is quite contradictory to the studies reported earlier for albino rats (Hayes *et al.*, 1990), where **Ya<sub>1</sub>** was shown to be the major form of Ya GSTs. It is not clear why **Ya<sub>2</sub>** was the more abundant form in the present study. One difference between the present work and the previous reports is the use of female rats instead of male rats. These **subunits** seem to have different **inducibility**. **Ya<sub>2</sub>** is much more inducible than **Ya<sub>1</sub>** in liver tissue of vit.E and Se deficient animals (Fig. 31A,B&C).

Lai *et al* (1984) for the first time isolated a full length clone of Ya, **pGTR 261**, which encompasses the cDNA described by **Kalinyak** and Taylor (1982). Further Ya subunit which was deduced from the clone **cDNA pGTB 38** was described by Pickett *et al* (1984). The **subunits** encoded by pGTB 38 and pGTR **261** show considerable sequence homology and over their 222-amino-acid length show residue differences in only eight positions. At these positions (residues **31**, 34, 96, 107, 117, 206, 207 and 219) pGTB 38 encodes **glutamic acid**, leucine, serine, isoleucine, arginine, proline, alanine and valine respectively, while pGTR 261 encodes aspartic **acid**, phenylalanine, threonine, methionine, **lycine**, leucine, proline and isoleucine at the respective positions. Hayes *et al* (1990) showed sequence data for Ya that include five of the eight 'difference residues' (namely 31, **34**, 96, 107 and **117**) and at each of these positions **Ya<sub>1</sub>** shows sequence

identity with pGTR 261. **Ya<sub>2</sub>** also includes five of the eight different residues (namely 31, 34, 107, 117 and 219), and at all of these positions **Ya<sub>2</sub>** contains the **amino** acids that would be predicted by pGTB 38. This provides the proof for the existence of multiple Ya-type subunits at the protein level. Hayes *et al* (1990) also reported that **Ya<sub>2</sub>** subunit was over-expressed in liver bearing aflatoxin-induced preneoplastic nodule, which was appear to be an adaptive response to **aflatoxin** exposure.

**Waxman et al (1992)** used gene specific oligonucleotide probes to monitor the expression of individual GST mRNA in liver and kidney of adult rats treated with different drugs. The study provided an unambiguous discrimination between the closely related GST **Ya<sub>1</sub>** and **Ya<sub>2</sub>** mRNA and have shown differential induction of these messages by different agents. They can not be distinguished at the RNA level using conventional cDNA probes (Lai *et al.*, 1984; Pickett *et al.*, 1984) or by **immunoprecipitation** analysis (Pemble *et al.*, 1986). GST **Ya<sub>1</sub>** is the major Ya form expressed in kidney while **Ya<sub>2</sub>** is induced in response to dexamethasone or phenobarbital treatment without any changes in **Ya<sub>1</sub>**. Important differences were also observed between the responses of these two GST class a mRNA to cisplatin, which suppressed **Ya<sub>1</sub>** without any effect on **Ya<sub>2</sub>** levels. Our previous studies (Veera Reddy *et al.*, 1995) have revealed that **Ya<sub>1</sub>** subunit is induced in response to exercise training in female rats.

Regulation of GST expression is a very complex process. They are subjected to developmental **control**, with tissue and sex specific **expression**. They are responsive to physiological stress and are inducible by many drugs and chemicals. The GSTA1 (**Ya<sub>1</sub>**) and GSTA2 (**Ya<sub>2</sub>**) subunits in rodent liver are markedly inducible by drugs. The rat GSTA2 gene appears to contain at least four cis-acting elements in the **5'-flanking** region that respond to xenobiotics. One of these elements is responsible for induction by PAH and is identical to the xenobiotic-responsive-element (XRE) found in the rat CYP1A1 gene (Rushmore *et al.*, 1990). A second element on the rat **GSTA2** gene has been designated as the antioxidant-responsive element (ARE) because it mediates responsiveness to

phenolic antioxidants (**Rushmore *et al.*, 1991**). The third element identified in this gene is identical to the glucocorticoid-responsive element (GRE) and may render expression of GSTA2 responsive to dexamethasone (Rushmore *et al.*, 1993). A fourth element exists in rat **GSTA2** which is responsible for the induction of this gene by barbiturates. The activation of transcriptional Ya gene through ARE by **H<sub>2</sub>O<sub>2</sub>** was clearly shown by Rushmore *et al* (1990). **β-Naphthoflavone**, a planar aromatic compound activates the gene through either XRE or ARE, but the presence of Ah receptors and metabolism of **β-naphthoflavone** by **cytochrome P-450 IA** are required for its transcriptional **activation**. On the other **hand**, **t-butyl hydroquinone**, a phenolic antioxidant, activates through ARE, independently of Ah receptors or cytochrome **P-450 IA1**. In the presence of Ah receptors, XRE reacts with **2,3,7,8-tetrachlorodibenzo-p-dioxin**, but ARE does not. These results support the proposal by Spencer *et al* (1991) that phase II drug metabolizing **enzymes**, including GSTs are induced by **monofunctional** and bifunctional inducers by different mechanisms and that induction by **mono** functional inducers such as t-butyl hydroxyquinone is mediated by an electrophilic signal independently of Ah receptor. The difference between ARE and XRE is its their capacity to induce phase I (cytochrome P450) gene expression. The XRE mediates induction of both phase I and phase II enzymes while ARE mediates induction of only phase II enzymes (Belinsky and Jaiswal, **1993**). The induction of phase I enzymes by XRE element in response to xenobiotics may cause increased risk of mutagenecity and carcinogenecity as the products of xenobiotics activated by phase I enzymes increase the oxidative damage to DNA and membranes. The ARE-mediated phase II enzymes, on the other **hand**, detoxify the XRE-activated xenobiotics. Therefore, the ARE mediated increase in phase II enzymes is the safety way to stimulate the chemoprotective power of the cells.

The observed induction of **Ya<sub>2</sub>** subunit in the present study (Fig. **31A,B&C**) like the induction of Ya GST in Se deficiency (Chang *et al.*, 1990), may be the livers response to rising hydroperoxide levels or free radicals when antioxidant systems are impaired due to vit.E and Se deficiency. Thus from studies

on affinity **purification**, western blot of crude cytosolic fractions, **subunit** concentration on **SDS-PAGE** and RP-HPLC, it is concluded that **Ya<sub>2</sub>** and **Yc** subunits are induced in liver tissue in response to vit.E and Se deficiency. The **induction** of **Ya<sub>2</sub>** subunit in vit.E and Se deficiency states might be regulated by ARE.

#### 4.3.2.0. Structural characterization of lung GSTs

In comparison to liver, there is limited information on lung GSTs and their involvement in oxidative stress. In the present study lung GSTs resolved into four bands on SDS-PAGE, which were designated as Yc, Yb, **Yk** and Yp (Fig. 33). Further separation of **affinity** purified GSTs on RP-HPLC showed **Yb<sub>1</sub>**, **Yb<sub>2</sub>**, Yp, Yc and Yk among which Yp is the major subunit (Fig. 36). Both a- and u- class GSTs are found in low concentrations as reported by Cossar *et al* (1990) and Coursin *et al* (1992). Rat lung GST 7-7 is **immunologically** identical to the rat **placental** form GST-P (Robertson *et al.*, 1986).

Lung is the first and foremost tissue exposed to airborne toxicants and pollutants. Also **it** is more vulnerable to oxidative stress compared to other tissues. Lung is equally well equipped with antioxidant defenses, though not to the extent observed in liver. This is evident by an increase in **lipid** peroxides and GSSG levels in response to vit.E and Se deficiency (Fig. **18&21**).

It is noteworthy that Ya which shows a high **inducibility** in liver is absent in lung. The lower recovery of liver vs lung GSTs (70% vs 90%) may be due to some of the isozymes specific to liver were not completely bound to affinity column or may be due to higher flow through loss (Table **8vs13**). In the present study vit.E and Se deficiency significantly induced Yc subunit (7.76 fold) of a class in the lung tissue (Fig. 37). The increased GST activity might be aimed to compensate for the loss of Se-GSH Px during Se deficiency and to improve antioxidant defenses which were impaired due to **vit.E** deficiency.

From these studies it is concluded that GSTs exhibit tissue-specific **expression**. After **purification**, western blot analysis of cytosolic proteins, subunit concentration on **SDS-PAGE** and RP-HPLC it is concluded that **Ya<sub>2</sub>** and Yc subunits are induced significantly in liver and Yc subunit in lung in response to oxidative stress induced by **vit.E and/or** Se deficiency. The results demonstrate that **Ya<sub>1</sub>** and **Ya<sub>2</sub>** have differential **inducibility**, **Ya<sub>2</sub>** being more inducible than **Ya<sub>1</sub>**. However it is not clear whether the GSTs induced in liver and lung tissues in response to **vit.E and/or** Se deficiency are involved in any antioxidant **protection**. Further studies on their functional characterization will throw more light on the participation of GSTs in cellular antioxidant defenses.

# ***CHAPTER III***

### 5.1.0.0. INTRODUCTION

While **lipid** peroxidation is generally associated with widespread and irreversible damage to essential cell components, enzymatically controlled lipid peroxidation is involved in the biosynthesis of eicosanoids, hormone like substances required for maintaining tissue and cellular homeostasis. The immediate oxygenation products of arachidonic acid by the way of lipoxygenase and cyclooxygenase pathways include **PGG<sub>2</sub>** and HPETE respectively. Not only do these products serve as precursors for the biosynthesis of PGs and LTs, but they also have **significant** influence on the activities of various enzymes associated with arachidonic acid including cyclooxygenase and lipoxygenase. Thus, an enzyme system that can reduce these reactive hydroperoxides has the potential for modulating the arachidonic acid cascade.

Glutathione peroxidases, with the potential for reducing these hydroperoxides and endoperoxides, influence the biosynthesis of biologically active eicosanoids. Se-GSH Px catalyzes the reduction of both organic and inorganic hydroperoxides. In addition to these a group of Se-independent GSH Pxs (non-Se-GSH Px) associated with certain forms of GSTs are involved in the reduction organic hydroperoxides (Lawrence and Burke, 1976). Both types of peroxidases are ubiquitously distributed in animals. The cellular Se-GSH Px is located primarily in the cytosolic and **mitochondrial** compartments, while the non-Se-GSH Px has been identified in both cytosolic and microsomal cell fractions (Reddy *et al*, 1981). The relative abundance of these two types of GSH Pxs within a given tissue is species specific. The relative contribution of these two enzymes in antioxidant defenses can best be studied by knocking out these enzymes one at a time. Induction of Se deficiency forms one such situation wherein Se-GSH Px **activity** is eliminated. As shown in the second **chapter**, Se deficiency and **thus** elimination of Se-GSH Px resulted in the induction of GSTs. The GSTs have been implicated in the synthesis of prostaglandins including **PGF<sub>2α</sub>**. **PGF<sub>2α</sub>** is a biological mediator in a variety of physiological **functions** including contractions of

uterine smooth muscle and pulmonary arteries. Research from Reddy's group has provided evidence that the GSH Px activity of GSTs is associated with the reduction of PGH<sub>2</sub> to **PGF<sub>2α</sub>**, with the **α-class** or Ya-containing subunits being the most active (Burgess *et al.*, 1987; Chang *et al.*, 1987a; Hong *et al.*, 1989). In addition to their role in PG biosynthesis, GSTs also play a role in lipoxygenase pathway at the level of reduction of hydroperoxides and in the formation of peptidoleukotrienes. GSTs, especially Yb containing subunits were shown to conjugate GSH to **LTA<sub>4</sub>** to produce **LTC<sub>4</sub>**, the most potent vasoconstricting and bronchoconstricting compound (Chang *et al.*, 1987b). Hence in the present study GSTs from the various dietary oxidant stress conditions were screened for their potential impact on the enzymatic lipid peroxidation pathways of the arachidonic acid.

## 5.2.0.0. RESULTS


### 5.2.1.0. CM-Cellulose column chromatography

The affinity purified GSTs from liver cytosol of +E+Se rats were further separated into different isozymes on **CM-cellulose** column chromatography. As shown in the typical **chromatogram** (Fig. 38) eight GST activity peaks, designated as peaks I to VIII according to the order of elution, were consistently resolved on the CM-cellulose column chromatography with two linear salt gradients used in **succession**, i.e., 0 to 75 mM KCl and 75 to 200 mM KCl, in 10 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 6.0. Peak I isozyme, which did not bind to the **CM-cellulose** column is referred to as the anionic GST isozyme. The other isozyme peaks which were **eluted** by the salt gradient are referred to as the cationic GST isozymes.


**SDS-PAGE** analysis of each peak fraction demonstrated that all of them were **electrophoretically pure** (Fig. 39). Peak I, II, IV and VI were composed of Yb subunits only. Peak III was a Ya homodimer. Peak VII and VIII were **Yc homodimers**. Peak V consisted of equal amounts of Ya and Yc subunits as previously reported for transferases (Bass *et al.*, 1977; Tu and Reddy, 1985).



Fig. 38: Separation of affinity purified hepatic GST isozymes of +E+Se rats on CM- cellulose column chromatography



**Fig.39 : SDS-PAGE of liver GST isozymes  
+E+Se rats separated on CM-cellulose  
column chromatography**



Lane: 1. Rat liver affinity purified GSTs

Peak fraction #

2. 21	3.58	4.85
5. 99	6. 107	7. 128
8. 143	9.227	

10. Rat liver affinity purified GSTs

### 5.2.2.0. DE 52 cellulose column chromatography

The anionic form of GSTs obtained from the **CM-cellulose** column flow through fractions were subjected to anion-exchange chromatography on DE 52 cellulose column for further separation. No protein was observed in the effluent prior to the start of a linear gradient of 0-100 **mM** KCl in 10 **mM** Tris-HCl, pH 8.0. All the protein bound to the column was eluted at approximately 60 mM KCl as a single **peak**, coincident with the GST activity (Fig. 40).

### 5.2.3.0. GST catalyzed reduction of classical substrates

The substrate specificity studies have shown **that** , the **isozymes** containing Ya **and/or** Yc subunits can be clearly distinguished from the isozymes containing Yb subunits by their relatively low activities with DCNB and high non-Se-GSH Px activity (Table **15&16**). These results indicate that all of the rat liver GST isozymes may be classified into two groups, Ya and Yc containing isozymes and Yb **subunit** containing isozymes according to their physical and chemical properties as well as biological activities. The YaYc heterodimeric protein is always eluted after the Ya **homodimer** and before Yc homodimer **during** CM-cellulose chromatography (Fig. 38). The activity levels with different substrates for peak V (YaYa) are approximately intermediate between those of peak III (YaYc) and peak VII (YcYc). Peak III (Ya homodimer) is characterized by having the highest activity with 1,2-dichloro-4-nitrobenzene; **1,2-epoxy-3-(p-nitrophenoxy)propane**;  **$\Delta^5$ -androstene-3,17-dione**; **bromosulphthalein**, **p-nitrophenyl** acetate and **13-hydroperoxyoctadecadienoic acid (13-HPODE)** as well as **PGF<sub>2a</sub>** formation (Table **15&16**). Peak VII (Yc homodimer), on the other **hand**, showed the highest activity with ethacrynic acid as well as organic hydroperoxides (Table **15&16**). In contrast to the Ya **and/or** Yc containing isozymes, peaks I, II, **IV** and VI all contained only Yb subunits. However, they eluted at different salt concentrations on CM-cellulose columns indicating their varied structural characteristics. For example, peak I was eluted in the CM flow through fractions, whereas peak II, **IV** & VI were eluted at different salt concentrations. In addition to their structural

**Fig. 40: Anion exchange chromatography of +E+Se rat liver CM-cellulose column flow through fraction on DE 52 cellulose column chromatography**




TABLE 15 : SUBSTRATE SPECIFICITIES OF +E+Se RAT LIVER GST ISOZYMES SEPARATED ON CM-CELLULOSE COLUMN CHROMATOGRAPHY TO CLASSICAL SUBSTRATES

Substrate	I YbYb	II YbYb	III YaYa	IV YbYb	V YaYc	VI YbYb	VII YcYc	VIII YcYc
1,2-Dichloro-4-nitrobenzene	0.17	1.10	0.82	1.07	0.6	1.96	0.06	0.07
1-Chloro-2,4-dinitrobenzene	3.66	14.44	21.0	17.1	19	19.6	8.88	2.17
$\Delta^5$ -Androstene-3,17-dione	0.01	0.02	1.0	0.03	0.8	0.05	0.04	0.03
1,2-Epoxy-3-(p-nitrophenoxy)propane	0.30	ND	0.10	0.095	0.1	0.07	ND	ND
4-Nitropyridine-N-oxide	0.015	0.12	0.03	0.12	0.1	0.14	0.14	0.02
p-Nitrobenzyl chloride	0.78	3.27	1.86	3.84	1.3	0.83	1.20	1.01
Ethacrynic acid	0.15	0.36	0.70	0.44	0.9	0.13	1.25	0.9
p-Nitrophenyl acetate	0.20	0.2	0.38	0.42	0.3	0.57	0.20	0.17
Bromosulphothalein	0.01	0.02	0.06	0.02	0.03	ND	ND	0.01

Values expressed as  $\mu\text{moles/min/mg protein}$ .

**TABLE 16: SUBSTRATE SPECIFICITIES OF +E+S<sub>e</sub> RAT LIVER GST ISOZYMES SEPARATED ON  
CM-CELLULOSE COLUMN CHROMATOGRAPHY TO CONVENTIONAL SUBSTRATES**

<b>Substrate</b>	<b>I</b> YbYb	<b>II</b> YbYb	<b>III</b> YaYa	<b>IV</b> YbYb	<b>V</b> YaYc	<b>VI</b> YbYb	<b>VII</b> YcYc	<b>VIII</b> YcYc
Cumene hydroperoxide	0.56	0.040	5.12	1.05	5.43	1.42	8.0	10.5
t-Butyl hydroperoxide	0.05	0.21	1.32	0.41	1.4	0.71	2.25	1.90
13-HPODE	0.04	0.03	2.1	0.11	1.30	0.18	0.61	0.3
* PGH <sub>2</sub> to PGF <sub>2α</sub>	15	125	1520	250	552	120	328	287
* LTA <sub>4</sub> Me	123	7.9	6.2	69.7	1.6	ND	ND	ND

Values expressed as μmoles/min/mg protein.

\* Values expressed as nmoles/min/mg protein.

differences, they also showed varied functional characteristics. For example, peak I showed highest activity towards **1,2-epoxy-3-(p-nitrophenoxy)propane** and **LTA<sub>4</sub> Me**; followed by peak IV with less activity and peak VI with no activity (Table 16). Similarly peak I, IV and VI showed relatively low, intermediate and very high activities respectively with DCNB, 4-nitropyridine **n-oxide**,  **$\Delta^5$ -androstene-3,17-dione** and **p-nitrophenyl acetate** (Table 15).

#### 5.2.3.1. GST catalyzed reduction of cumene hydroperoxide


Se-GSH Px acts both on **H<sub>2</sub>O<sub>2</sub>** and organic hydroperoxides whereas  **$\alpha$ -class** GSTs act only on organic hydroperoxides which was designated as non-Se-GSH Px. The non-Se-GSH Px activity when measured with cumene hydroperoxide in the crude cytosolic fractions showed very high activity in the liver tissues of -E+Se (**103 %**), +E-Se (236 %) and -E-Se (304 %) animals when compared to the +E+Se animals (Fig. **41 A**). Similarly, in lung tissue non-Se-GSH Px activity was induced in -E+Se (121 %), +E-Se (267 %) and -E-Se (572 %) animals (Fig. **41B**). The activity levels in -E-Se were much higher when compared to that of **+E-Se** animals.

In the affinity purified GSTs, a clear induction of peroxidase activity is observed in liver and lung tissues of vit.E **and/or** Se deficient animals (Fig. **42A&B**), however, the induction being much higher in the cytosolic fractions.

#### 5.2.3.2. GST catalyzed reduction of 13-hydroperoxyoctadecadienoic acid (13-HPODE)

The total GSH Px activity measured with 13-HPODE in the crude cytosolic **fractions**, decreased in the liver tissues of +E-Se (-64 %) and -E-Se (-61 %) animals when compared to that of **+E+Se** animals (Fig. **43A**). Similarly in lung tissue, significantly lower levels of peroxidase activity were observed in +E-Se (**-51%**) and -E-Se (-30 %) groups compared to that of **+E+Se** animals (Fig. **43B**).


**Fig. 41:** Activity levels of GSTs with CHP in cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets



Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).




**Fig. 42: Activity levels of non-Se-GSH Px with CHP in the affinity purified GSTs of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**




Each value is the mean + SD of six individual observations.  
 Data was analyzed with a one way ANOVA followed by SNK test.  
 Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 43: Activity levels of GSTs with 13-HPODE in cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 44: Activity levels of GSH Px with 13-HPODE in the affinity purified GSTs of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by **SNK** test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

In contrast, the affinity purified GSTs showed a clear induction of peroxidase activity in liver tissues of -E+Se (21 %), +E-Se (50%) and -E-Se (54 %) and lung tissues of -E+Se (140 %), +E-Se (197 %) and -E-Se (340 %) when compared to the corresponding tissues from +E+Se animals (Fig. 44A&B).

### 5.2.3.3 GST catalyzed reduction of 15-hydroperoxyeicosatetraenoic acid (15-HPETE)

Total GSH Px activity levels in liver tissues were significantly lower in +E-Se (-61 %) and -E-Se (-56 %) animals when compared to that of +E+Se animals (Fig. 45A). Similarly, significantly lower levels of total GSH Px were observed in lung tissues of +E-Se (-56 %) and -E-Se (-27 %) animals when compared to that of +E+Se animals (Fig. 45B). GSH Px activity towards fatty acid hydroperoxides decreased significantly in liver and lung crude cytosols Se deficient animals, but not in those of vit.E deficient animals.


In contrast, the affinity purified GSTs showed significantly increased peroxidase activity in liver tissues of all vit.E and Se deficient [-E+Se (21 %), +E-Se (32 %) and -E-Se (34 %)] animals when compared to +E+Se animals (Fig. 46A). Similarly higher peroxidase activity levels were observed in lung tissues of -E+Se (91 %), +E-Se (**136** %) and -E-Se (249 %) animals compared to that of +E+Se animals (Fig. 46B).

### 5.2.3.4. GST catalyzed prostaglandin formation

Equal amounts of affinity purified liver and lung GSTs from vit.E **and/or** Se supplemented and deficient animals were analyzed for GST catalyzed prostaglandin **formation**. The prostaglandins were identified by the Rf values corresponding to the prostaglandin standards separated on TLC (Fig. 47).


The GST catalyzed **PGF<sub>2α</sub>** forming activity in the affinity purified GSTs were significantly higher from liver tissues **of -E+Se** (32 %), +E-Se (51 %) and -E-Se (92 %) animals compared to that of +E+Se animals (Table 17). This correlates well with the observation that the Ya **subunit**, which exhibits maximum

**Fig. 45: Activity levels of GSTs with 15-HPETE in cytosolic fractions of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**




Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test. Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 46: Activity levels of GSH Px with 15-HPETE in the affinity purified GSTs of liver and lung tissues of rats fed on vit.E and/or Se supplemented and deficient diets**



Each value is the mean + SD of six individual observations. Data was analyzed with a one way ANOVA followed by SNK test Bars labelled with same letter are not significantly different from one another ( $p < 0.05$ ).

**Fig. 47: Separation of prostaglandin standards  
on TLC**



**Table 17: Synthesis of prostaglandins catalyzed by liver affinity purified GSTs of vit.E and/or Se supplemented and deficient rats**

PG	-E+Se	+E-Se	-E-Se	+E+Se
PGD <sub>2</sub>	34.7 ± 6.93 <sup>a</sup>	32.06 ± 7.57 <sup>a</sup>	33.12 ± 5.46 <sup>a</sup>	39.48 ± 9.1 <sup>a</sup>
PGE <sub>2</sub>	42.5 ± 6.43 <sup>a</sup>	43.06 ± 6.39 <sup>a</sup>	46.47 ± 6.61*	41.66 ± 7.2 <sup>a</sup>
PGF <sub>2α</sub>	22.8 ± 2.72 <sup>a</sup>	24.84 ± 4.14*	30.40 ± 4.1 <sup>b</sup>	15.80 ± 3.75 <sup>c</sup>

Values represent mean ± SD of five individual experiments and are expressed in terms of percent ratios of total PGs formed. Data was analyzed with a one-way ANOVA followed by SNK test. Significance was set at  $p \leq 0.05$ . The same alphabet denotes no significant difference between the two groups in each row.

**Table 18: Synthesis of prostaglandins catalyzed by lung affinity purified GSTs of vit.E and/or Se supplemented and deficient rats**

PG	-E+Se	+E-Se	-E-Se	+E+Se
PGD <sub>2</sub>	88.62 ± 15.8*	88.11 ± 15.5 <sup>a</sup>	89.24 ± 19.11 <sup>a</sup>	88.74 ± 22.4 <sup>a</sup>
PGE <sub>2</sub>	8.52 ± 1.60 <sup>a</sup>	8.88 ± 1.75 <sup>a</sup>	8.34 ± 2.4*	8.37 ± 0.72*
PGF <sub>2α</sub>	2.84 ± 0.69 <sup>a</sup>	2.99 ± 0.75 <sup>a</sup>	2.56 ± 0.23 <sup>a</sup>	2.89 ± 0.24 <sup>a</sup>

Values represent mean ± SD of three individual experiments and are expressed in terms of percent ratios of total PGs formed. Data was analyzed with a one-way ANOVA followed by SNK test. Significance was set at  $p \leq 0.05$ . The same alphabet denotes no significant difference between the two groups in each row.



peroxidase activity, was also induced significantly in the livers from **vit.E** and Se deficient animals (II chapter).

**PGF<sub>2α</sub>** forming activity was also investigated with rat lung affinity purified GSTs from vit.E and Se deficient and supplemented animals. In contrast to the results observed in liver, **PGF<sub>2α</sub>** synthesis was barely detectable in the lung tissue (Table 18). No significant changes were observed in PGE2 or PGD2 formation in both lung and liver tissues in response to vit.E **and/or** Se deficiency (Table 17&18).

#### 5.2.3.5. GST catalyzed leukotriene formation

Among various rat liver **isozymes**, the anionic **isozyme** (peak I), a homodimer of Yb **subunit**, showed the highest LTC<sub>4</sub> Synthase activity, followed by peak IV GST isozymes (Table 16). When 5,6 **LTA<sub>4</sub>** methyl ester was incubated with equal amounts (100 **µg**) of liver affinity purified GSTs from vit.E **and/or** Se deficient animals for 10 min in the presence of **GSH**, most of the LTA<sub>4</sub> methyl ester was converted into an acid-resistant **compound**, **LTC<sub>4</sub> Me**, which eluted around 5 min on RP-HPLC (Fig. 48). The UV-absorption spectrum of the compound showed a typical LTC<sub>4</sub> spectrum with maximum absorption at 280 **nm** and shoulders at 270 and 292 **nm**. Basing on the **UV/VIS** spectrum and co.chromatography with authentic **standard**, the compound with RT 5 min was identified as **LTC<sub>4</sub> Me**. In contrast to **liver**, the lung GSTs showed significantly higher **LTC<sub>4</sub>** Synthase activity. However, there were no significant differences in **LTC<sub>4</sub>** Synthase activity of GSTs in **vit.E and/or** Se deficient and supplemented animal tissues (Table 19).


### 53.0.0. DISCUSSION

#### 5.3.1.0. Functional characterization of liver GSTs

The non-Se-GSH Px activity was significantly increased in liver cytosol fractions and affinity purified GSTs of **vit.E** and Se deficient animals (Fig.

**Fig. 48: RP-HPLC analysis of GSTs catalyzed LTC<sub>4</sub> formation**

Inset: UV/VIS absorption spectrum of 5,6 LTC<sub>4</sub> peak in methanol



Column: ODS,  $\mu$  Bondapak (Waters)  
 Solvents: Methanol:Water:Acetic acid  
 (65:35:0.1) pH 5.7  
 Flow rate: 280  $\mu$ l/min

**Table 19: LTC<sub>4</sub> Synthase activity of affinity purified liver and lung GSTs of vit.E and/or Se supplemented and deficient rats**

TISSUE	-E+Se	+E-Se	-E-Se	+E+Se
Liver	4.40 ± 0.8 <sup>1</sup>	<b>4.6 ± 1.9<sup>a</sup></b>	<b>4.64 ± 1.54<sup>a</sup></b>	5.6 ± 1.6 <sup>a</sup>
Lung	12.8 ± 0.4 <sup>a</sup>	<b>11.6 ± 3.4<sup>a</sup></b>	<b>15.4 ± 3.6<sup>a</sup></b>	12.6 ± 3.6 <sup>a</sup>

Values are mean + SD of five individual observations and are expressed as **nmol/min/mg protein**. Data was analyzed with a one-way ANOVA followed by SNK test. Significance was set at p< 0.05. The same alphabet denotes no significant difference between the two groups in each row.

**41&42).** This increased non-Se-GSH Px activity correlated well with increase in the **Ya** and **Yc** subunit containing GSTs (chapter II). Also **Ya** and **Yc** subunits exhibit maximum activity towards CHP as substrate (Table **16**).

In addition to Se-GSH **Px**, non-Se-GSH Px activity associated with GSTs also reduce fatty acid hydroperoxides. Fatty acid hydroperoxidase activity measured in the crude cytosol of vit.E **and/or** Se deficient and supplemented animal tissues with **13-HPODE** and **15-HPETE** showed significantly reduced activity levels in Se deficient animals (+E+Se; -E-Se) compared to Se supplemented animals (-E+Se; +E+Se) (Fig. 43&45). The fatty acid hydroperoxidase activity measured in the crude cytosol of Se supplemented animals (-E+Se; +E+Se) is contributed by both Se-GSH Px as well as non-Se-GSH Px activity of GSTs. Thus a more accurate measure of GSH Px activity would be achieved by subtracting **H<sub>2</sub>O<sub>2</sub>** (Se-GSH Px) activity as is traditionally done in estimating non-Se-GSH Px activity with CHP. Indeed, such a calculation would closely approximate the value measured when the fatty acid hydroperoxidase activities were measured in the **affinity** purified fraction. Fatty acid hydroperoxidase activity of GSTs was increased by 54% with 13-HPODE and 34% with 15-HPETE in vit.E and /or Se deficient animals compared to supplemented groups. This induction of fatty acid hydroperoxidase activity in **vit.E and/or** Se deficient animals must have been contributed by **Ya** and **Yc** subunits in liver tissue as these isozymes exhibit maximum peroxidase activity (Table **15**) and these are the subunits induced in liver tissues of vit.E **and/or** Se deficient animals (chapter II). It is to be noted that all fatty acid hydroperoxides are good substrates for Se-GSH **Px**, and is 50 times more efficient than non-Se-GSH Px in catalyzing the reduction of fatty acid hydroperoxides.

In addition to the fatty acid hydroperoxidase activity, GSTs also were reported to be involved in the biosynthesis of prostaglandins and leukotrienes. **Ya** subunits of GSTs were shown to be involved in **PGE<sub>2</sub>** and **PGF<sub>2α</sub>** synthase activity (Chang *et al.*, 1987a). In the present study liver affinity purified GSTs of **+E+Se**

animals when incubated with **PGH<sub>2</sub>** resulted in the formation of **PGE<sub>2</sub>**, **PGD<sub>2</sub>** and **PGF<sub>2α</sub>**, the relative abundance being in the same order (Table 17). In the **vit.E and/or Se deficient** animals, there was significantly higher formation of **PGF<sub>2α</sub>** compared to that of supplemented animals with no change in the formation of **PGE<sub>2</sub>** and **PGD<sub>2</sub>** (Table 17). Hope *et al* (1975) have reported increase in the formation of **PGE<sub>2</sub>** and **PGF<sub>2α</sub>** in rat blood in response to **vit.E** deficiency. Cooper and Carpenter (1987) found no effect of diet on **PGE<sub>2</sub>** production by sertoli cells isolated from the testes of rats maintained on vit.E altered diets. Hepatic **PGF<sub>2α</sub>** was significantly increased along with GST activities in phenobarbital treated rats which suggests that induction of Ya containing GSTs may play a physiologically important role in the synthesis of **PGF<sub>2α</sub>**, which may account, at least in part, for the tumor-promoting effects of phenobarbital (Hendrich *et al.*, 1991).

No significant changes were observed in the leukotriene synthesis of **vit.E and/or Se** deficient animals compared to that of +E+Se animals (Table 19). The formation of LTC<sub>4</sub> has been demonstrated in mouse myocytoma cells, rat basophilic leukemia cells, rat mononuclear cells and in human and guinea pig lungs (Piper, 1984; Dahinden *et al.*, 1985). GST **Yn<sub>1</sub>-Yn<sub>1</sub>** purified from rat brain has the highest LTC<sub>4</sub> synthase activity so far found in rat cytosolic GSTs and accounts for the majority of LTC<sub>4</sub> synthase activity in the brain (Tsuchida *et al.*, 1987). In the present study peak I with **Yb<sub>2</sub>Yb<sub>2</sub> subunits (CM-cellulose fractions)** showed maximum LTC<sub>4</sub> Synthase activity in the liver tissue (Table 15). As shown in the chapter II, liver contains very little or no **Yn<sub>1</sub>Yn<sub>1</sub>** isozymes and **Yb<sub>2</sub>Yb<sub>2</sub>** is not induced in vit.E **and/or Se** deficiency. Thus GSTs induced by antioxidant deficiency are unlikely to alter LT synthesis directly.

The accumulated peroxides in Se deficiency could activate the transcription of the specific GST genes which would result in non-Se-GSH Px activity. This **further** implies that environmental factors and pathological conditions which result in increased **lipid** peroxidation or otherwise increased peroxide levels might also induce changes in GST **expression**, especially those

involved in their reduction and detoxification. In the present study induction of Ya and Yc subunits in the liver tissue of vit.E **and/or** Se deficient animals appears to be aimed at the reduction of hydroperoxides as well as endoperoxides. GSTs with Ya and Yc, more so with Yc, are more involved in the reduction of hydroperoxides while GSTs with Ya subunits being more specific for reduction of endoperoxides.

### 5.3.2.0 Functional characterization of lung GSTs

The lung tissue of vit.E and/or Se-deficient animals is under increased oxidative stress as evidenced by increased GSSG levels and reduced Se-GSH Px activity levels (I chapter, Fig. **21&19**). The increased non-Se-GSH Px activity of GSTs with CHP as the substrate in **vit.E and/or** Se deficient animals observed in the present study (Fig. **41B&42B**) may be a compensatory mechanism to protect the lung tissue from the increased oxidative stress. The induction of GSTs with Yc subunits in lung tissue of **vit.E** and/or Se-deficient animals (II chapter) supports such a possibility as they exhibit very high peroxidase activity. Fatty acid hydroperoxidase activity was measured with affinity purified lung GSTs with **13-HPODE** as well as **15-HPETE** (Fig. 44&46). Fatty acid hydroperoxidase activity was much higher in Se-deficient animal tissue compared to Se-supplemented ones. This pattern is very much similar to that observed for liver tissue except that **it** correlated with elevated Yc rather than predominantly Ya GSTs.

GSTs can reduce **electrophilic** substrates like reactive alkenes; a,P **unsaturated** aldehydes, including highly toxic **4-hydroxyalkenals** and epoxides formed during **lipid** peroxidation. Among all the GST isozymes, GST 8-8 (**YkYk**) showed maximum activity towards **4-hydroxynonenal**, which is a product of peroxidative degradation of arachidonic acid (Stenberg *et al.*, 1992). Rat lung which contains YkYk **isozyme**, is thus involved in the reduction **of** hydroxyalkenals produced in lipid **peroxidation**. Even though Yk was not elevated in vit.E **and/or**

Se deficiency, the increased activity during oxidative stress could partially account for elevated GSSG in lung (chapter I).

Earlier studies have shown that glutathione peroxidase activity of GSTs was restricted to ferry acid hydroperoxides, which suggests that membrane phospholipids must be first cleaved by phospholipase **A<sub>2</sub>** before they could be utilized as substrates by GSTs (Tan *et al.*, 1984). However the later studies have shown that the **α-class** GSTs including those of human lung can effectively reduce the intact phospholipid hydroperoxides through GSH Px activity (Singhal *et al.*, 1992). Hence it can be suggested that the **α-class** GST isozymes (**Yc** & **Yk**) play a predominant role in detoxification of **lipid** peroxides particularly in **lung** tissue. GST *n* which constitutes about 90% GST activity towards electrophilic **substrates**, on the other hand is known for the detoxification of xenobiotics (Batist *et al.*, 1986; Tsuchida and Sato, 1992; Zhang, 1994).

In rat lung, however, dietary **vit.E and/or** Se status had no effect on the conversion of **PGH<sub>2</sub>** to **PGF<sub>2α</sub>** or in the formation of other prostaglandins (Table 18). This result can be explained by the observation that rat lung lacks Ya **subunit** (Reddy *et al.*, 1982), which is known for endoperoxidase activity. This association of prostaglandin endoperoxide reduction with Ya subunit is consistent with the fact that rat brain cytosolic GSTs which lack this subunit also showed very little **PGF<sub>2α</sub>** forming activity (Thyagaraju *et al.*, 1986b).

Compared to liver tissue, lung tissue of +E+Se animals showed 3-fold higher **LTC<sub>4</sub>** synthase activity (Table 19). This may be due to the presence of GSTs with more of Yb subunits than in the liver tissue, which exhibit **very high** LTC<sub>4</sub> synthase activity. LTC<sub>4</sub> synthase activity in vit.E **and/or** Se deficient animals showed no significant differences when compared with +E+Se animals. This observation coincides well with the data on GST Yb subunits, where no significant changes were observed (chapter II).

From these studies it can be concluded **that**, induction of **Y<sub>a2</sub>** and Yc subunits in liver and Yc subunits in lung tissue with increase in peroxidase activity in vit.E **and/or** Se deficient animals compared to **vit.E** and Se supplemented animals, is a compensatory mechanism towards impaired antioxidant defenses as a result of nutritional deficiency.



## ***SUMMARY AND CONCLUSIONS***

## SUMMARY AND CONCLUSIONS

Glutathione S-transferases (GSTs, EC 2.5.1.18) constitute a complex family of enzymes with multiple functions that are mostly associated with the **biotransformation/detoxification** of a wide spectrum of xenobiotics. They exist in complicated but distinct isozyme forms in different mammalian tissues. They are distinguishable by catalytic and immunological properties and by primary structure as well. Though their role in detoxification of xenobiotics is well **known**, their involvement in antioxidant defenses especially during oxidative stress is not well defined. In the present study structural and functional characterization was undertaken for GSTs from liver and lung tissues of animals subjected to oxidative stress. Female albino rats at weanling stage were fed on diets deficient and/or supplemented with vit.E **and/or** Se for a period of 13 weeks to induce oxidative stress by impairing vit.E and Se-GSH Px antioxidant activities.

1. Feeding of female albino rats with vit.E **and/or** Se deficient diets for a period of 13 weeks reduced vit.E and Se levels in hepatic and **lung** tissues to almost negligible levels.
2. Vitamin E and Se deficiency resulted in the stimulation of enzymes involved in GSH **metabolism**.
3. Vitamin E **and/or** Se deficiency in female albino rats resulted in oxidative stress in liver and lung tissues as evidenced by increased levels of **lipid** peroxides and decreased Se-GSH Px levels. Of these two, lung tissue is relatively more susceptible to oxidative damage.
4. Oxidative stress by Se deficiency resulted in the induction of GSTs both in liver and lung tissues as evidenced by increased specific **activity** of GSTs in cytosolic fractions, increased total affinity purified GST protein and decreased purification fold of Se deficient groups.

5. Western blot analysis of crude cytosol fractions, **SDS-PAGE** and RP-HPLC analysis of affinity purified proteins of vit.E **and/or** Se deficient animals revealed induction of **Ya<sub>2</sub>** and Yc subunits in liver tissue compared to that of +E+Se animals.
6. In the lung tissue, which lacked Ya subunits, only GSTs with Yc subunits were induced in response to vit.E **and/or** Se deficiency.
7. Substrate specificity studies have revealed that GSTs with Ya subunits exhibit maximum activity with fatty acid endoperoxides such as PGH<sub>2</sub>, whereas Yc containing subunits showed maximum activity with organic hydroperoxides.
8. Substrate specificity of cytosol fractions and affinity purified GSTs from liver and lung tissues of vit.E and Se deficient animals showed increased activity with CHP, the organic hydroperoxides including **15-HPETE** and **13-HPODE**..
9. The increase of GSTs with peroxidase activity of GSTs towards organic peroxides like CHP, **15-HPETE** and **13-HPODE** observed in vit.E **and/or** Se deficient animals is consistent with an adaptive mechanism to enhance antioxidant defenses under oxidative stress.
10. Liver GSTs from vit.E **and/or** Se deficient animals had significantly higher **PGF<sub>2α</sub>** synthase activity in comparison to vit.E and Se supplemented animals. This observation coincides well with the increased GST Ya subunit in **vit.E and/or** Se deficient animals, which exhibits endoperoxidase activity. No significant differences, however, were observed in PG formation in the lung tissue of vit.E **and/or** Se deficient animals.
11. **LTC<sub>4</sub>** synthase activity of GSTs when measured in liver and lung tissues showed higher activity in the lung compared to liver tissue. This was attributed to high concentration of Yb subunits present in lung tissue, which exhibits higher **LTC<sub>4</sub>** synthase activity.

From these studies it is concluded that, GSTs in addition to their role in **detoxification** of xenobiotics, play a predominant role in antioxidant defense and are selectively induced during oxidative stress.

## ***REFERENCES***

- Alfhan G. (1984)** *Anal. Chim. Acta* 165, 187-194.
- Arriess G.R., **Chagchitt C.**, Chen L.-C. and Chow **C.K. (1988)** *Nutr. Res.* 8, 653-661.
- Arthur J.R., Morrice P.C., **Nocol F.**, Beddows S.E., Boyd **R.**, Hayes J.D. and Beckett G.J. (1987) *Biochem. J.* 248, 539-544.
- Arun S. and Ajay **K. (1990)** *Indian J. Exp. Biol.* 28, 780-782.
- Awad J.A., Morrow J.D., Hill **K.E.**, Roberts L.J. and Burk **R.F. (1994)** *J. Nutr.* 124, 810-816.
- Awasthi **Y.C.** and Singh S.V. (1985) *Comp. Biochem. Physiol.* 82B, 17-23.
- Bass N.M., Kirsch R.E., **Tuff S.A.**, Marks I. and Saunders S.J. (1977) *Biochim. Biophys. Acta* 492, 163-168.
- Batist G., Tulpurle **A.**, Sinha B., Katki **A.G.**, Meyers C.E. and Cowan K.H. (1986) *J. Biol. Chem.* 261, 15544-15549.
- Beatty P.W.** and Reed D.J. (1980) *Arch. Biochem. Biophys.* 204, 80-87.
- Beckett G.J. and Hayes J.D. (1993) *Adv. Clin. Chem.* 30, 281-300.
- Belinsky M. and Jaiswal A.K. (1993) *Cancer Metastasis Rev.* 12, 103-117.
- Benson A.M., Talalay P., Keen J.H. and Jakoby W.B. (1977) *Proc. Natl. Acad. Sci. USA.* 47, 158-162.
- Bird R.P., Hung **S.S.O.**, **Hadley M.** and Draper H.H. (1983) *Anal. Biochem.* 128, 240-244.
- Booth J., Boyland E. and Sim P. (1961) *Biochem. J.* 79, 516-524.
- Borroz K.I., Buetler T.M. and Eaton D.L. (1994) *Toxicol. Appl. Pharmacol.* 126, 150-155.
- Bray T.M. and Taylor **C.G. (1993)** *Can. J. Physiol. Pharmacol.* 71, 746-751.
- Brown L.A.S., Bai C. and Jones D.P. (1992) *Am. J. Physiol.* 262, L305-L312.
- Brucchausen F., **Wurm G.** and Just I. (1988) in *Cellular Antioxidant Defense Mechanisms* (Chow **C.K.** ed.) Vol.1, pp. 117-137, CRC Press, Boca Raton, Florida.

- Bucher J.R., Tien M. and Aust S.D. (1983) *Biochem. Biophys. Res. Commun.* **111**, 777-784.
- Burdon R.H.** (1992) *Proc. Roy. Soc.* 99B, 169-176.
- Burgess J.R., Hong Y., Chang M., Rao M.K., Tu C.-P.D. and Reddy C.C. (1987) *Biochem. Biophys. Res. Commun.* 142,441-447.
- Burton G.W.** and Ingold K.U. ( 1989) *Ann. N. Y.Acad. Sci.* 570, 7-31.
- Cadenas E. (1984) *Photochem. Photobiol.* 40, 823-830.
- Cagen L.M., Pisano J.J., Ketley J.N., Habig W.H. and Jakoby W.B. (1975) *Biochim. Biophys. Acta* 398, 205-208.
- Carlberg I. and Mannervik B. (1985) *Methods Enzymol.* **113**, 484-490.
- Carmichael J.**, Forrester L.M., Lewis **A.D.**, Hayes J.D., Hayes P.C. and Wolf **C.R.** (1988) *Carcinogenesis* 9, **1617-1621**.
- Carpenter M.P. (1981) *Fed. Proc.* 40, **189**.
- Carrillo **M.-C.**, Nokubo **M.**, **Kitani K.**, Satoh **K.** and Sato **K.** (1991) *Biochim. Biophys. Acta* 1077, **325-331**.
- Chan A.C., Allen C.E. and Hegarty P.V.J. (1980) *J. Nutr.* **110**, 66-73.
- Chang M., Burgess J.R., Scholz **R.W.** and Reddy C.C. (1990) *J. Biol. Chem.* 265, 5418-5423.
- Chang M., Hong Y., Burgess J.R., Tu C.-P.D. and Reddy C.C. (1987a) *Arch. Biochem. Biophys.* 259, 548-557.
- Chang **M.**, Rao **M.K.**, Reddanna P., Li C.-H., Tu C.-P.D., Corey E.J. and Reddy C.C. (1987b) *Arch. Biochem. Biophys.* 259, 536-547.
- Charles Kumar T., Veera Reddy **K.**, Prasad M., Thyagaraju K. and Reddanna P. (1992) *Mol. Cell. Biochem.* **111**, **109-115**.
- Chasseaud L.F. (1979) *Adv. Cancer Res.* 29, 175-274.
- Chow C.K. and Tappel A.L. (1974) *J. Nutr.* **104**, **444-451**.
- Christ -Hazelhof E., Nugteren D.H. and Van Drop **D.A.** (1976) *Biochim. Biophys. Acta* 450, **450-461**.

- Christensen M.J., Nelson B.L. and Wray C.D. (1994) *Biochem. Biophys. Res. Commun.* 202, 271-277.
- Chu F.F., Dorshow J.H. and Esworthy **R.S.** (1993) *J. Biol. Chem.* 268, 2571-2576.
- Clashen P.C., Moison R.M.W., Holtzer C.A.Z. and Berger H.M. (1992) *Pediatric Res.* 32, 399-401.
- Coles B. and Ketterer B. (1990) *Crit. Rev. Biochem. Mol. Biol.* 25, 47-70.
- Cooper **D.R.** and Carpenter M.P. (1987) *Biochem. J.* 241, 847-855.
- Cossar D., Bell J., Strange R., Jones M., Sandison A. and Hume **R.** (1990) *Bochim. Biophys. Acta* 1037, 221-226.
- Coursin D.B., **Cihla** H.P., Oberley T.D., and Oberley L.W. (1992) *Am. J. Physiol.* 263, L679- L691.
- Crapo** J.D., Barry B.E., Foscue H.A and **Shelburne** J. (1980a) *Am. Rev. Respir. Dis.* 122, 123-143.
- Crapo J.D., Barry B.E., Foscue **H.A.** and **Shelburne** J. (1980b) *Am. Res. Environ. Exercise Physiol.* 44, 364-369.
- Crinton **R.A.P.** and O'Connor J.P. (1978) *Irish Vet. J.* 32, 81-86.
- Cucurou C, Battioni P., Daniel **R.** and Mansuy D. (1991) *Biochim. Biophys. Acta* 1081,99-105.
- Dahinden C.A., Clancy **R.M.**, Gross M., Chiller J.M. and **Hugli** T.E. (1985) *Proc. Natl. Acad. Sci. USA* 82, 6632-6636.
- Dahlen S-E., Hedqvist P., Hammarstrom S. and **Samuelsson** B. (1980) *Nature* 288, 484-486.
- DeLeve L.D. and **Kaplowitz** N. (1990) *Semin. Liver Dis.* 10, 251-266.
- Deneke S.M. and Fanburg B.L. (1989) *Am. J. Physiol.* 257, L163-L173.
- Derbel **M.**, Igarashi T. and Satoh T. (1993) *Arch. Biochem. Biophys.* 1158, 175-180.
- Diplock A.T. (1985) (ed.) in *Fat Soluble Vitamins, their Biochemistry and Applications*, pp. 319, Heineman, London.



- Elasayed N.M., **Kass R.**, Mustafa M.G., Hacker A.D., **Ospital J.J.**, Chow **C.K.** and Cross C.E. (1988) *Drug Nutr. Interact.* 5, 373-386.
- Esterbauer H., Schaur R.J. and Zollner H. (1991) *Free Rad. Biol. Med.* 11, 81-128.
- Esterbauer H., Zollner H. and Schaur R.J. (1990) in *Membrane Lipid Oxidation* (**Vigo-Pelfrey C.** ed.) pp. 239-267, CRC Press, Florida.
- Esworthy **R.S.**, Chu F.F., Paxton R.J., **Akman S.** and Doroshov J.H. (1991) *Arch. Biochem. Biophys.* 286, 330-336.
- Fiske C.H. and Subbarow Y. (1925) *J. Biol. Chem.* 66, 375-400.
- Flohe L.**, Gunzler **W.A.** and Schock H.H. (1973) *FEBS Lett.* 32, **132-134.**
- Forman H.J.** and Thomas M.J. (1986) *Ann. Rev. Physiol.* 48, 669-680.
- Forman H.J.**, **Rotman E.I.** and Fisher **A.B.** (1983) *Lab. Invest.* 49, 148-153.
- Freeman **B.A.** and Crapo J.D. (1982) *Lab. Invest.* 47, 412-426.
- Fridovich I.** (1989) *J. Biol. Chem.* 264, 7761-7764.
- Gershman R.**, **Gilbert D.L.**, Nye S.W., Dwyer P. and Fenn W.O. (1954) *Science* 119, **623-626.**
- Gey **K.F.**, Brubacher G.B. and Stahelin H.B. (1987) *Am. J. Clin. Nutr.* 45, **1368-1377.**
- Gilbert H.G. (1984) *Methods Enzymol.* 107, 330-351.
- Gutteridge J.M.C.** and Halliwell B. (1990) *TIBS* 15, **129-135.**
- Habig W.H. and Jakoby W.B. (1981) *Methods Enzymol.* 77, 398-405.
- Habig W.H., Pabst M.J., Fleischner G., **Gatmaitan Z.**, Arias I.M. and Jakoby W.B. (1974) *Proc. Natl. Acad. Sci. USA.* 71, 3879-3882.
- Hafeman D.G.** and Hoekstra W.G. (1977) *J. Nutr.* 107, 666-672.
- Halliwell B.H. (1990) *Free Rad. Res. Commun.* 9, 1-32.
- Halliwell B.H. (1994) *Nutr. Rev.* 52, 253-265.
- Halliwell B.H. and Chirico S. (1993) *Am J. Clin. Nutr.* 57, **715S-725S.**

- Halliwell B.H. and Gutteridge J.M.C. (1989) in *Free Radicals in Biology and Medicine*. 2<sup>nd</sup> ed. Clarendon Press, Oxford, England.
- Hamberg M, Svensson J., Wakabayashi T. and Samuelsson B. (1974) *Proc. Natl. Acad. Sci. USA*. 71, 345-349.
- Hammarstrom S. and Samuelsson B. (1980) *Biochem. Biophys. Res. Commun.* 92, 946-953.
- Hammond B. and Hess M.L. (1985) *J. Am. Coll. Cardiol.* 6, 215-220.
- Harman D. (1956) *J. Geront.* 11, 298-300.
- Hatayama C, Satoh K. and Sato K. (1986) *Biochem. Biophys. Res. Commun.* 140, 581-588.
- Hawker F.H., Ward H.E., Stewart P.M., Wynne L.A. and Snitch P.J. (1993) *Eur. Respir. J.* 6, 1317-1323.
- Hayes J.D. (1986) *Biochem. J.* 233, 789-798.
- Hayes J.D. (1988) *Biochem. J.* 255, 913-922.
- Hayes J.D. and Mantle T.J. (1986) *Biochem. J.* 237, 779-788.
- Hayes J.D. and Pulford D.J. (1995) *Crit. Rev. Biochem. Mol. Biol.* 30, 445-600.
- Hayes J.D., Judah D.J. and Neal G.E. (1993) *Cancer Res.* 53, 3887-3894.
- Hayes J.D., Kerr L.A., Harrison D.J., Cronshaw A.D., Ross A.G. and Neal G.E. (1990) *Biochem. J.* 268, 295-302.
- Hendrich S., Krueger S.K., Chen H.-W. and Cook L. (1991) *Prost. Leuk. Essent. Fatty acids* 42, 45-50.
- Hill K.E. and Burk R.F. (1982) *J. Biol. Chem.* 257, 10668-10672.
- Hill K.E., Burk R.F. and Lane J.M. (1987) *J. Nutr.* 117, 99-104.
- Hinchman C.A. and Ballatori N. (1994) *J. Toxicol. Environ. Health* 41, 387-409.
- Hiratsuka A., Sebata N., Kawashima K., Okuda H., Ogura K., Watanabe T., Satoh K., Hatayama I., Tsuchida S., Ishikawa T. and Sato K. (1990) *J. Biol. Chem.* 265, 11973-11981.

- Hong Y., Li C.H., Burgess J.R., Chang **M.**, Salem A., Srikumar **K.** and Reddy **C.C.** (1989) *J. Biol. Chem.* 264, 13793-13800.
- Hope W.C., Dalton C, Machlin L.F., Filiposki R.J. and Vane F.M. (1975) *Prostaglandins* 10, 557-578.
- Horwitt **M.K.** (1986) *Am. J. Clin. Nutr.* 44, 973-985.
- Hwang C, Sinskey A.J. and Lodish H.F. (1992) *Science* 257, **1496-1502**.
- Igarashi T., **Irokawa N.** and Ono S. (1987) *Xenobiotica* 17, 127-137.
- Igarashi T., Satoh T., Hoshi **K.**, **Ueno K.** and Kitagawa H. (1982) *Life Sci.* **31**, 2655-2665.
- Ip C.** and Ganther H. (1990) *Cancer Res.* 50, **1206-1211**.
- Ip C.** and Hayes C. (1989) *Carcinogenesis* 10, 921-925.
- Jaackson R.M. and Veal C.F. (1990) *Am. J. Physiol.* 259, **H518-524**.
- Jain **A.**, Martensson J., Mehta T., Krauss **A.N.**, **Auld P.A.M.** and Meister A. (1992) *Proc. Natl. Acad. Sci. USA.* 89, 5093-5097.
- Jakobson I., Warholm M. and Mannervik (1979) *Biochem. J.* 177, 861-868.
- Jakoby W.B. and Habig W.H. (1980) in *Enzymatic Basis of Detoxification*, (Jakoby, W.B. ed.) vol. 2, pp. 63-94, **Academic Press**, New York.
- Jamieson D., Chance B., Cadenas E. and Boveris A. (1986) *Annu. Rev. Physiol.* 48, **703-719**.
- Jayatileke E.** and Shaw S. (1993) *Anal. Biochem.* 214, **452-457**.
- Jenkinson S.G., Jordan **J.M.** and Duncan C.A. (1989) *Am. J. Physiol.* 257, L393-L398.
- Jenkinson S.G., Spence T.H., Lawrence R.A., Hill **K.E.**, Duncan **C.A.** and Johnson **K.H.** (1987) *J. Appl. Physiol.* 62, 55-60.
- Ji L.L. and **Fu R.** (1992) *J. Appl. Physiol.* 72, 549-554.
- Ji L.L., Stratman F.W. and Lardy H.A. (1988) *Arch. Biochem. Biophys.* 263, 150-160.
- Ji L.L., Stratman F.W. and Lardy H.A. (1992a) *J. Am. Coll. Nutr.* **11**, 79-86.

- Ji X., Zhang P., Armstrong R.N. and Gilliland G.L. (1992b) *Biochemistry* 31, 10169-10184.
- Johnson J.A., Finn K.A. and Siegel F.L. (1992) *Biochem. J.* 282, 279-289.
- Johnson K.J., Fantone J.C., Kaplan J. and Ward P.A. (1981) *J. Clin. Invest.* 67, 983-993.
- Kagan V.E., Spiricheu V.B. and Erin A.E. (1989) in *Nutrition in Exercise and Sport* (Hickson F.J. and Wolinsky I. eds) pp. 255-278, CRC Press, Boca Raton, Florida.
- Kalinyak J.E. and Taylor J.M. (1982) *J. Biol. Chem.* 257, 523-530.
- Kanter M.M. (1994) *Int. J. Sport Nutr.* 4, 205-220.
- Kauf E., Janitzky E., Vogt L., Winnefeld K., Dawczynski H., Forberger M., Jahreis G. and Vogel H. (1995) *Med. Klin.* 90, 41-45.
- Kensler T.W., Egner P.A., Davidson N.E., Roebuck B.D., Pikul A. and Groopman J.D. (1986) *Cancer Res.* 46, 3924-3931.
- Ketterer B. and Christodoulides L.G. (1994) *Adv. Pharma.* 27, 37-69.
- Ketterer B., Meyer D.J. and Clark A.G. (1988) in *Glutathione Conjugation, Mechanism and Biological Significance* (Sies H. and Ketterer B. eds.) pp. 74-135, Academic Press, London.
- Kim Y.S. and Combs Jr. G.F. (1993) *Nutr. Res.* 13, 455-463.
- Kitahara A., Satoh K., Nishimura K., Ishikawa T., Ruike K., Sato K., Tsuda H. and Ito N. (1984) *Cancer Res.* 44, 2698.
- Koppenol W.H. (1990) in *Membrane Lipid Oxidation* (Vigo-Pelfrey C. ed.) pp. 1-13, CRC Press, FL.
- Korpela H., Kumpulainen J., Luoma P.V., Arranto A.J. and Sotaniemi E. (1985) *Am. J. Clin. Nutr.* 42, 147-151.
- Kretzschmar M. and Klinger W. (1990) *Exp. Pathol.* 36, 145-164.
- Krinsky I.N. (1992) *Proc. Soc. Exp. Biol. Med.* 200, 248-254.
- Laemmli U.K. (1970) *Nature* 227, 680-685.

- Lai H.-C.J., Li **N.Q.**, Weiss **M.H.**, Reddy C.C. and Tu C.-P.D. (1984) *J. Biol. Chem.* 259, 5536-5542.
- Lands W.E.M., Kulmacz R.J. and Marshall P.J. (1984) in *Free Radicals in Biology* (Pryor W.A. ed.) Vol. VI, pp. 39-61, Academic Press, New York.
- Landstein **R.**, Epp **O.**, Huber R. and Wendel A. (1981) *IBID* 33-43.
- Landstein **R.**, Epp **O.**, Bartels **K.**, Jones A., Huber **R.** and Wendel **A.** (1979) *J. Mol. Biol.* 134, **199-218.**
- Larsson A., Orrenius S., Holmgren A. and Mannervik B. (1983) in *Functions of Glutathione- Biochemical, Physiological, Toxicological and Clinical Aspects*, Raven Press, New York.
- Lauterburg B.H., Adams J.D. and Mitchell **J.R.** (1984) *Hepatology* 4, 586-590.
- Lawrence R.A. and Burke **R.F.** (1976) *Biochem. Biophys. Res. Commun.* 71, 952-958.
- Lawrence R.A., Parkhill **L.K.** and **Burk R.F.** (1978) *J. Nutr.* 108, 981-987.
- Lee C.W., Lewis **R.A.**, Corey E.J. and Austen **K.F.** (1983) *Immunology* 48, 27-35.
- Lei D.N., Wang L.Q., Ruebner B.H., Msieh D.P., Wu B.F., Zhu **C.R.** and Du M.J. (1990) *Biomed. Environ. Sci.* 3, 65-80.
- Lomnitski L., Bergman M., Schion I. and Grossman S. (1991) *Biochim. Biophys. Acta* **1082**, 101-107.
- Lowry **O.H.**, Roserbrough N.J., Farr **A.L.** and Randall **R.L.** (1951) *J. Biol. Chem.* 193, 265-275.
- Luoma P.V., Nayha S., Sikkila K. and Hassi J. (1995) *J. Intern. Med.* **237**, 49-54.
- Maddipati **K.R.** and Marnett L.J. (1987) *J.Biol. Chem.* 262, 17398-17403.
- Mannervik B. (1986) *Chemica Scripta* 26B, 281-284.
- Mannervik B. and Danielson U.H. (1988) *Crit. Rev. Biochem. Mol. Biol.* 23, 283-337.
- Mannervik B., Alin P., Guthenberg C., Jensson H., Tahir **M.K.**, Warholm M. and Jorvall H. (1985) *Proc. Natl. Acad. Sci. USA.* 82, 7202-7206.

- Martensson J., Jain A., Frayer W. and Meister A. (1989) *Proc. Natl. Acad. Sci. USA.* 86, 5296-5300.
- Martensson J., Jain A., Stole E., Frayer W., **Auld** P.A.M. and Meister A. (1991) *Proc. Natl. Acad. Sci. USA.* 88, 9360-9364.
- McCay P.B. and King M. (1980) in *Vitamin E: A Comprehensive Treatise* (Machlin W. ed.) pp. **289-317**, Marcel Dekkar, New York.
- McCord J.M. and Fridovich I. (1968) *J. Biol. Chem.* 244, 6049-6055.
- McIntyre** T.M. and Curthoys N.P. (1980) *Int. J. Biochem.* 12, **545-551**.
- Mehlert A. and Diplock A.T. (1985) *Biochem. J.* 227, **823-831**.
- Meister A. (1991) *Pharmacol. Ther.* 51, 155-194.
- Meister A. and Anderson M.E. (1983) *Annu. Rev. Biochem.* 52, **711-760**.
- Meydani S.N., Shapiro A.C., Meydani M. and **Blumberg** J.B. (1992) *J. Nutr.* 122, 1627-1633.
- Meyer D.J. (1993) *Xenobiotica* 22, 823-834.
- Meyer D.J., Harris J.M., **Gilmore** K.S., Coles B., Kensler T.W. and Ketterer B. (1993) *Carcinogenesis* 14, 567-572.
- Moncada** S., Palmer **R.M.J.** and Higgs E.A. (1991) *Pharmacol. Rev.* 43, 109-142.
- Murata T., **Hatayama** I., Satoh **K.**, Tsuchida S. and Sato **K.** (1990) *Biochem. Biophys. Res. Commun.* 171, **845-851**.
- Niki** E., Tsuchiya J., Tanimura **R.** and **Kamiya** Y. (1982) *Chem. Lett.* 789-792.
- Oakley **B.R.**, Kirsch D.R. and Morris **R.N.** (1980) *Arch. Biochem. Biophys.* 105, 361-363.
- Ogorachi T., Utiyara M. and Narumiya S. (1987) *J. Neurochem.* 48, 900-909.
- Ostero and Prellwitz W. (1990) *Biol. Trace Elem. Res.* 24, 91.
- Ostlund F., Meyer D.J., Coles B., **Soutlan** C, **Aitken** A., Johnson P.J. and Ketterer B. (1987) *Biochem. J.* 245, 423-428.
- Panganamala **R.U.** and **Cornwell** D.G. (1980) *Ann. N. Y. Acad. Sci.* 393, 376-391.

- Panus P.C., Shearer J. and Freeman B.A. (1988) *Exp. Lung Res.* 14, 959-976.
- Panush **R.S.** and Delafuente J.C. (1985) *World Rev. Nutr. Diet* 45, 97-132.
- Pemble** S.E., Taylor J.B., Craig R.K. and Ketterer B. (1986) *Biochem. J.* 238, 373-378.
- Penrose J.F., Gagnon L., **Goppelt-Struebe** M., Meyers P., Lam B.K., Jack R.M., Austen K.F. and **Soberman R.J.** (1992) *Proc. Natl. Acad. Sci. USA.* 89, 11603-11606.
- Pickett** C.B., **Telakowski-Hopkins** C.A., Ding G.J.-F., Algenbright L. and **Lu** A.Y.H. (1984) *J. Biol. Chem.* 259, 5182-5188.
- Piper P.J. (1984) *Physiol. Rev.* 64, 744-761.
- Potter D.W. and Tran T-B. (1993) *Toxicol. Appl. Pharmacol* 120, 186-192.
- Primiano T. and Novak R.F. (1992) *Toxicol. Appl. Pharmacol.* 113, 64-73.
- Reddanna P., Maddipati **K.R.** and Reddy C.C. (1985) *FEBS Lett.* 193, 39-43.
- Reddanna P., Whelan J. and Reddy C.C. (1988) *Ann. N. Y Acad. Sci.* 524, 391-392.
- Reddanna P., Whelan J., Burgess **J.R.** Eskew M.L., Hildenbrandt G., Zarkower A., Scholz R.W. and Reddy C.C. (1989) *Ann. N. Y Acad. Sci.* 570, 136-145.
- Reddy C.C., Whelan J. and Scholz R.W. (1988) in *Cellular Antioxidant Defense Mechanisms* (Chow C.K. ed.) Vol.1, pp. **139-149**, CRC Press, Florida.
- Reddy C.C., Burgess J.R., Gong Z.Z., Massaro E.J. and Tu C.-P.D. (1983) *Arch. Biochem. Biophys.* 224, 87-101.
- Reddy C.C., Grasso T.C., Scholz **R.W.**, Labosh T.J., Thomas C.E. and Massaro E.J. (1982) *Prostaglandins and Cancer Intl. Conference* (Powells T.J., **Ramwell** P.W., **Honn K.V.** and **Bockman R.S.** eds.) pp. **149-154**, Alan R. Liss, New York.
- Reddy C.C., Tu C.-P.D., Burgess **J.R.**, Ho C-Y., Scholz **R.W.** and Massaro E.J (1981) *Biochem. Biophys. Res. Commun.* 101, 970-978.
- Reed D.J. (1990) *Annu. Rev. Pharmacol. Toxicol.* 30, **603-631**.
- Reuter A. and **Klinger** W. (1992) *Exp. Toxicol. Pathol.* 44, 339-343.

- Richman P.G. and Meister A. (1975) *J. Biol. Chem.* **250**, 1422-1426.
- Robertson I.G.C., Jensson H., Mannervik B. and Jernstrom (1986), *Carcinogenesis* **7**, 295.
- Rokizki L., Logemann E., Sagredos A.N., Murphy M., **Wetzel-Roth W.** and **Keul J.** (1994) *Acta Physiol. Scand.* **151**, 149-158.
- Rotruck J.T., Pope A.L., Ganther H.E., Swasson A.B., Hafeman D. and Hoekstra W.G. (1973) *Science* **179**, 588-590.
- Rushmore T.H.**, Morton M.R. and Pickett C.B. (1991) *J. Biol. Chem.* **266**, **11632-11639**.
- Rushmore T.H., Nguyen T. and Pickett C.B. (1993) in *Structure and Function of Glutathione S-Transferase* (Tew **K.D.**, Pickett C.B., Mantle T.J., Mannervik B. and Hayes J.D. eds.) pp. **119-128**, CRC Press, Boca **Raton, Florida**.
- Rushmore T.H., King R.G., Paulson **K.E.** and Pickett C.B. (1990) *Proc. Natl. Acad. Sci. USA.* **87**, 3826-3830.
- Samuelsson B.** (1983) *Science* **220**, 568-575.
- Sato **K.** (1989) *Adv. Cancer. Res.* **52**, 205.
- Satoh T., Takenaga M., Kitagawa H. and **Itoh S.** (1980) *Res. Comm. Chem. Path. Pharmacol.* **30**, 151-161.
- Scandalios J.G. (1993) *Plant Physiol.* **101**, 7-12.
- Schwartz K. and **Foltz CM.** (1957) *J. Am. Chem. Soc.* **79**, 3292-3293.
- Schwartz L.H., Urban T. and Hercberg S. (1994) *Presse-Med.* **23**, 1826-1830.
- Scott M.L. (1978) in *The Fat-Soluble Vitamins* (DeLuka H.F. ed.) pp. 133-210, Plenum Press, New York.
- Seidegard J. and Pero R.W. (1985) *Human Genet.* **69**, 66-68.
- Sen **C.K.**, Marin E., **Kretzchmar M.** and Hanninen O. (1992) *J. Appl. Physiol.* **73**, 1265-1272.
- Simons **P.C.** and Vander Jagt L. (1977) *Methods Enzymol.* **77**, 235-237.
- Singhal S.S., Saxena M., Ahmad H., Awasthi S., Haque A. and Awasthi **Y.C.** (1992) *Arch. Biochem. Biophys.* **299**, 232-241.



- Sjodin B., Hellsten-Westng Y. and Apple F.S. (1990) *Sports Med.* 10, 236-254.
- Smedegard G., Hedqvist P., Dahlen S-E., Revenas B., **Hammarstrom S.** and **Samuelsson B.** (1982) *Nature* 295, 327-334.
- Smith L.J. and Anderson J. (1992) *Am. Rev. Respir. Dis.* 146, 1452-1457.
- Smith **C.M.**, Kelsey **K.T.**, Wiencke J.K., Leyden K., Levin S. and Christiani **D.C.** (1994) *Biomarkers Prev.* 3,471-477.
- Soderstrom M.**, Hammarstrom S. and Mannervik B. (1988) *Biochem. J.* 250, 713-718.
- Spencer S.R., Xue L., **Klenz E.M.** and Talalay P. (1991) *Biochem. J.* **273**, 711-717.
- Stenberg G., **Rodderstrom M.**, Engstrom A., **Pemle S.E.** and Mannervik B. (1992) *Biochem. J.* 284, **313-319**.
- Stuart M. (1982) *Ann. N. Y. Acad. Sci.* 293, 277
- Sunde R.A. and Hoekstra W.G. (1980) *Nutr. Rev.* 38, 265-273.
- Svovoda D.J.** and Higginson J. (1963) *Am. J. Pathol.* 43, 477-495.
- Tahir M.K., Guthenberg C. and Mannervik B. (1989) *Biochem. J.* 257, 215-220.
- Talay P. and Spencer **S.R.** (1990) in *Glutathione S-Transferase and Drug Resistance* (Hayes J.D., Pickett C.B. and Mantle T.J. eds.) pp. **176-185**, Taylor and Francis, London.
- Tan K.H., Meyer D.J., **Belin J.** and Ketterer B. (1984) *Biochem. J.* 220, 243-252.
- Tan K.H., Meyer D.J., Gillies N. and Ketterer B. (1988; *Biochem. J.* 254, 841-845.
- Tappel A.L. (1962) in *Vitamins and Hormones* pp. **493-510**, Academic Press, Orlando, Florida.
- Tappel A.L. (1980) *Ann. N. Y. Acad. Sci.* 355, 212-216.
- Tappel A.L., **Hawkes W.C.**, **Wilhelmsen E.C.** and Monsenbocker M.A. (1984) *Methods Enzymol.* 107, 602-619.

- Tate S.S., Thompson G.A. and Meister A. (1976) in *Glutathione Metabolism and Function* (Arias I.M. and Jakoby W.B. eds.) pp. 45-55, Raven Press, New York.
- Tateishi N., Higashi T., Naruse A., **Nakashima K.**, Shiozaki H. and Sakamoto Y. (1977) *J. Nutr.* **107**, 51-60.
- Taylor S.L., **Lamden M.P.** and Tappel A.L. (1976) *Lipids* **11**, 530-538.
- Thyagaraju **K.**, Burgess J.R., Hong Y., Reddanna P., Tu C.-P.D. and Reddy C.C. (1986a) *Fed. Proceed AS*, 1000.
- Thyagaraju **K.**, Burgess J.R., Reddanna P., Hong Y., Tu C.-P.D. and Reddy C.C. (1986b) *Fed. Proceed.* **45**, 1652.
- Tiidus P.M., Behrens W.A., Madere **R.**, Kim J.J. and Houston M.E. (1993) *Nutr. Res.* **13**, 219-224.
- Tipping E. and Ketterer B. (1981) *Biochem. J.* **195**, 441-442.
- Towbin H., Staehelin T. and Gordon J. (1979) *Proc. Natl. Acad. Sci. USA.* **76**, 4350-4354.
- Tsuchida S. and Sato K. (1990) *Biochem. J.* **266**, 461-465.
- Tsuchida S. and Sato K. (1992) *Crit. Rev. Biochem Mol. Biol.* **27**, 337-384.
- Tsuchida S., **Izumi T.**, **Shimizu T.**, Ishikawa T., **Hatayama I.**, Satoh **K.** and Sato **K.** (1987) *Eur. J. Biochem.* **170**, 159-164.
- Tu C.-P.D. and Reddy C.C. (1985) *J. Biol. Chem.* **260**, 9961-9964.
- Tu C.-P.D., Weiss M.J., Li N.Q. and Reddy C.C. (1983) *J. Biol. Chem.* **258**, 4659-4662.
- Urcini F., Maiorino M., Valente M., Ferri L. and Gregolin C. (1982) *Biochim. Biophys. Acta* **710**, 197-211.
- Van **Vleet J.F.** (1982) *Am. J. Vet. Res.* **43**, 851-857.
- Vander Jagt G.L., Hunsaker L.A., Garcia **K.B.** and Royer **R.E.** (1985) *J. Biol. Chem.* **260**, **11603-11610**.
- Van-Poppel G.**, Kardinnal A., Prince H. and Kok F.J. (1994) *Annu. Med.* **26**, 429-434.

- Veera Reddy **K.**, Anuradha D., Charles Kumar T. and Reddanna P. (1995) *Arch. Biochem. Biophys.* 323, 6-10.
- Vos R.E.M. and Van Bladderin P.J. (1990) *Chem. Biol. Interaction* 75, 241-265.
- Warburg C. and Christian W. (1941) *Biochem. Z* 310, 402.
- Waxman** D.J., Sundseth S.S., Srivastava P.K. and Lapenson D.P. (1992) *Cancer Res.* 52, 5797-5802.
- Whanger P.D** (1989) *J. Nutr.* 119, 1236-1239.
- Whelan J., Reddanna P., Burgess **J.R.** and Reddy C.C. (1986) *Fed. Proc. Fed. Am. Soc. Exp. Biol.* 45, 1935.
- Yamamoto** S. (1982) *Methods Enzymol.* 186, 55-60.
- Zhang L. (1994) *Carcinogenesis* 15, 105-109.